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 Eukaryotic pre-mRNA is processed within the 3’-untranslated region (3’-UTR) resulting 
in cleavage and polyadenylation.  The efficiency of the cleavage reaction is dependent on the 
binding activity of the 64-kDa subunit of CstF, CstF-64, to the pre-mRNA and is increased with 
elevated levels of CstF-64.  There is evidence that alternative polyadenylation occurs in the 
presence of increased CstF-64.  Our results showed that CstF-64 levels increased with LPS 
stimulation of RAW 264.7 macrophages while the expression of other pre-mRNA processing 
factors remained unchanged.  Because of the evidence that several macrophage genes exhibit 
alternative polyadenylation and post-transcriptional regulation under LPS stimulation, we used a 
reporter mini-gene to identify alternative polyadenylation in LPS-stimulated RAW macrophages.  
Upon LPS stimulation we measured a 2.5-fold increase in proximal poly(A) site selection that 
correlated with elevated levels of CstF-64.  Forced expression of CstF-64 demonstrated similar 
alternative polyadenylation.  Microarray analysis demonstrated 515 genes changed expression 
with LPS stimulation, 15 of which also changed with CstF-64 over-expression.  A closer analysis 
of 5 of these 15 genes demonstrated alternative polyadenylation within their 3’-UTR.  Closer 
analysis of the 3’-UTRs showed putative AU-rich regulatory elements.  There is also evidence 
that pre-mRNA processing is coupled with transcription.  Previous work has shown that the 
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 carboxy-terminal domain (CTD) of RNAP-II is necessary for 3’-end processing, that CstF binds 
to RNAP-II CTD and that this binding is CTD phosphorylation dependent.  Because our lab has 
also shown that increases in CstF-64 binding activity upon B-cell differentiation causes 
alternative polyadenylation on the Ig heavy chain gene and occurs in the absence of CstF-64 
increases, we believe that the local concentration of CstF-64 to the nascent pre-mRNA is 
increased in plasma cells through the phosphorylation-dependent recruitment of CstF-64 to 
RNAP-II CTD.  Using chromatin immunoprecipitation (ChIP), we measured an increase in 
Serine-2 and Serine-5 phosphorylation of the RNAP-II CTD at the promoter and variable regions 
of the Ig heavy chain gene in plasma cells compared to memory B cells.  We believe that this 
increase in RNAP-II CTD phosphorylation plays a role in either increased transcription of the Ig 
heavy chain gene or recruitment of pre-mRNA processing factors to the transcriptional 
machinery.
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1. STATEMENT OF THE PROBLEM 
 The importance of alternative polyadenylation to gene expression has been demonstrated 
for the Immunoglobulin (Ig) gene.  Selection of the promoter-distal poly(A) site on the Ig gene 
allows inclusion of membrane spanning exons into the final gene transcript, thus creating the 
membrane form of Ig that is primarily expressed in naïve and memory B lymphocytes.  Upon B-
cell differentiation into a plasma cell, there is a switch to the use of the promoter-proximal 
poly(A) site that precludes the incorporation of the membrane spanning exons, thus creating the 
secretory form of Ig.  Alternative polyadenylation demonstrates influences on gene expression 
beyond the change in the final structure of the protein as shown for Ig.  For example, alternative 
polyadenylation can influence gene expression when a change in poly(A) site use precludes the 
incorporation of mRNA regulatory elements within the 3’-UTR that control stability and 
translation of the final gene transcript.  This mechanism of gene expression control has been 
demonstrated in a variety of genes of the immune system that are involved in the acute defense 
response such as cytokines, COX-2, lysozyme and TNF-α.  Although the mechanism of cleavage 
and polyadenylation is well understood, the regulation of selection of one poly(A) site over 
another is less clear and appears to be influenced by a variety of things including, but not limited 
to: 1) competition between splicing and 3’-end processing, as occurs on the Ig gene; 2) the 
abundance of cleavage and polyadenylation factors, in particularly CstF-64, in the cellular 
environment; 3) the strength of one poly(A) site over another, which is strongly influenced by 
the exact sequence of and around the cleavage and polyadenylation site; and 4) the abundance of 
auxiliary factors that regulate the cleavage and polyadenylation machinery by either increasing 
or decreasing its efficiency.   
19 
  Although alternative polyadenylation events have been described on a number of LPS-
induced macrophage genes, the cause of these events has not been elucidated.  Through the 
studies outlined in this thesis, we have attempted to elucidate the contribution CstF-64 has on 
both the alternative polyadenylation of genes that possess more than one poly(A) site and on 
global gene expression in general in macrophages activated by gram-negative bacteria.   
 Furthermore, there has been substantial evidence linking transcription and pre-mRNA 3’-
end processing on yeast genes by demonstrating that yeast mRNA processing factors are 
recruited to the CTD of RNAP-II during transcription in a phosphorylation dependent manner.  
Because similar work in the mammalian system has yet to be performed, particularly on an 
inducible gene, and because of the impact 3’-end processing has on the expression of Ig heavy 
chain mRNA isoforms, we reasoned that the phosphorylation state of RNAP-II CTD across the 
Ig heavy chain gene locus may be different between memory B-cells and Ig-secreting plasma 
cells.  We also reasoned that these differences in the phosphorylation state of RNAP-II CTD may 
be associated with changes in mammalian mRNA processing factor binding to the transcriptional 
machinery, thus influencing poly(A) site switch on the Ig heavy chain gene transcript.  
Therefore, we have attempted to demonstrate a link between transcription and pre-mRNA 
cleavage and polyadenylation of the Ig heavy chain gene by identifying changes in the 
phosphorylation state of RNAP-II CTD across the Ig heavy chain genomic locus that correlates 
with the increased production of the secretory form of Ig that is observed when B-cells 
differentiate into Ig-secreting plasma cells. 
20 
  
2. SPECIFIC AIMS 
AIM 1 – We will test the hypothesis that the stimulation of the RAW 264.7 murine macrophage 
cell line with LPS or IFN-γ causes an increase in 3’-end processing activity that correlates with 
an increase in CstF-64 protein expression. 
AIM 1a.  We plan to assess by Western blot changes in protein expression for an array of factors 
and enzymes involved in mRNA 3’-end processing between unstimulated, LPS-stimulated, and 
IFN-γ−stimulated RAW macrophages.  We also plan to measure the same protein expression 
profile in murine, bone marrow macrophages (BMMs) stimulated with LPS or INF-γ. 
AIM 1b.  We plan to measure changes in 3’-end processing activity between untreated and LPS 
or IFN-γ treated RAW macrophages.  We aim to correlate any measured change in 3’-end 
processing activity after stimulation to changes in the protein expression profile of the factors 
monitored in AIM 1a that occur under the same stimulating conditions.   
AIM 1c.  We plan to over-express recombinant CstF-64 in RAW 264.7 macrophages and 
measure changes in 3’-end processing activity in the absence of LPS stimulation. 
AIM 1d.  We plan to perform microarray analysis on untreated, LPS-stimulated and CstF-64 
over-expressing RAW macrophages in an attempt to identify similar changes in gene expression 
between the LPS-stimulated and CstF-64 over-expressing RAW macrophages. 
AIM 1e.  We plan to identify alternative polyadenylation events within the 3’-UTR of genes in 
RAW macrophages whose expression has changed under both LPS-stimulating and CstF-64 
over-expressing conditions. 
AIM 2 – We will test the hypothesis that differential phosphorylation of RNAP II CTD along the 
Ig gene locus occurs between B-cells and plasma cells. By employing the technique of chromatin 
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 immunoprecipitation (ChIP) along the length of the Ig gene, we aim to ascertain the 
phosphorylation state of the CTD of RNAP II along the length of the Ig heavy chain gene.  Any 
changes in the phosphorylation state of the CTD upon B-cell differentiation will be determined 
by comparing ChIP results between A20 memory B-cell and AxJ plasma cell lines which share 
the IgG2a gene but regulate poly(A) site usage on the IgG2a pre-mRNA differently.   
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3. INTRODUCTION 
3.1.  mRNA Processing 
 The amount of protein product that results from gene activation is influenced by multiple 
biological mechanisms, including the rates of transcription, mRNA processing, mRNA export to 
the cytoplasm, mRNA stability and translational efficiency of the gene transcript.  Post-
transcriptional RNA processing is essential in creating translationally competent mRNA.  The 
5’-end of pre-mRNA is capped with a modified guanosine residue placed in a 5’-5’ orientation.  
Non-coding intron sequences are removed by splicing.  Endonucleolytic cleavage of nascent pre-
mRNA occurs primarily at an adenosine residue within its 3’-UTR, although it has been 
determined that endonucleolytic cleavage can occur at alternative residues resulting in minor 
heterogeneity at the extreme 3’-end of the transcript (106).  Following 3’-end cleavage is the 
addition of ~200 adenosine residues, thus creating a poly(A) tail [reviewed in (43) and (158)].    
Proteins, such as poly(A) binding protein (PABP) and eIF4E, that possess specific poly(A) tail 
and 5’-cap binding capabilities, respectively, promote interaction between the two ends of the 
mature mRNA conferring stability, exportability, and translational efficiency of the transcript 
[reviewed in (150)].   
3.2.  Required Factors for mRNA 3’-end Processing 
 In vitro reconstitution studies have revealed that there are a minimum number of defined 
factors necessary for successful pre-mRNA 3’-end cleavage and polyadenylation.  These factors 
include the Cleavage Polyadenylation Specificity Factor (CPSF) (see below) that binds the 
conserved AAUAAA poly(A) signal and the Cleavage Stimulatory Factor (CstF) (see below) 
that binds to the downstream GU-rich region (Figure 1).  Other required factors include 
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 mammalian Cleavage Factor I and II (CF-Im and CF-IIm), poly(A) polymerase (PAP) and 
poly(A) binding protein (PABP) [reviewed in (43) and (158)], and are not discussed further here.     
3.2.1.   Cleavage Polyadenylation Specificity Factor 
 The Cleavage Polyadenylation Specificity Factor (CPSF) is composed of four protein 
subunits: a 30-kDA subunit (CPSF-30), a 73-kDa subunit (CPSF-73), a 100-kDa subunit (CPSF-
100) and a 160-kDa subunit (CPSF-160) (11).  CPSF-160 contains an RNA recognition motif 
(RRM), divergent from other conserved RRMs (96), that binds to the consensus poly(A) signal 
AAUAAA (71) found in the majority of RNA polymerase II transcribed eukaryotic genes 
(Figure 1).  Protein-protein interaction between the CPSF complex and the CstF complex is 
facilitated through CPSF-160 (96) and is required for efficient pre-mRNA 3’-end cleavage and 
polyadenylation.  Recently, CPSF-73 has been described as a member of the metallo-β-lactamase 
family of enzymes (4) and implicated as the 3’-end processing factor that is responsible for the 
endonucleolytic cleavage of the pre-mRNA (123).  UV-crosslinking studies have shown that 
CPSF-73 binds to the pre-mRNA near the cleavage site in an AAUAAA-dependent manner and 
the removal of Zn+2 from the in vitro reaction demonstrated a requirement for metal ions for the 
cleavage reaction, a requirement other members of the metallo-β-lactamase enzyme family 
exhibit (123). 
3.2.2.   Cleavage Stimulatory Factor 
 The Cleavage Stimulatory Factor (CstF) complex is composed of three protein subunits: a 
50-kDa subunit (CstF-50), a 64-kDa subunit (CstF-64), and a 77-kDa subunit (CstF-77).  
Homologues of CstF-64 and CstF-77 have been described in Saccharomyces cerevisiae (37, 57) 
Drosophila melanogaster (61, 94) and Bos Taurus (34).  The CstF trimeric complex is assembled 
by CstF-77 forming a bridge between CstF-64 and CstF-50 (135).  CstF-77 is also the subunit 
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 that tethers CstF to the 160-kDa subunit of the CPSF (96) and contains a nuclear localization 
signal that allows transport of the CstF trimer into the nucleus where CstF functions (135).  CstF-
50 possesses seven contiguous WD-40 protein-protein interaction domains (137) that are 
necessary for binding to CstF-77 (136).  Furthermore, the WD-40 repeats appear to play a role in 
the binding of CstF-50 to the CTD of RNA polymerase II (89) and to BRCA1-associated RING 
domain protein (BARD1) (74), and may be responsible for regulation of CstF function.  CstF-64 
is comprised of a conserved RNA recognition motif (RRM) near its N-terminus (134) that binds 
preferentially to GU-rich regions [(138) and Figure 1].  Structural analysis of CstF-64 by nuclear 
magnetic resonance has shown that the RRM forms a β-sheet and demonstrates highest affinity 
to GU-rich regions that contain a pair of consecutive uridines (108).  CstF-64 also contains a 
hinge region immediately downstream of the RRM that is responsible for binding to CstF-77 and 
symplekin (136), a protein known to also bind CPSF (66).  Two proline/glycine-rich domains 
surround twelve repeats of the consensus MEARA/G amino acid sequence near the C-terminus 
that form an alpha-helix secondary structure (134) that has been ascribed as having protein 
binding characteristics similar to alpha-helical possessing transcription factors (115).  The 
function of the C-terminal domain of CstF-64 has yet to be described, but a report that 
demonstrates an interaction between the C-terminal domain of CstF-64 and the transcription 
elongation factor PC4 (18) further supports the view that transcription and pre-mRNA processing 
are physically linked mechanisms (32, 47, 81, 124). 
3.2.2.1. The Variant Form of CstF-64 
 It has been shown that many mRNAs from male germ cells do not contain the canonical 
poly(A) signal AAUAAA, yet are efficiently processed to mature mRNA (147).  Although there 
is approximately 250-fold more CstF-64 mRNA expressed in testicular cells compared to liver 
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 cells (33), further investigation of the known CstF-64 in mouse male germ cells revealed absence 
of its expression in mitotic spermatocytes.  This was explained through the mapping of the CstF-
64 gene to chromosome X (147), a chromosome inactivated during male meiosis (60).  However, 
a 70-kDa variant form of CstF-64 was found to be expressed in mitotic spermatocytes and post-
mitotic spermatids (147).  The mouse variant form of CstF-64, called mτCstF-64, was mapped to 
chromosome 19 and explains how mRNAs in mitotic germ cells can be properly processed in the 
absence of expression of the X-chromosomal form of CstF-64 (35).  A human form of the CstF-
64 variant, hτCstF-64, was similarly mapped to chromosome 10 (34).  A critical difference 
between the somatic CstF-64 and τCstF-64 is a Proline-to-Serine amino acid substitution in the 
RRM, which may instill altered RNA binding specificity, thereby explaining the differences in 
cleavage and polyadenylation observed in male germ cells (35).  Other amino acid substitutions 
between both the mouse and human forms of CstF-64 and τCstF-64 are the result of the 
exclusion of protein coding exons (34).  Critical analysis of the functional differences between 
these alternative forms of CstF-64 has yet to be performed.  Interestingly, a reciprocal 
translocation at 10q22 observed in an oligospermic male was mapped to the location of the 
hτCstF-64 gene (14), supporting the hypothesis that lesions in this gene, although not fatal, may 
cause male sterility. 
3.2.3. Auxiliary Factors that Influence pre-mRNA 3’-end Processing 
 The heterogeneous nuclear ribonucleoproteins H, H’ and F, three proteins that have 
similar sequence identities and possess RRM-like regions (67), have been implicated in the 
regulation of pre-mRNA splicing (50) and 3’-end processing (6, 68).  Studies from our lab have 
shown that hnRNP H’ and hnRNP F have some influence on the regulated cleavage and 
polyadenylation on the Ig heavy chain gene in B-lymphocytes (146).  Specifically, the elevated 
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 expression of hnRNP F relative to hnRNP H’ observed in memory B-cells reduced the binding 
activity of CstF-64 to GU-rich regions downstream of the Ig secretory poly(A) site (pAs) (146).  
However, reduced expression of hnRNP F in Ig-secreting plasma cells lifts its inhibitor effect on 
CstF-64 binding to the pAs allowing for an increase in secretory Ig production (146).  
Furthermore, we have shown that the transcriptional elongation factors PC4 and ELL2 are 
upregulated in plasma cell (data not shown).   PC4 and ELL2 are proteins that regulate RNAP-II 
transcription elongation rates [(51, 131) and reviewed in (130)].  Furthermore, PC4 has been 
shown to interact with the C-terminal domain of CstF-64 (18) and elongation factors have been 
shown to regulate the incorporation of skipped exons in in vivo splicing reactions (70).  Because 
of the implicated balance of splicing and cleavage/polyadenylation that occurs at the secretory 
poly(A) site of the Ig gene during B-cell development (15, 110), the roles PCR and ELL2 
specifically play in the selection of pAs in plasma cells is currently being investigated in our lab.  
3.3.  Factors that Contribute to Poly(A) Site Strength 
 The process of post-transcriptional pre-mRNA cleavage and polyadenylation, although 
essential in creating translationally competent mRNA, is a greatly under-appreciated contributor 
to the regulation of gene expression.  It has been estimated that only approximately 30% of all 
pre-mRNA transcripts made are successfully processed into a mature RNA species (69).  The 
frequency with which a poly(A) site is selected for the cleavage/polyadenylation reaction is 
greatly impacted by the strength of that poly(A) site.  One factor in cis that contributes to the 
strength of a poly(A) site is the deviation of the poly(A) signal from the consensus sequence 
AAUAAA (129, 151).  In fact, database analysis has shown that as many as 26% of all human 
genes possess poly(A) signals that deviate from the consensus AAUAAA (9) and that non-
consensus poly(A) signals are less often selected for 3’-end cleavage.  One study has discovered 
27 
 that a naturally occurring mutation in the poly(A) signal of alpha-2 globin to AAUAAG results 
in a significantly reduced accumulation of the gene product (64).  Other factors that contribute to 
the strength of a particular poly(A) site are the U-richness of upstream elements (USE) and 
downstream elements (DSE) that flank the poly(A) site (79, 98), and the distances the poly(A) 
signal and the GU-rich region are from the cleavage site (21).  More specifically, Chen et al. 
determined that cleavage cannot occur closer than 11 nor farther than 23 nucleotides from the 
poly(A) signal (21).  Furthermore, the GU-rich region is usually located between 10 and 30 
nucleotides downstream from the cleavage site [(21) and Figure 1A].  The efficiency of 3’-end 
processing drops dramatically when the distances of these cis-elements are located outside the 
ranges listed above.  An additional G-rich sequence (GRS) has been identified downstream of 
the CstF-64-binding GU-rich region.  Binding of the trans-acting factor hnRNP H’ to the GRS 
has demonstrated its contribution to the efficiency of the cleavage reaction (7).  Secondary 
structures of the 3’-UTR have also been implicated in contributing to the strength of viral 
poly(A) sites (152).  The frequency of cleavage/polyadenylation at a specific poly(A) site is also 
sensitive to the abundance and/or activity of trans-acting mRNA processing factors in the 
cellular environment (24, 139, 146).   
3.4.  Types of 3’-end regulation 
3.4.1. Differences in poly(A) tail length and shortening.   
 An additional regulatory influence the 3’-UTR has on gene expression pertains to the 
controlled length of the poly(A) tail.  The mouse form of tumor necrosis factor-α (TNF-α) 
mRNA demonstrates heterogeneous sizes between unstimulated and LPS-stimulated 
macrophages (31).  Closer analysis revealed that this heterogeneity results from changes in 
poly(A) tail length, where mRNA in unstimulated macrophages possesses an uncharacteristically 
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 short poly(A) tail.  Subsequent stimulation of the macrophages with LPS causes a marked 
increase in length of the poly(A) tail, resulting in enhanced mRNA stability, mRNA translation 
and protein production (31).  Similarly, an increase in the poly(A) tail length of the lysozyme 
gene transcript occurs as a result of LPS stimulation of the HD11 myelomonocytic cell line and 
significantly contributes to the accumulation of lysozyme mRNA (54). 
3.4.2. AU-rich Elements and Their Contribution to Gene Expression 
 The stability of a particular mRNA species can have a profound effect on the amount of 
protein product generated.  Excluding the contributions of transcription, the mere increase in the 
half-life of an mRNA has been shown to directly correlate with the amount of protein produced.  
Cis-elements that control mRNA half-life are typically AU-rich and often possess a consensus 
AUUUA core element [reviewed in (150)].  However, novel non-AUUUA containing AREs with 
looser sequence requirements have been identified (20, 107).  An abundance of trans-acting 
factors have been shown to bind to AREs and exhibit a variety of functions.  For example, 
binding of AUF1 to the monomer UUAUUUAUU promotes mRNA instability (36), while 
binding of HuR/HuA to AUUUA-containing mRNA elements increased the half-life of the 
mRNA (46, 97).  Interestingly, it has been shown that the TIA-1 and TIAR proteins are recruited 
to AREs and regulate translation on TNF-α  (59, 111).  COX-2 is a gene whose 3’-UTR 
possesses both mRNA stability elements and translational control elements (27) and 
demonstrates alternative polyadenylation under various cellular stimuli (101). 
3.4.3.   Alternative Polyadenylation 
 As the majority of eukaryotic RNAP-II transcribed mRNAs possess a poly(A) site that 
facilitates the addition of a poly(A) tail, scores of genes have been identified that possess more 
than one poly(A) site [reviewed in (45) and (140)].  The choice of one poly(A) site over another 
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 can have significant consequences on the expression and, in some cases, the structure of the final 
gene product (45). 
3.4.3.1. Consequences of Alternative polyadenylation 
 Database analysis of human ESTs has revealed that approximately 54% of human genes 
and 32% of mouse genes possess multiple poly(A) sites (140) and that selection of one poly(A) 
site over another is tissue-specific (10).  In general, selection of one poly(A) site over another on 
the same gene will result in an alteration of the 3’-end of the mature transcript.  According to the 
review by Edwalds-Gilbert et al., there are three categories of exon arrangement for a gene with 
multiple poly(A) sites [(45) and Figure 2].  The first arrangement type is called “Tandem 
Poly(A) Sites” and occurs when all poly(A) sites of a gene are located downstream from the last 
protein coding exon (Figure 2A).  In this case, alternative polyadenylation will alter the length of 
the 3’-UTR, but it will have no effect on the structure of the protein.  However, choice of one 
poly(A) site over another can determine the absence or presence of regulatory cis-elements 
(AREs) in the final transcript, thereby influencing mRNA half-life and translation.  The human 
and murine COX-2 genes are well-studied examples of how alternative polyadenylation can 
profoundly effect the expression of the gene by the elimination or retention of mRNA regulatory 
elements (26, 27, 101). 
 The second arrangement is called the “Composite Internal/terminal Exon” and occurs 
when a poly(A) site lies between two protein coding exons (Figure 2B).  Use of the more 
upstream poly(A) site will result in a shorter mature gene transcript that excludes downstream 
protein coding regions.  This would result in a C-terminal truncated form of the protein.  
However, skipping of the promoter-proximal poly(A) site occurs from the selection of an internal 
splice site that lies within the exon immediately upstream from the proximal poly(A) site.  
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 Selection of this upstream internal splice site will subsequently create a composite exon of the 
one containing the internal splice site and the downstream exon possessing the splice site 
acceptor.  This splicing event removes the proximal poly(A) site from the mature transcript along 
with the intron it lies within creating a composite exon and a larger form of the protein.  The 
most studied example of this form of alternative polyadenylation is the immunoglobulin gene in 
B-lymphocytes (see below).  Another example of the “Composite Internal/terminal Exon” 
alternative polyadenylation event is the NF-ATc transcription factor (25).  Selection of the distal 
poly(A) site occurs in naïve T-cells and creates a longer form of NF-ATc that exhibits reduced 
trans-activating effects.  In effector T-cells, the shorter form of NF-ATc is produced as a result of 
the increased selection of the promoter-proximal poly(A) site (25).  Another rather unique 
example occurs on the gene transcript for the FCA RNA-binding protein in Arabidopsis (82).  
FCA auto-regulates its expression when the full-length version of the protein (encoded by 13 
exons) binds, with the pre-mRNA 3’-end processing factor FY, to it’s own transcript and 
promotes the selection of the proximal poly(A) site (132).  This proximal poly(A) site selection 
results in cleavage and polyadenylation after the third exon of the transcript and produces a non-
functional truncated form of the protein.  The combination and timing of these two forms of FCA 
exhibit flowering control in Arabidopsis (116).   
 The third and final arrangement is called “Skipped Exons” and occurs on genes that 
contain two or more terminal exons each with their own downstream poly(A) site (Figure 2C).  
An alternative splicing event would then control which C-terminal exon is incorporated into the 
final gene product.  Therefore, two proteins with alternative C-terminal domains can be 
produced.  One example of this is the sex-determining doublesex (dsx) Drosophila melanogaster 
gene (63).  Splicing of exons 1, 2, 3, 5 and 6 result in the use of the exon-6 associated poly(A) 
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 site and results in a male phenotype.  Conversely, splicing of exons 1, 2, 3, and 4 result in the use 
of the exon-4 associated poly(A) site and results in a female phenotype (17). 
   
4. AIM 1 AND THE FIRST MANUSCRIPT FOR PUBLICATION:  Elevated Levels of the 
64-kDa Cleavage Stimulatory Factor (CstF-64) in LPS-Stimulated Macrophages Influence 
Gene Expression and Induce Alternative Poly(A) Site Selection (Long Form) 
4.1. ABSTRACT 
 LPS activation of murine RAW 264.7 macrophages influences the expression of multiple 
genes through transcriptional and post-transcriptional mechanisms.  We observed a 5-fold 
increase in CstF-64 expression following LPS treatment of RAW macrophages.  The increase in 
CstF-64 protein was specific in that several other factors involved in 3’-end processing were not 
affected by LPS stimulation.  Activation of RAW macrophages with LPS caused an increase in 
proximal poly(A) site selection within a reporter mini-gene containing two linked poly(A) sites 
that occurred concomitant with the increase in CstF-64 expression.  Furthermore, forced over-
expression of CstF-64 protein also induced alternative poly(A) site selection on the reporter 
mini-gene.  Microarray analysis performed on CstF-64 over-expressing RAW macrophages 
revealed that elevated levels of CstF-64 altered the expression of 52 genes, 15 of which showed 
similar changes in gene expression with LPS stimulation.  Sequence analysis of the 3’-
untranslated regions of these 52 genes revealed that over 46% possess multiple putative poly(A) 
sites.  Five of these 52 genes demonstrated alternative polyadenylation under both LPS-
stimulating and CstF-64 over-expressing conditions.  We conclude that the physiologically 
increased levels of CstF-64 observed in LPS-stimulated RAW macrophages contribute to the 
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 changes in expression and alternative polyadenylation of a number of genes, thus identifying 
another level of gene regulation that occurs in macrophages activated with LPS.  
4.2. INTRODUCTION 
 As a critical component of the innate immune system, macrophages respond to LPS from 
gram-negative bacteria by activating multiple signaling pathways that result in the rapid 
expression of pro-inflammatory cytokines and arachidonic acid metabolites.  The induced 
expression of many of these genes is attributed to the activation of transcription factors linked to 
Toll-like Receptor 4 (TLR4) related signal transduction pathways [reviewed in (104) and (143)].  
Aside from transcriptional contributions to gene expression in stimulated macrophages, post-
transcriptional mechanisms have also been shown to influence gene expression.  For example, 
the half-lives of TNF-α (31) and lysozyme (54) mRNAs are increased following LPS-
stimulation by a lengthening of the poly(A) tail.  Additionally, translational regulatory and/or 
mRNA stability elements have been identified in the 3’-untranslated region (3’-UTR) of human 
Il-1ra (153) and the LPS-inducible mRNAs encoding COX-2 (26, 27, 38) and TNF-α (76, 157). 
 Post-transcriptional pre-mRNA cleavage and polyadenylation, although essential in 
creating translationally competent mRNA, is a greatly under-appreciated contributor to the 
regulation of gene expression.  Because it has been estimated that only 30% of primary 
transcripts are polyadenylated (69), changes in 3’-end processing can have a profound effect on 
the amount of mature transcript produced.  The frequency with which a poly(A) site is selected 
for the cleavage/polyadenylation reaction is greatly impacted by the strength of that poly(A) site.  
Relevant to the present study, the frequency of cleavage/polyadenylation at a specific poly(A) 
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 site is also sensitive to the abundance and/or activity of trans-acting mRNA processing factors 
(24, 139, 146). 
  Studies of pre-mRNA processing in vitro have identified soluble trans-acting factors that 
are required for the cleavage and polyadenylation of gene transcripts.  The 160-kDa subunit of 
the tetrameric complex Cleavage Polyadenylation Specificity Factor (CPSF-160) binds to the 
consensus poly(A) signal AAUAAA that is located upstream of most functional poly(A) sites 
(96).  The Cleavage Stimulatory Factor (CstF) trimeric complex binds to the downstream 
element, a guanosine/uridine rich (GU-rich) region located downstream of the cleavage site (21) 
through its 64-kDa subunit (CstF-64) (138).  CstF-64 is comprised of a conserved RNA 
recognition motif (RRM) near its N-terminus (134) that binds preferentially to GU-rich regions 
(138).  Additional factors involved in pre-mRNA processing include Cleavage Factor Im and IIm 
and poly(A) polymerase (PAP).  We investigated the expression of CstF-64 and other 
cleavage/polyadenylation factors after stimulation of murine RAW 264.7 macrophages and 
murine bone marrow-derived macrophages (BMDMs) with LPS.  We found that LPS stimulation 
of RAW macrophages and murine BMDMs for 18 hours significantly increased CstF-64 protein 
expression. Because LPS stimulation of macrophages arrests the cell cycle (144, 145), the 
increase in CstF-64 protein expression occurs in the absence of cellular proliferation.  This is in 
contrast to the increases in CstF-64 expression observed in cells that were induced to proliferate 
(86, 139).  Because exogenous over-expression of CstF-64 in chicken B-lymphoma DT40 cells 
increased the use of the weak poly(A) site in the IgM heavy chain gene product (139), we 
hypothesized that the increased levels of CstF-64 observed in LPS-stimulated macrophages 
would have a similar effect on poly(A) site choice in many genes.  To test this, we first 
monitored the effect increased levels of CstF-64 in RAW macrophages had on poly(A) site 
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 choice by using a stably transfected reporter construct that contained two linked poly(A) sites.  
We observed an increase in the use of the weaker promoter-proximal poly(A) site in the reporter 
construct concomitant with an increase in CstF-64 protein levels following LPS stimulation.  
Because of the pleiotropic effects LPS stimulation has on macrophages, we stably over-
expressed CstF-64 in RAW macrophages to ascertain if CstF-64 specifically influences poly(A) 
site choice.  Indeed, RAW macrophages that stably over-express CstF-64 also demonstrated an 
increase in weak poly(A) site choice on the reporter construct.  We therefore hypothesized that 
induction of CstF-64 by LPS has a functional consequence for gene expression in activated 
macrophages.  To determine how many genes could be influenced, we performed microarray 
analysis of gene expression from RAW macrophages stably over-expressing CstF-64.  We found 
that 10-fold constitutive over-expression of CstF-64 in RAW macrophages significantly altered 
the expression of 52 genes, of which over 25% share common gene expression changes with 
LPS-stimulated RAW macrophages that exhibited a 5-fold maximal increase in CstF-64 
expression.  Closer analysis of five of the genes whose expression changed under both LPS-
stimulating and CstF-64 over-expressing conditions, Id-2, CTE-1, MMP-9, Tyki and Fabp-4, 
revealed that an alternative polyadenylation event does occur on these gene transcripts and that 
this change in poly(A) site choice may contribute to the abundance of mature transcripts by the 
removal of mRNA instability or addition of mRNA stability elements.  From this, we conclude 
that increases in expression of the pre-mRNA cleavage factor CstF-64 observed in LPS-
stimulated macrophages significantly contribute to changes in the expression of a multitude of 
genes through alternative polyadenylation events that occur in the context of infection by gram-
negative bacteria. 
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 4.3.  MATERIALS AND METHODS 
4.3.1. Cell Culture and Treatment 
 Murine BMDMs were derived from C57BL/6 bone marrow based on adherence.  In brief, 
the bone marrow from euthanized mice was flushed out of the femur and tibia bones with 
Dulbecco’s modified Eagle medium (DMEM)(Life Tech.) as previously described (13).  The 
bone marrow suspension was then washed twice with 2% FBS (Atlanta Biologicals, Norcross, 
GA) in PBS.  Non-tissue culture-treated petri dishes (Labtek) were seeded at 2 x 106 cells per 
dish in 25 ml of macrophage media (25% L-cell supernatant, 20% fetal bovine serum, 1% L-
glutamine, 1% pyruvate, and 1% nonessential amino acids). After 4 days in culture the cells were 
fed with 10 ml of fresh macrophage media.  BMDMs were grown until approximately 80% 
confluent, then treated with 100 ng/ml LPS (Sigma, strain O111:B4) for 18 hours.   
 RAW 264.7 murine macrophages (ATCC) were maintained in DMEM with 10% FBS, 10 
mM HEPES, and 0.1% penicillin-streptomycin.  Cells were grown in culture flasks until 
approximately 80% confluent, then treated with 100 ng/ml LPS for 18.  Stably transfected 
polyclonal cell lines were also maintained under G418-neomycin (Cellgro) and/or mycophenolic 
acid (MPA) (GIBCO-BRL) antibiotic pressure, depending on the incorporated plasmid(s). 
4.3.2. Western Blot Analysis and Antibodies 
 Ten micrograms of whole cell lysates were loaded per lane unless otherwise indicated.  
Proteins were visualized after treatment of the appropriate secondary antibody with the 
Renaissance™ Chemiluminescence system (NEN) according to manufacture’s instructions.  All 
Western blots were re-probed with GAPDH to demonstrate equal loading between lanes.  
Quantification of signal intensities was performed on the Kodak Imaging Station 2000R and 
associated 1D analysis software.  CstF-64 expression was normalized to the GAPDH signal on 
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 the same blot.  Rabbit antiserum recognizing murine CstF-64 was generated for peptide 
CIAMLPPEQRQSILILKEQIQKSTGAP, corresponding to the 26 C-terminal amino acids (a 
cysteine residue was added to the N-terminus to aid KLH coupling).  Injections and collections 
of serum were performed at Charles River Pharmservices.  The anti-CstF-50 and anti-CstF-77 
rabbit anti-peptide antibodies were made in our laboratory as previously described (86) as well as 
anti-hnRNP F and anti-hnRNP H/H’ rabbit polyclonal antibodies (146).  Anti-CPSF-30 (rabbit 
polyclonal) and anti-CPSF-100 (rabbit polyclonal) were generously provided by Walter Keller 
(University of Basel).  We purchased the mouse monoclonal anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) antibody from Chemicon.  HRP-conjugated secondary antibodies for 
mouse IgG (Sigma A7282) and rabbit IgG (Sigma A0545) were used according to 
manufacturer’s instructions.   
4.3.3. Measurement of Cell Proliferation by [3H] Thymidine Incorporation 
 RAW macrophages were plated in 35-mm culture dishes and allowed to grow to ~80% 
confluency (3 x10 6 cells/plate) with 5 ml of medium and left untreated or stimulated with LPS. 
To measure DNA synthesis (99), 10 μCi of [3H]dT (6.7 Ci/mmole) in aqueous solution was 
added to the cells covered with 3 ml of medium.  After 6, 14.5 and 18 hours at 370 C, the 
medium was removed and the cells were washed twice with 1X PBS and then trypsinized.  Cells 
were collected, spun down and resuspended in 1 ml PBS; cell number was determined from an 
aliquot.  Triplicate 200-μl samples were removed.  Nucleic acids were precipitated by 10% 
trichloroacetic acid (TCA) and collected on glass fiber filters.  Radioactivity was determined 
using scintillation counting and the [3H]dT incorporated was normalized for cell counts. 
4.3.4. RNA Isolation and Poly(A)+ RNA Purification 
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  Total RNA was extracted from RAW macrophages using the Ultraspec RNA isolation 
system (Biotecx, Houston, TX) according to the manufacturer’s instructions.  Poly(A)+ RNA was 
purified from total RNA using Oligo(dT) Cellulose (Stratagene) according to manufacturer’s 
instructions.  Purified mRNA was suspended in DEPC (Sigma) treated water and 2 volumes 95% 
ethanol and stored at -20°C until needed. 
4.3.5.  T2 RNase Protection Assay 
 RAW macrophages were stably transfected with a guanine phosphotransferase (gpt)-
containing plasmid with linked poly(A) sites and cultured in the presence of MPA,  as previously 
described (87).  The gpt gene has a weak poly(A) site from the α2-globin gene upstream of the 
strong SV40 late poly(A) site that is contained in the pSV2gpt vector (95).  The RAW 
macrophages that contain the gpt-encoding reporter gene are subsequently referred to as RAW-
α2 macrophages. RNase protection assays were performed using an anti-sense radiolabeled 
riboprobe that hybridizes to the 3’-UTR of the gpt mRNA to detect poly(A) site usage (see 
Figure 5A).  The riboprobe was synthesized with a specific activity of ~7.3x107 cpm/μg as 
previously described (87).  Radioactivity contained in the proximal and distal poly(A) site 
protected fragments was measured with a PhosphorImager (MD 860, Molecular Dynamics, CA) 
and quantification was performed using ImageQuant software (Molecular Dynamics).  The 
proximal/distal ratio (P/D) was computed using Office XP Excel (Microsoft) and all ratios from 
experimental samples were normalized to the untreated control within each experiment.  
Statistical significance of the data was calculated using SEM and the paired student’s t-test on 
from two to three trials performed from at least two separate RNA preparations, for a total of five 
trials from each condition. 
4.3.6.  Over-expression of CstF-64 in RAW 264.7 Murine Macrophages 
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  The complete open reading frame of human CstF-64 [CstF-2] was cloned into the EcoR I 
sites of pBluescript II SK (+) (pBSSK-64) (CAM 375) using EcoR I linkers as described (134) 
and was a gift from Jim Manley (Columbia University).  Having difficulties with CMV promoter 
activity in RAW 264.7 macrophages, we used pEF1/Myc-His B (Invitrogen), a plasmid driven 
by the human EF-1α promoter that has been shown to achieve high levels of exogenous gene 
expression in RAW macrophages (72).  A double digest of both pBSSK-64 and pEF1/Myc-His B 
with Kpn I (Boehringer Mannheim) and Xba I (Boehringer Mannheim) was performed followed 
by gel purification of an ~2.0 kb fragment from pBSSK-64 and an ~6.5 kb fragment from 
pEF1/Myc-His B.  Ligation of the purified plasmid fragments with T4 DNA ligase (NEB) was 
done in a 16°C waterbath overnight followed by direct transformation of the ligation reactions 
into One Shot MAX Efficiency DH5α-1 competent cells (Invitrogen) resulting in a sufficient 
number of colonies on Penicillin G (Sigma) LB plates for miniprep screenings.  The resulting 
CstF-64 expression plasmid is called pEF1-64 (CAM 508).   
 RAW-α2 macrophages were stably transfected using FuGene 6 (Roche) with pEF1-64 or 
pEF1-lacZ, as a control, as instructed by the manufacturer.  In brief, RAW-α2 macrophages were 
seeded in 6-well culture dishes and grown until approximately 75% confluent.  Macrophages 
were transfected with a FuGene 6 (μl):DNA ratio (μg) of 8:1 in the presence of serum.  At day 3 
post-transfection, the cells were split and placed under selective pressure of 400 μg/ml G418 
sulfate (Cellgro) and MPA.  Media was changed as needed.  After 18 days of selective pressure, 
poly-clonal populations of RAW-α2-64 or RAW-α2-LacZ cells were stored in liquid nitrogen. 
Raw-α2-64 cultures were assessed for constitutive CstF-64 expression by Western blot. 
4.3.7. Affymetrix Gene Chip Analysis 
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  Three unique samples of RNA from each treatment (untreated, 100 ng/ml LPS treated for 
18 hours and constitutively over-expressed CstF-64) were used to create biotinylated cRNA at 
the PittArray DNA microarray facility of the Genomics and Proteomics Core Laboratories 
(GPLC) of the University of Pittsburgh.  Fifteen micrograms of fragmented RNA were 
hybridized to the murine 430A Affymetrix gene chip according to manufacturer’s instructions. 
Affymetrix gene chips were scanned using MAS 5.0 (Affymetrix) to obtain raw expression 
values and signal calls (i.e. Present, Absent or Marginal) for each probe set on the array chip 
(GEO Accession No. GSE2002).  Data sets of intensities for 22,690 probe sets per expression 
array were analyzed by BRB-ArrayTools v3.02 (http://linus.nci.nih.gov/BRB-ArrayTools.html).  
Data was filtered through the software using the following parameters: all signals with an 
intensity value below 10 were given a threshold value of 10 and each array was normalized to 
the 64 Affymetrix control probe sets intrinsic to the murine 430A chip.  Furthermore, probe sets 
were excluded from all arrays under the following conditions: when less than 30% (i.e. 0, 1, or 2 
of 9) of expression data values have a 2-fold change in either direction from the probe set’s 
median value or when 50% or more of the data for a probe set is missing or absent.  Using these 
filtering parameters, 1145 probe sets passed the criteria.  To identify genes that demonstrated 
statistically significant changes in expression between control and treatment (LPS or CstF-64 
over-expressing) groups, the probe sets that had passed the initial filtering process also had to 
pass the following criteria: 1)  the mean of the treatment group must have demonstrated a 2-fold 
increase or decrease in signal over the mean of the control group, 2) the signal values for each 
probe set must have passed a statistical univariant significance test with p-value<0.05 with 1000 
permutations and specifying a random variance for each calculation (Class Comparison feature 
of BRB Array Tools), and 3) a probe set was excluded if it scored an Absent call in at least 2 out 
40 
 of 3 measurements for the treatment group (for up-regulated genes) or scored an Absent call in at 
least 2 out of 3 measurements for the control group (for down-regulated genes).  Marginal calls 
were considered Absent for this criterion.   
 A statistical algorithm was designed to test if the genetic overlap between LPS-stimulated 
and CstF-64 over-expressing conditions was beyond the random chance of occurrence.  Briefly, 
the test was designed with one set consisting of a draw of 515 random numbers from a pool of 
22,690 and another set consisting of a draw of 52 random numbers again from a pool of 22,690 
numbers.  The test was run 30,000 times looking for the number of random chance over-laps 
from the two sets of randomly selected numbers.  A graph depicting the frequency of zero 
numbers of overlaps, one number, two numbers, etc. up to fourteen numbers from 30,000 trials 
was constructed using Microsoft Excel and appears in Figure 10. 
4.3.8. Semi-quantitative RT-PCR 
 Single-stranded cDNA was synthesized for each condition from 10 μg total cellular RNA 
using the Superscript First-Strand Synthesis System for RT-PCR with oligo dT primers 
(Invitrogen).  PCR reaction mixtures were assembled in quadruplicate for each primer pair using 
either 0.5 or 1.0 μl cDNA, 50 pmol of each primer, 800 nM dNTP mix, 5 μl 10X Taq buffer and 
2.5 Units Taq (Genechoice) in 50 μl volumes.  At the conclusion of 20, 25 and 30 cycles, 
reaction tubes were removed from the PCR machine and placed on a heat block for a 7 minute, 
72°C final extension.  The last tube of each set of four reactions was allowed to complete the 
PCR program to 35 cycles on the thermocycler.  Ten microliter aliquots of the PCR reactions 
representing 20, 25, 30 and 35 cycles were loaded on 1.5% agarose gels, stained with ethidium 
bromide, and visualized using the Kodak Imaging Station 2000R.  The HPRT gene, which is 
shown to be equally expressed between the RAW macrophage culture conditions on the 
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 microarray data (GSE2002) and has been previously shown to be a good candidate for RT-PCR 
loading control (49) was used to demonstrate equal cDNA concentrations between preparations.  
The nucleotide sequences for the primer pairs used for semi-quantitative RT-PCR are listed in 
Table 1.  Primer sequences were designed from GenBank cDNA sequences using Primer3 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) unless otherwise indicated. 
4.3.9. PCR-based Identification of Alternative Polyadenylation (MRP-PCR) 
 A multiple reverse primer PCR (MRP-PCR) approach was implemented to identify a 
poly(A) site switching event in the 3’-UTR of selected genes.  This MRP-PCR approach used 
one primer pair that lies upstream of all putative poly(A) sites that would amplify all gene 
transcripts regardless of the poly(A) site usage.  A second anti-sense primer that targets the 
downstream sequence between two putative poly(A) sites was used in conjunction with the 
common sense primer to identify the abundance of gene transcript that had been processed at the 
distal poly(A) site.  The longest GenBank sequence for each gene that demonstrated significant 
2-fold or greater changes under CstF-64 over-expressing conditions was scrutinized for possible 
alternative poly(A) sites and AU-rich elements.  A putative poly(A) site was considered one that 
contains either a consensus AAUAAA or non-consensus AUUAAA poly(A) signal followed 30-
60 nucleotides downstream by a GU-rich element that possess at least two contiguous uridines.  
Possible AU-rich regulatory elements were based on the functional AU-rich motifs listed in the 
review by Carol Wilusz et al. (150).  Using these criteria, five candidate genes were chosen to 
test for the possibility of alternative polyadenylation within their 3’-UTR: Id-2, CTE-1, MMP-9, 
Tyki, and Fabp-4.  Single stranded cDNA from each condition was subject to PCR using a sense 
primer (F) and an antisense primer (R1) that lies upstream to all putative poly(A) sites or an 
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 antisense primer (R2) that lies between the putative proximal and putative distal poly(A) sites 
(Figure 11).  The nucleotide sequences used for MRP-PCR are listed in Table 4. 
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 4.4.  RESULTS 
4.4.1. LPS stimulation of RAW macrophages specifically increases CstF-64 protein 
expression. 
 We treated RAW macrophages with increasing amounts of LPS for 18 hours and 
measured CstF-64 protein expression by Western blot.  We observed that CstF-64 protein levels 
increased with LPS stimulation of RAW macrophages and that this increase is LPS dose-
dependent (Figure 3A).  The induced expression of CstF-64 plateaued at 100 ng/ml LPS (Figure 
3A).  A semi-quantitative Western blot revealed that 100 ng/ml LPS stimulation of RAW 
macrophages for 18 hours resulted in a 4-5 fold increase in CstF-64 expression (Figure 3B).  
Quantification of the luminescence from the Western blot using the Kodak Imaging Station 
2000R corroborated the semi-quantitative Western data by measuring the induction of CstF-64 
with 100 ng/ml LPS at 5-fold that of unstimulated RAW 264.7 macrophages (see Methods).  
Therefore, we conclude that LPS treatment of RAW macrophages increased CstF-64 protein 
expression approximately 5-fold.  From these observations, 100 ng/ml LPS treatment for 18 
hours was used for all subsequent experiments.   
 LPS stimulation of B lymphocytes not only increases CstF-64 expression (139), but also 
induces cell cycle progression resulting in rapid clonal expansion (117).  We have previously 
shown that CstF-64 protein levels increase when serum-starved, resting mouse 3T3 fibroblasts 
were induced into the S-phase of the cell cycle by the addition of serum-containing media (86).  
Both of these examples demonstrate that CstF-64 protein levels increase in the presence of cell 
cycle progression.  Notably, LPS stimulation of macrophages induces cell cycle arrest (144, 
145).  By monitoring the incorporation of [3H] thymidine under LPS stimulating conditions, we 
confirmed cell-cycle arrest upon LPS treatment of RAW macrophages (Figure 3C).  Therefore, 
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 we conclude that LPS stimulation of RAW macrophages induces a 5-fold increase in CstF-64 
protein expression that is not obligatorily coupled to the cell cycle.   
 The protein levels of several other cleavage/polyadenylation factors were also assessed 
under LPS stimulating conditions.  Western blots showed no measurable change for CPSF-30, 
CstF-77, and CF-Im-68 in LPS stimulated RAW macrophages (Figure 4, left panel).  
Furthermore, the expression of hnRNP H/H’ and hnRNP F, RNA processing factors we have 
found to have effects on cleavage/polyadenylation in B lymphocytes and plasma cells (146), also 
remained unchanged (Figure 4, left panel).  To determine if the specific increase in CstF-64 
protein expression observed in the transformed RAW cell line also occurred in primary 
macrophages, we stimulated murine bone marrow derived macrophages (BMDMs) with 100 
ng/ml LPS for 18 hours.  CstF-64 protein was increased approximately 10-fold in murine 
BMDMs stimulated with 100 ng/ml LPS (Figure 4, right panel).  As with the RAW macrophage 
cell line, no other mRNA processing factors assayed changed expression upon LPS stimulation 
(Figure 4, right panel).  Studies have shown that CstF-64 is the limiting component for CstF 
trimer formation, the active form of CstF (86, 139).  Therefore, we hypothesized that the specific 
increase in CstF-64 observed in LPS stimulated RAW macrophages and BMDMs has a 
significant impact on 3’-mRNA processing and would thus alter the expression of specific genes. 
4.4.2. LPS stimulation of RAW macrophages induces a poly(A) site switch on a 
reporter mini-gene.  
 Previous studies have shown that increases in CstF-64 expression in LPS-stimulated 
splenic B-lymphocytes are associated with an increase in weak poly(A) site selection on the IgM 
heavy chain gene (139).  With the specific increase in CstF-64 protein observed in LPS-
stimulated macrophages (Figure 4), we hypothesized that the nuclear mRNA processing 
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 machinery has a heightened level of mRNA 3’-end processing in activated macrophages that 
results in an increased selection of weak poly(A) sites.  To test this, we stably transfected into the 
RAW macrophage cell line a reporter mini-gene that possesses two contiguous poly(A) sites of 
differing strengths in its 3’-UTR (Figure 5A).  The reporter mini-gene codes for the bacterial 
gene guanosyl phosphotransferase (gpt) and is under the control of the SV40 early promoter 
(95).  Stable incorporation of the mini-gene in the RAW macrophages is thus conferred through 
mycophenolic acid (MPA) resistance.  Contained in the 3’-UTR of the mini-gene is the weak α2-
globin poly(A) site upstream of the strong SV40 early poly(A) site (Figure 5A).  The RAW 
macrophage cell line that stably expresses the α2-globin poly(A) site containing gpt min-gene is 
referred to as RAW-α2.  LPS-stimulation of RAW-α2 macrophages exhibited the same protein 
expression levels for CstF-64 and the other cleavage/polyadenylation factors measured in 
untransfected RAW macrophages (Figure 4 and data not shown).  Previous studies using this 
same reporter mini-gene in different B-cell lines demonstrated that the upstream, weaker poly(A) 
site was selected more often in the plasma cell environment which exhibits heightened 3’-end 
processing activity than in memory B-cell lines (87).  Here, we wished to test the hypothesis that 
the LPS-stimulation of RAW macrophages that exhibit elevated levels of CstF-64 expression 
induces an increase in weak promoter-proximal poly(A) site selection on the reporter mini-gene. 
 We performed T2 RNase protection assays on mRNA isolated from unstimulated or LPS-
stimulated RAW-α2 macrophages to measure poly(A) site selection within the 3’-UTR of the gpt 
reporter mini-gene, as previously described (87).  The full-length probe is 564 nucleotides in 
length.  A protected fragment 487 nucleotides in length indicates that the promoter-distal poly(A) 
site was chosen for mRNA cleavage and polyadenylation (Figure 5A).  Likewise, a protected 
fragment 185 nucleotides in length indicates the choice of the promoter-proximal poly(A) site for 
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 mRNA processing.  Importantly, the poly(A)-containing RNA for the T2 RNase protection assay 
was harvested at 18 hours after LPS stimulation.  This allowed the cells to achieve the 5-fold 
increase in CstF-64 protein expression we had previously observed (Figure 3B).  A 
representative result of the RNase protection experiment displays the protected, radio-labeled 
riboprobe fragments separated on a denaturing urea gel (Figure 5B). Quantification of the 
amount of transcripts corresponding to each protected fragment was performed using a 
Phosphorimager and the ImageQuant software package (see Methods).  By calculating the 
proximal to distal ratio (P/D) of the protected fragments, we were able to obtain a relative 
measurement of poly(A) site usage that can be compared between experiments and treatments.  
An increase in P/D for a particular treatment indicates that there is an increase in selection of the 
weaker promoter-proximal poly(A) site of the gpt mini-gene transcripts relative to the stronger 
promoter-distal poly(A) site.  Likewise, a decrease in P/D would indicate increased selection of 
the stronger promoter-distal poly(A) site.  Although the absolute values of transcripts processed 
at the upstream and downstream poly(A) sites vary between experiments, the P/D ratio between 
samples in a particular experiment were reproducible.  By normalizing the P/D for LPS-treated 
RAW-α2 macrophages relative to the unstimulated control, we measured a 2.4-fold increase in 
the P/D in macrophages stimulated with LPS indicating an increase in upstream, weak poly(A) 
site selection (Figure 5C).  Because of the steady-state pool of mature gpt transcripts that is in the 
cell prior to LPS-induced elevation of CstF-64 protein, we believe that the observed 2.4-fold 
increase in P/D is a conservative measurement of increased mRNA 3’-end processing associated 
with LPS-induced CstF-64 protein levels.   Elevated levels of CstF-64 therefore correlate with an 
increased selection of the promoter-proximal poly(A) site in LPS-treated RAW-α2 macrophages. 
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 4.4.3. Over-expression of CstF-64 in RAW macrophages induces a poly(A) site 
switch on a reporter mini-gene. 
 Over-expression of CstF-64 in chicken B-lymphoma DT40 cells demonstrated an 
increase in weak poly(A) site selection of the Ig heavy-chain gene, resulting in an increase in the 
secretory form of the IgM transcript (139).  Likewise, over-expression of CstF-64 in NIH-3T3 
cells increases promoter-proximal poly(A) site selection in Testis Brain RNA-binding protein 
(24).  In order for us to be certain that the observed 5-fold increase in CstF-64 protein expression 
observed in LPS-stimulated RAW-α2 macrophages is responsible for the switch in poly(A) site 
selection on the gpt transcript, we stably over-expressed CstF-64 in RAW-α2 macrophages.  
Using a mammalian expression vector driven by the human EF1α promoter, we achieved a 
stable 10-fold increase in CstF-64 protein expression in RAW-α2 macrophages as quantified 
using the Kodak Imaging Station 2000R (see Methods and Figure 6A). Cells exhibiting 
constitutive over-expression of CstF-64 in RAW-α2 macrophages are referred to as the RAW-
α2-64 macrophage cell line.  Because it was the human form of CstF-64 that was constitutively 
over-expressed in the murine RAW 264.7 macrophage cell line, it is important to explain the 
differences between the mouse and human forms of CstF-64.  There is 94% amino acid sequence 
homology between the two forms of the protein (Figure 7).  More importantly, the functional 
portions of the protein have a much greater degree of homology.  For example, the RRM of the 
human protein is an exact match to the mouse form.  Furthermore, the hinge region that is 
responsible for binding to CstF-77 (136) has only one amino acid difference (serine to threonine; 
S118T) as does the carboxy-terminal domain of the protein (asparagine to serine; N528S) that as 
been shown to bind PC4 (18).  One other notable difference between the human and mouse form 
of CstF-64 is a triple proline insert that appears in the mouse form and is located downstream of 
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 Proline 350.  The effect of this extra proline triplet in the mouse protein has not been functionally 
characterized.  However, because the proline triplet lies within the less conserved 
proline/glycine-rich region that has yet to be functionally characterized, we believe the lack of 
these prolines in the over-expressed human form of CstF-64 will not detract from our studies of 
cleavage and polyadenylation in the murine cell line.  Because of the sequence similarities 
between the human and mouse forms of CstF-64, we believed that using the human form of 
CstF-64 in the murine RAW 264.7 macrophage cell line was an acceptable approach to achieve 
CstF-64 over-expression. 
 Western blots for the same array of proteins measured in the LPS studies (Figure 4) 
revealed no significant changes in these proteins under CstF-64 over-expressing conditions (data 
not shown).  In the RAW-α2-64 macrophages, we measured the effect increased levels of CstF-
64 protein had on poly(A) site selection by T2 RNase protection assays, as previously performed 
in the LPS-stimulation studies.  From our observations that LPS stimulation of RAW-α2 
macrophages increased CstF-64 protein expression and induced an increase in weak promoter-
proximal poly(A) site selection of our gpt reporter mini-gene, we hypothesized that over-
expression of CstF-64 alone would induce some observable increase in weak poly(A) site 
selection of the gpt reporter mini-gene.  We found that in the RAW-α2 macrophages that 
constitutively over-expression CstF-64, there was a 2.0-fold increase in the P/D ratio compared 
to unstimulated RAW-α2 macrophages (Figure 6B).  From these observations, it is clear that 
increased levels of CstF-64 protein alone have as significant an impact on poly(A) site choice as 
that measured under LPS stimulating conditions. 
 We conclude that elevated levels of CstF-64 protein expression in LPS-stimulated 
macrophages contributes to an increase in weak poly(A) site selection in RAW macrophages on 
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 the gpt reporter mini-gene.  From this, we reasoned that elevated levels of CstF-64 might have an 
effect on macrophage gene expression in the context of LPS stimulation. 
4.4.4. Microarray analysis reveals that forced over-expression of CstF-64 in RAW 
macrophages changes the expression of multiple genes. 
 We have demonstrated that both LPS stimulation and CstF-64 over-expression induced 
an increase in the selection of weak poly(A) sites in RAW macrophages on a reporter mini-gene 
that possesses two contiguous poly(A) sites of varying strengths.  Because of the impact that 
post-transcriptional processing has on gene expression, we compared global gene expression 
profiles in unstimulated, LPS-stimulated, and CstF-64 over-expressing RAW macrophages using 
the microarray technique.  RNA from untreated and CstF-64 over-expressing RAW macrophages 
and RAW macrophages stimulated with 100 ng/ml LPS for 18 hours was used for microarray 
analysis.  Using Affymetrix murine gene chip 430A, 22690 genes were examined from 3 
replicates of each treatment group (see Methods).  Statistical analysis was performed as 
described in Methods using BRB Array Tools developed by the National Cancer Institute 
(http://linus.nci.nih.gov/BRB-ArrayTools.html).   
 Treatment of RAW macrophages with 100 ng/ml LPS for 18 hours resulted in a 
statistically significant 2-fold or greater increase in the expression of 245 known genes and 45 
expressed sequence tags (ESTs) and a 2-fold or greater decrease in the expression of 162 known 
genes and 63 ESTs (Appendix A and B).  To ensure that our data sets from LPS-stimulated 
macrophages accurately represent an activated macrophage gene expression profile, we 
performed semi-quantitative RT-PCR using the same RNA sample used for the microarray 
experiment to measure TNF-α, iNOS and COX-2 transcript levels, all of which are identifiers of 
macrophage activation.  As with the microarray data, we have shown that TNF-α, iNOS and 
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 COX-2 transcript levels all significantly increased in the presence of LPS stimulation (Figure 8).  
We also confirmed the change in expression of several other genes by RT-PCR (Figure 8).  None 
of the CPSF subunits, poly(A) polymerase (PAP), or poly(A) tract binding protein (PABP) 
changed expression upon LPS stimulation  (Appendix A and B).  Probes for CstF-77, CstF-50, 
hnRNP F, hnRNP H/H’ or CF-Im-68 were not included on the Affymetrix 430A murine gene 
chip.   
 Microarray analysis of RAW-α2 macrophages over-expressing CstF-64 protein 
approximately 10-fold over basal levels showed a statistically significant 2-fold or greater 
increase in the expression of 21 known genes and 2 ESTs, of which 12 of the genes demonstrated 
a significant increase in LPS stimulation (Table 2 and Figure 9).  Likewise, 29 known genes 
showed a 2-fold or greater decrease in the expression with CstF-64 over-expression, of which 3 
of the genes also demonstrated a significant decrease with LPS stimulation (Table 3 and Figure 
9).  We developed a statistical algorithm that tested the chance that the selection of 15 genes 
from each experimental pool (i.e. LPS-stimulated and CstF-64 over-expressed) would occur at 
random (see Methods).  Our results clearly show that the 15 genes that change expression in both 
LPS-stimulated and CstF-64 over-expressing RAW macrophages did not occur at random and 
was thus a real biological observation (Figure 10).  Analysis of the 3’-UTRs of all 52 genes that 
change expression under CstF-64 over-expression revealed that over 46% of them (24 of 52) 
possess two or more putative poly(A) sites (Table 2 and 3).  Putative poly(A) sites were chosen 
by their consensus AAUAAA or nonconsensus AUUAAA poly(A) signal (shown to be greater 
than 58% and 14%, respectively, of the functional poly(A) signals determined from human 
database analysis (9)) and an associated GU-rich region that possesses at least two contiguous 
uridines which lies within 20-60 nucleotides downstream of the poly(A) signal.  Many of these 
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 genes that may support an alternative polyadenylation event also possess adenosine/uridine 
(AU)-rich elements (AREs) that may, themselves, dictate mRNA stability or translatability 
[reviewed in (150) and (157)]. 
 Notably, we did not detect increases in CstF-64 gene expression in LPS-stimulated RAW 
macrophages by microarray analysis.  This result was not unexpected because repeated attempts 
to measure changes in CstF-64 gene expression in LPS-stimulated RAW macrophages by 
Northern blot or RT-PCR demonstrated no change in CstF-64 message (data not shown).  This 
result led us to believe that the observed increase in CstF-64 protein is the result of a post-
transcriptional/translational control mechanism, a characteristic of other genes in LPS-stimulated 
macrophages (27, 157).  Furthermore, we were unable to measure increases in CstF-64 gene 
expression in RAW-α2-64 macrophages by microarray because 9 out of the 11 probe pairs in the 
CstF-64 probe set for the murine 430A gene chip target 3’-UTR genomic sequences (Affymetrix 
NETAFFXTM Analysis Center, http://www.affymetrix.com/analysis/index.affx) which are not 
contained in the CstF-64 expression vector that is stably incorporated into the RAW macrophage 
genome.  Nevertheless, the Western blot data for both LPS-stimulated (Figures 3A and 3B) and 
CstF-64 over-expressing (Figure 6A) RAW macrophages firmly established that protein levels 
are indeed increased over basal levels under both conditions.  
 Therefore, we conclude that increased expression of CstF-64 contributes, in part, to the 
gene expression changes that accompany the late macrophage response to LPS stimulation.  
4.4.5. Increased levels of CstF-64 induce alternative polyadenylation on several 
LPS-responsive genes in RAW macrophages 
 Interested in whether elevated levels of CstF-64 in the RAW macrophage influence the 
poly(A) site choice of LPS-responsive genes, we set out to detect by PCR a possible poly(A) site 
52 
 switch on genes that possess multiple putative poly(A) sites, have an AU-rich element (ARE), 
and whose expression changes in both LPS-stimulated and CstF-64 over-expressing RAW 
macrophages.   Figure 11A describes our multiple reverse primer PCR (MRP-PCR) approach to 
detect the use of alternative poly(A) sites under LPS-stimulating and CstF-64 over-expressing 
conditions.  By pairing the common forward primer (F) with the upstream reverse primer (R1), 
we were able to detect all of the mature transcripts regardless of which poly(A) site was chosen.  
Furthermore, by pairing the F primer with the downstream reverse primer (R2), we were able to 
detect the portion of the mature gene transcript that was cleaved and polyadenylated at a more 
distal poly(A) site (FR2). 
 Interestingly, for Id-2, CTE-1 and MMP-9, we were able to detect a reduction in FR2 
PCR product compared to FR1 PCR product, which represents total gene expression, under LPS-
stimulating conditions compared to the untreated control (Figure 11B).  Likewise, we also 
detected a reduction in FR2 PCR product for Id-2 and MMP-9 under CstF-64 over-expressing 
conditions compared to FR1 PCR product (Figure 11B).  Since we demonstrated an increase in 
the total gene transcript using the FR1 primer pair for Id-2 and MMP-9 under LPS-stimulating 
and CstF-64 over-expressing conditions, this proves that the decrease in FR2 PCR product 
observed is the result of an increase in proximal poly(A) site selection, an event similar to what 
was observed on our reporter mini-gene (Figure 5).  Because total CTE-1 expression is greatly 
reduced under CstF-64 over-expressing conditions (Table 3 and Figure 8), we were unable to 
determine if loss of the FR2 PCR product was due to an authentic poly(A) site switch or that the 
switch did not occur and the FR2 PCR product was merely undetectable due to low abundance of 
over-all gene product.   
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  Unexpectedly, we observed an increase in FR2 PCR product under LPS-stimulating 
conditions for Fabp-4 and Tyki (Figure 11C).  Likewise, a similar increase in FR2 PCR product 
was observed under CstF-64 over-expressing conditions (Figure 11C).  Counterintuitive to our 
observation of increased proximal poly(A) site selection under elevated levels of CstF-64 
(Figures 5 and 11B), these results clearly demonstrate that there is an increase in the distal 
poly(A) site selection for Fabp-4 and Tyki under LPS-stimulating conditions and this can be 
contributed, in part, to elevated levels of CstF-64. 
4.4.6. Genes that demonstrate alternative polyadenylation with CstF-64 increases 
possess putative regulatory elements within their 3’-UTR. 
 By identifying a poly(A) site switch in both Id-2, CTE-1, MMP-9, Tyki and Fabp-4 under 
LPS-stimulating conditions, we focused our attention on the region between the proximal and 
distal poly(A) sites of these gene transcripts in the hopes to gain some insight on a biological 
effect a change in poly(A) site use would have on these genes’ expression.   In Figure 12, we 
highlight the putative AREs of all five genes that lies between the proximal and distal poly(A) 
sites.  Interestingly, all of these regions possess AU-rich elements and/or U-rich regions that 
resemble biologically functional AREs that have been previously described to influence mRNA 
half-life and/or translation [(150) and Table 5].    
 From this, we conclude that the physiological increase in CstF-64 protein through LPS 
stimulation causes, in part, a shift in poly(A) site usage on LPS-inducible genes and that this shift 
in poly(A) site usage may contribute to the final amount of the gene transcript and influence the 
translatability of that transcript, thus profoundly effecting the amount of protein produced. 
4.4.7. Post-transcriptional regulation of CstF-64 in LPS-stimulated RAW 
macrophages 
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  We reported an increase in CstF-64 protein approximately 5-fold over basal levels in 
RAW 264.7 murine macrophages stimulated with LPS (Figure 3).  However, we did not detect 
an increase in CstF-64 gene transcript with LPS stimulation by Northern Blot, RT-PCR (data not 
shown), or microarray (Appendix A).  Because we have consistently observed increases in 
protein expression in the absence of mRNA increases, we hypothesize that the increase in CstF-
64 protein results from either the accumulation of CstF-64 stemming from an increase in the 
protein half-life or an increase in translation of the steady-state mRNA under LPS-stimulating 
conditions.  Closer scrutiny of the 3’-UTR of CstF-64 mRNA revealed that it contains two 
poly(A) sites with an ARE core sequence and associated U-rich elements that lie immediately 
upstream of the distal poly(A) site (Figure 13).  Interestingly, previous work from our lab has 
shown by Northern Blot that there are two main species of CstF-64 mRNA in mouse B-
lymphocytes and that the increase in a short 2.2 kb form is observed over a longer 4.2 kb form in 
plasma cells relative to naïve and memory B-cells (Souan MS thesis).   Support for the existence 
of two forms of CstF-64 mRNA also stems from two GenBank entries for the mouse form of 
CstF-64 that exhibit different lengths.  The shorter form of the mouse CstF-64 transcript 
(Accession AF317552) uses a poly(A) site that creates an approximate 2.1 kb form of the 
transcript.   The longer form of the mouse CstF-64 transcript (Accession NM_133196) uses a 
distal poly(A) that creates an approximate 4.4 kb transcript.  Because we have not assessed the 
abundance of CstF-64 mRNA by Northern Blot in RAW 264.7 macrophages, we cannot say 
whether there exist alternative forms of the message that stem from a change in poly(A) site 
usage occurring under LPS-stimulating conditions.  However, because the amount of mRNA 
transcript is unchanged under LPS-stimulating conditions, we hypothesize that there are cis-
elements within the transcript that control translation which is responsible for the increased 
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 protein production observed with LPS stimulation.  Northern Blot analysis of CstF-64 message 
in RAW macrophages would provide evidence for multiple CstF-64 transcripts and MRP-PCR 
would determine if a poly(A) site switch occurs under LPS-stimulating conditions. 
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 4.5. DISCUSSION 
 We have shown that LPS stimulation of murine RAW macrophages stimulated with LPS 
for 18 hours exhibited CstF-64 expression levels approximately 5-fold over basal expression, and 
occurred during the cessation of the cell cycle (Figure 3).  This finding is noteworthy due to 
studies from our lab and others that have shown that CstF-64 expression levels increase with cell 
cycle progression (86, 139).  Furthermore, we showed that LPS stimulation of both RAW 
macrophages and murine BMDMs increased CstF-64 specifically, in that several other proteins 
associated with pre-mRNA cleavage/polyadenylation did not change expression (Figure 4). 
 Through RNase protection assays, we measured a 2.4-fold increase in the selection of the 
weaker promoter-proximal poly(A) site of the reporter mini-gene in LPS-stimulated RAW 
macrophages that exhibit increases in CstF-64 protein expression (Figure 5).  Constitutive over-
expression of CstF-64 approximately 10-fold higher than basal levels further demonstrated that 
specific increases in CstF-64 protein expression were sufficient to induce a 2.0-fold increase in 
selection of the weaker promoter-proximal poly(A) site on the reporter mini-gene (Figure 6).      
 Microarray analysis revealed that LPS stimulation of RAW macrophages for 18 hours 
significantly increased the expression of 245 known genes and 45 unique ESTs (Appendix A).  
We also identified a significant decrease in the expression of 162 known genes and 63 unique 
ESTs in LPS-stimulated RAW macrophages (Appendix B).  This data demonstrates that the 
effects of LPS stimulation on macrophage gene expression are sustained beyond the initial 
induction of gene transcription and thus could be contributed to by a variety of secondary effects. 
Furthermore, we measured a significant increase in 21 known genes and 2 ESTs, and a 
significant decrease in 29 known genes in RAW macrophages that over-express CstF-64.  
Because the only identified function of CstF-64 to date is its required role in the 3’-end cleavage 
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 step of pre-mRNA processing, we propose that genes that exhibit expression increases in the 
context of CstF-64 over-expression do so because: (1) more gene transcript is cleaved and 
polyadenylated from the nascent pool of pre-mRNA of that gene, especially in the context of a 
single, weak poly(A) site; (2) an alternative polyadenylation event occurs that removes mRNA 
instability elements from the mature mRNA transcript; or (3) there are secondary effects from 
genes that regulate transcription which are themselves directly effected by elevated levels of 
CstF-64 (Figure 9).  Notably, there are at least three members in our list of CstF-64 inducible 
genes that have known transcriptional regulatory functions: CHOP/GADD153, Id2 and retinoic 
acid receptor beta (RARβ).  CHOP/GADD153 is a member of the C/EBP transcription factor 
family whose heterodimerization with other C/EBP transcription factors results in dominant 
negative inhibition.  However, contact with AP-1 containing complexes induces AP-1 associated 
gene expression (121, 142).  Id2 is a member of the bHLH family of transcription factors that 
lacks a DNA binding motif and represses transcription when heterodimerized to other bHLH-
containing transcription factor.  Id2 has also been shown to be upregulated in macrophages under 
hypoxia-induced stress (16, 133). Retinoic acid receptor beta (RARβ) has been found to be a 
constitutive activator of retinoic acid response element (RARE)-containing genes irregardless of 
the presence of its ligand retinoic acid (62).  Likewise, we believe the genes that exhibit a 
decrease in expression with CstF-64 over-expression are influenced by: (2) an alternative 
polyadenylation event that removes an mRNA stability element from the mature mRNA 
transcript, or (3) the transcriptional regulators that increase in expression under elevated levels of 
CstF-64 repress the expression of these genes (Figure 9). 
 Interestingly, 12 of the 23 genes that increased and 3 of the 29 genes that decreased in the 
context of CstF-64 over-expression also demonstrated similar gene expression changes with LPS 
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 stimulation (Tables 2 and 3).  By designing a statistical algorithm that tests the random chance of 
the same 15 genes out of the 22,690 on the array being selected from two separate pools at 
random, we found that this overlap between the LPS stimulation and CstF-64 over-expression 
would occur far less than once in 30,000 trials (Figure 10).  We therefore believe that the overlap 
is highly unlikely to have occurred at random and thus has biological significance.  From this we 
conclude that some of the gene expression changes observed with LPS stimulation of RAW 
macrophages can be attributed to, at least in part, elevated pre-mRNA cleavage induced by 
increases in CstF-64 protein expression.  A possible explanation of why not every gene that 
demonstrated expression changes in RAW macrophages over-expressing CstF-64 was not 
identified in LPS-stimulated RAW macrophages is that the stable 10-fold over-expression of 
CstF-64 is able to influence the expression of genes that are unaffected by the LPS-induced 5-
fold increase.  Examples of genes that changed expression with CstF-64 and not with LPS 
stimulation are PLOD-2, Ph4a2, RARβ, and CD48 (Table 2 and Figure 8).  Furthermore, stable 
over-expression of CstF-64 indefinitely elevates the pre-mRNA cleavage of the cell.  This 
sustained elevation of mRNA 3’-end cleavage acts on all newly synthesized RNA.  In the context 
of LPS stimulation, CstF-64 levels increase to 5-fold over basal expression 18 hours post 
treatment and therefore heightened levels of pre-mRNA cleavage due to elevated levels of CstF-
64 primarily act on gene transcripts produced late in macrophage activation.  Transcripts 
produced before increases in CstF-64 expression, especially those with lengthy mRNA half lives, 
can dampen the measurable effect elevated levels of CstF-64 have on newly transcribed genes.    
 Our studies have shown that the mechanism of alternative polyadenylation is strongly 
influenced by the physiological increase in the expression of CstF-64, resulting in an increase in 
the selection of a weaker promoter-proximal poly(A) site over a stronger promoter-distal poly(A) 
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 site on a reporter mini-gene.  Analyses of EST databases have estimated that as many as 54% of 
human genes and 32% of mouse genes possess more than one poly(A) site, often of varying 
strengths (9, 140).  Indeed, a multitude of studies have demonstrated how the inclusion or 
exclusion of regions of the 3’-UTR to the final gene product through alternative polyadenylation 
can have a profound effect on mRNA half-life (1, 40, 78, 101), the translational efficacy of the 
gene transcript (88, 157), and the final structure of the protein [(25) and reviewed in (45)].  
Analysis of the longest 3’-UTRs available through the GenBank database of the genes that 
demonstrate changes in abundance with CstF-64 over-expression revealed that 24 out of 52 of 
these genes possess more than one putative poly(A) site.  Furthermore, many of these genes also 
possess ARE-containing cis-elements that may regulate mRNA stability.  Therefore, increases in 
CstF-64 protein levels can, in theory, dictate the presence or absence of these mRNA regulatory 
elements in the mature transcript by inducing an alternative polyadenylation event.   
 To ascertain whether increases in CstF-64 protein cause a poly(A) site switch in LPS-
induced genes as demonstrated for our reporter mini-gene, we found, through a PCR-based 
approach, that the abundance of transcripts that result from distal poly(A) site usage for Id-2 and 
MMP-9 are reduced under LPS-stimulating and CstF-64 over-expressing conditions (Figure 
11B).  Similarly, the use of the distal poly(A) site on the CTE-1 transcript is reduced under LPS-
stimulating conditions (Figure 11B).  Because the over-all expression of CTE-1 is greatly 
reduced under CstF-64 over-expressing conditions (Table 2 and Figure 8), we could not ascertain 
whether a shift in poly(A) site choice occurred or that the amount of transcript generated from 
the distal poly(A) site is below our level of detection.  A more sensitive technique such as 
Northern Blot or RNase protection assay will need to be performed to determine the effects of 
CstF-64 over-expression on the CTE-1 transcript.  Interestingly, the same technique used to 
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 demonstrate a decrease in distal poly(A) site use on Id-2, CTE-1 and MMP-9 transcripts showed 
a definitive increase in distal poly(A) site selection on Tyki and Fabp-4 transcripts under both 
LPS-stimulating and CstF-64 over-expressing conditions (Figure 11C).   
 Showing a change in the long form of the transcript under CstF-64 over-expression while 
also showing a change in overall gene production (Figures 8 and 11) proves that an alternative 
poly(A) site choice event does occur on these five genes and likely contributes to the measured 
change in gene expression.  Closer analysis of the nucleotide sequence that lies between these 
genes’ poly(A) sites shows the presence of a variety of putative AREs (Figure 12).  Functional 
AREs can have a variety of permutations, most of which contain the core element AUUUA and 
may have additional adenosine and/or uridine residues flanking it [Table 5 and reviewed in 
(150)].  Non-AUUUA containing U-rich regions have also been described [Table 5 and reviewed 
in (150)].  For Id-2, there are two AREs that possess the consensus core element AUUUA and a 
non-AUUUA containing U-rich element just 3’ to the proximal poly(A) site (Figure 12).  Use of 
any of the three distal poly(A) sites would result in the retention of these AREs to the final gene 
transcript.  Subsequently, preferred use of the proximal poly(A) site, as observed under LPS-
stimulating and CstF-64 over-expressing conditions would result in a transcript that lacks these 
putative regulatory elements (Figure 12).  For CTE-1, there are two basal ARE core elements 
just 5’ to the distal poly(A) site.  Most interesting is the extensive U-rich element that lies just 
downstream of three promoter proximal poly(A) signals, any of which could associate with the 
indicated GU-rich region to create a functional poly(A) site (Figure 12).  The U-rich element 
spans over 180 nucleotides and is 60% U-rich.  However, unlike the U-rich mRNA instability 
regions defined in the 3’-UTR of c-fos and c-jun that are also rich in adenosine residues (20, 
107), the remaining 40% of the U-rich region is composed primarily of cytidines (Figure 12).  
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 Because the removal of this CU-rich region correlates with a reduction in gene expression, this 
element might in fact be a novel mRNA stability element that bestows a greater half-life to the 
longer CTE-1 transcripts.  MMP-9 possesses two AUUUA-containing AREs between its two 
poly(A) sites.  Thus, preferred use of the proximal poly(A) site observed under LPS-stimulating 
and CstF-64 over-expressing conditions would remove these putative regulatory elements from 
the final gene product (Figure 12).  If these putative AREs are found to influence mRNA half-
life, this would explain how simply over-expressing CstF-64 in the RAW macrophages would 
increase the amount of final gene product.    Because the sequence requirements for an ARE to 
be functional are diverse, the authenticity of these putative cis-elements would have to be studied 
for each gene. 
 Surprisingly, we observed an increase in distal poly(A) site selection under LPS 
stimulation and CstF-64 over-expression for both Tyki and Fabp-4 (Figure 11C).  An increased 
selection of the distal poly(A) site of Tyki would incorporate two core element-containing AREs 
into the final transcript (Figure 12).  Likewise, distal poly(A) site usage in Fabp-4 would 
incorporate a fairly large U-rich element and a core ARE element with an associated stretch of 
uridines (Figure 12).  Because the gene expression of both Tyki and Fabp-4 are increased under 
LPS-stimulating and CstF-64 over-expressing conditions, the AREs of these genes that are 
retained in the long form of the transcript may display mRNA stabilizing characteristics.  The 
increase in distal poly(A)site usage observed for Tyki and Fabp-4 is the opposite of what we 
observed on our report mini-gene (Figure 5) and for Id-2, CTE-1 and MMP-9 gene transcripts 
(Figure 11B), and counterintuitive to our idea of increases in CstF-64 expression driving 
proximal poly(A) site use.  One possibility for the increased use of the distal poly(A) site under 
LPS-stimulating and CstF-64 over-expressing conditions would be if one of the proteins 
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 identified to increase in expression under these conditions (Table 2) binds to the mRNA near the 
proximal poly(A) site and prevents its use.  One candidate for this ascribed function is Hermes, a 
member of the largest family of RNA-binding proteins, a factor that has demonstrated a role in 
Xenopus laevis oocyte development (155) and is highly expressed in the myocardium of the 
developing heart (53).  Although the exact role Hermes has on RNA regulation is not known, 
researchers suspect that Hermes plays a role in regulating translation and/or mRNA stability in 
order to fine-tune the genetic program of developing tissue.  Further experiments exploring the 
RNA-binding specificity of Hermes and its possible gene-specific interaction to Tyki and Fabp-4 
transcripts would be necessary to test this hypothesis. 
 However, a gene need only possess a single poly(A) site for the cleavage step in pre-
mRNA processing to have an impact on gene transcript production.  Because of the diversity in 
sequence of the cis-elements both upstream and downstream of the cleavage site (9, 79), the 
cleavage step of pre-mRNA processing is sensitive to the amount of proteins that bind to these 
elements.  That is, increases in either CPSF-160 or CstF-64, as we have shown here, can 
theoretically increase the formation of the cleavage/polyadenylation complex at any particular 
poly(A) site, especially those that deviate from the consensus sequence parameters.  
Furthermore, due to the growing evidence that the efficiency of 3’-end cleavage of pre-mRNA is 
also influenced by auxiliary upstream and downstream elements that lie near the poly(A) signal 
and GU-rich elements (79, 98), the amounts of trans-acting factors that bind to these regions 
may also influence the cleavage reaction.  Indeed, hnRNP F and hnRNP H/H’ are factors that 
bind to G-rich elements in RNA (19), have been found within the cleavage/polyadenylation 
complex (146), and whose expression levels can influence pre-mRNA processing (5, 146).  
Regardless of the mechanism, an increase in 3’-end processing of pre-mRNA transcripts that 
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 contain a single poly(A) site would produce more mature mRNA to be template for protein 
production. 
 Through over-expressing CstF-64 in RAW 264.7 macrophages, we have demonstrated 
for the first time that altered expression levels of a single mRNA processing factor can influence 
the expression of multiple genes.  We showed that the mechanism of mRNA 3’-end processing 
contributes in part to the genetic profile changes observed upon macrophage stimulation with 
LPS, emphasizing the impact post-transcriptional 3’-end processing has on gene expression in 
macrophages stimulated by gram-negative bacteria.   
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 5. AIM 2:  Differential Phosphorylation of RNAP-II Carboxy-Terminal Domain in A20  
B-Lymphoma Cells and AxJ Plasma Cells 
5.1. ABSTRACT 
 In order for plasma cells to secrete immunoglobulin (Ig), a poly(A) site switch needs to 
occur within the 3’-UTR of the Ig heavy chain gene that would result in the exclusion of 
membrane spanning exons and the production of the secretory form of Ig.  This alternative 
polyadenylation event results from an increase in selection of a weak, promoter-proximal 
poly(A) site correlated with an increase in the binding activity of CstF-64, a protein involved in 
eukaryotic pre-mRNA 3’-end processing.  With the evidence that multiple pre-mRNA processing 
factors are recruited to the RNAP-II through the phosphorylation of the carboxy-terminal domain 
(CTD), we hypothesized that there is a change in the phosphorylation state of RNAP-II CTD 
between A20 memory B-cells and AxJ Ig-secreting plasma cells that contributes to this poly(A) 
site switch.  To obtain RNAP-II CTD phosphorylation data at the Ig heavy chain promoter, we 
sequenced the IgG2a promoter shared by both A20 and AxJ cells using a 5’-RACE PCR 
approach.  By employing the chromatin immunoprecipitation (ChIP) technique across the IgG2a 
heavy chain gene, we detected an increase in both Serine-2 and Serine-5 phosphorylation of 
RNAP-II CTD at the promoter and variable regions of AxJ cells over A20 cells.  We also 
detected a significant reduction in Serine-2 and Serine-5 phosphorylation at the Ig heavy chain 
intronic enhancer (Eμ) in both cell lines.  Levels of Serine-2 and Serine-5 phosphorylation 
beyond the Eμ were low and unchanged through the remaining portion of the genomic locus in 
both cell lines.  From these results, we conclude that the phosphorylation level of RNAP-II CTD 
that are different at the promoter and variable regions of the IgG2a heavy chain gene between 
A20 memory cells and AxJ plasma cells indicates either an increase in polymerase loading at the 
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 promoter in AxJ plasma cells or a change in the phosphorylation state of RNAP-II CTD.  
Experiments to test these hypotheses are outlined and interpretations of the possible results are 
discussed. 
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 5.2. INTRODUCTION 
5.2.1. Transcription initiation 
 RNA polymerase type 2 (RNAP-II) is the polymerase responsible for the transcription of 
the vast majority of eukaryotic genes.  RNAP-II is recruited to the TATA box of Pol-II 
promoters by the multi-subunit general transcription factor TFIID.  Recruitment of TFIID to the 
TATA box is facilitated by one of its subunits, TATA binding protein (TBP).  Sequential 
recruitment of the TFIIA, TFIIB, TFIIE, TFIIF, and TFIIH general TFs and RNAP-II follow 
thereafter forming the pre-initiation complex of transcription [reviewed in (30)].  To initiate 
promoter release of the polymerase and begin transcription initiation, the kinase activity of 
CDK7, CDK8 and CDK9, subunits of TFIIH, phosphorylates the carboxy-terminal domain 
(CTD) of RNAP-II (83, 114).   
5.2.2. RNA Polymerase II Carboxy-Terminal Domain 
 The CTD of RNAP-II consists of a conserved heptad amino acid stretch repeated 26 
times in budding yeast and 52 times in vertebrates and whose sequence is conserved across many 
eukaryotic species [(29) and reviewed in (105)].  The repeat amino acid sequence YSPTSPS 
possesses five residues that are phosphorylation acceptors; however Serine-2 and Serine-5 are 
the residues most commonly phosphorylated in vivo (156).  Because of this, RNAP-II purified 
from mammalian cell extracts has been observed in several forms based on the phosphorylation 
status of the CTD.  A hypophosphorylated form of RNAP-II CTD is associated with the pre-
initiation complex and designated RNAP-IIA (128).  Subsequently, the hyperphosphorylated 
form of RNAP-II CTD, designated RNAP-IIO, is associated with the release of the polymerase 
from the promoter and the beginning of transcription (128).  Notably, other intermediately 
phosphorylated forms of RNAP-II have been observed and correspond to an intermediate level 
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 of phosphorylation.  Indeed, the precise pattern of phosphorylation of the CTD of RNAP-II plays 
a significant role in the initiation of transcription and co-transcriptional mRNA processing (see 
below).   
5.2.3. Kinases that phosphorylate the CTD of RNAP-II 
 CTD phosphorylation has been shown to be required for promoter clearance and 
transcription initiation and elongation (85, 154).  A large variety of kinases have been reported 
that are responsible for the post-translational modifications of the CTD of RNAP-II and include 
cell-cycle dependent kinases (CDK) and map kinases (MAPK) (83, 103).  The activity and 
specificity of many of these kinases are highly regulated and are often coordinated with the cell 
cycle (83).  Furthermore, the specificity of these kinases is precise in that the particular residues 
within the CTD of RNAP II that are phosphorylated are kinase dependent and are affected by the 
phosphorylation state of neighboring residues (118, 119, 141).  As an added level of specificity 
control, the association of transcription factors can further dictate the precise CTD residues that 
are phosphorylated.  For example, CDK7 has been shown to phosphorylate both serine-2 and 
serine-5 residues.  However, the combinatorial effects of CDK7 and TFIIE enforce the 
preference of serine-5 phosphorylation (122).  As CTD phosphorylation is a highly regulated 
event, the removal of phosphates from the CTD by phosphatases is also regulated, however 
much less is known about these events [reviewed in (105)].   
5.2.4.  Early links between mRNA processing and transcription 
 One of the first pieces of evidence that transcription and mRNA processing are linked 
events was the detection of CPSF subunits during the purification of TFIID-associated proteins 
(32).   Subsequent reconstitution of an inducible, in vitro transcription system demonstrated that 
CPSF and TFIID are co-localized to the promoter.  However, upon chemical induction of 
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 transcription, TFIID remained at the promoter while CPSF migrated with the polymerase (32).  
Another early study had demonstrated that the 3’-end processing reaction is inhibited when the 
CTD of RNAP II is truncated (89).  In fact, reconstitution experiments demonstrated that RNAP 
II CTD is a required element for in vitro pre-mRNA cleavage reactions and that the addition of 
the hyperphosphorylated form of CTD (RNAP-IIO) provided more cleavage activity to the 
reaction than the hypophosphorylated form (RNAP-IIA) (65).   Furthermore, both CPSF and 
CstF proteins were shown to bind CTD affinity columns and were co-purified in RNAP II-
containing high-molecular-mass complexes (89).  Lastly, immunohistochemistry has co-
localized subunits from both CPSF and CstF to nuclear domains closely associated with actively 
transcribed genes and newly synthesized RNA (126); this association occurs during cell cycle 
progression (127). 
5.2.4.1. The Connection between RNAP-II CTD phosphorylation and mRNA 
processing 
 The CTD of RNAP-II has long been thought to behave as a landing platform for a variety 
of mRNA processing factors involved in the capping, splicing and 3’-end cleavage of nascent 
pre-mRNA.  Because the processing of mRNA is reduced concordantly with the prevention of 
CTD phosphorylation, the recruitment of these mRNA processing factors to the CTD has been 
shown to be phosphorylation dependent (12).  Crystallographic studies have shown that the 
phosphorylation of serine-2 within the heptad repeat stabilizes a β-turn that interacts with the 
CTD-interacting domains of 3’-end processing factors (91).  Biochemical studies have elucidated 
specific regions of the RNAP II CTD that are charged with different mRNA processing 
mechanisms.  By engineering truncated forms of the RNAP II CTD, it was discovered that the 
carboxy terminus of the CTD supports all three major pre-mRNA processing events, while the 
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 amino terminus of the CTD only supports capping (47).  A closer inspection of the ten unique 
amino acid residues that are located 3’ to the terminal heptad repeat show that this sequence also 
significantly supports splicing and 3’-end processing (48).  Interestingly, the phosphorylation 
state of this 10-residue sequence does not appear to be necessary for its role in pre-mRNA 
processing (48).   
5.2.4.2. Differential phosphorylation of RNAP-II CTD and the recruitment of 
mRNA processing factors 
 Although the conserved heptad repeat of the carboxy-terminus of RNAP-II possesses five 
phosphorylation accepting amino acid residues, the main residues targeted by CTD kinases are 
Serine-2 and Serine-5 (156).  Because of the necessity of CTD phosphorylation for promoter 
clearance and transcription elongation, the fact that pre-mRNA processing is dependent on CTD 
phosphorylation, and that pre-mRNA processing factors have been shown to bind to 
phosphorylated CTD, it was questioned whether pre-mRNA processing factors were associated 
to the transcriptional machinery throughout transcription or recruited in a phosphorylation-
specific and location-specific manner across the gene.  Employing the chromatin 
immunoprecipitation (ChIP) technique, researchers have been able to detect the phosphorylation 
state of the RNAP-II CTD on Serine-2 and Serine-5 across particular yeast (2, 73, 75, 125) and 
mammalian (23) genes in vivo.  Furthermore, this technique has been expanded to identify pre-
mRNA processing factors that are directly associated with the polymerase provided an 
appropriate immunoprecipitation-competent antibody for the protein of interest is available.   
 Using ChIP, the association of yeast pre-mRNA capping enzymes was shown to occur at 
the 5’ of RNAP-II transcribed genes and was concomitant with Serine-5 phosphorylation of the 
RNAP-II CTD (75, 125).  Furthermore, both the association of the capping enzymes and the 
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 Serine-5 phosphorylation state of RNAP-II CTD was reduced as the transcription machinery 
migrated toward the 3’-end of the gene (125).  Interestingly, as Serine-5 phosphorylation was 
reduced in the coding regions of yeast genes, it was shown that the Serine-2 phosphorylation 
state of RNAP-II CTD increased as the transcriptional machinery migrated toward the 3’-end of 
the gene (75).  Coupled to the increase in Serine-2 phosphorylation along the coding region of 
yeast genes was the association of RNAP-II elongation factors (113) and pre-mRNA 3’-end 
processing factors (2, 77, 81).  
 Consistent with what was observed in yeast, Serine-5 phosphorylation was strong at the 
promoter of the mammalian DHFR and γ-actin genes and was subsequently reduced as the 
transcriptional machinery migrated across the gene (23).  However, in contrast to what is 
typically observed on yeast genes, the Serine-2 phosphorylation of RNAP-II CTD was 
distributed more evenly across the genes (23).  Furthermore, Cheng et al. demonstrated that the 
high level of RNAP-II measured at the promoter of these genes, which was reduced within the 
open reading frame, was due to the RNAP-II falling off the gene and incomplete transcription 
(23).  The association of mammalian pre-mRNA processing factors to the transcriptional 
machinery and the correlation to the phosphorylation state of the RNAP-II CTD is currently 
unknown. 
 
5.2.5. Maturation of B-lymphocytes and Ig Secretion 
5.2.5.1. B-lymphocyte Biology 
 B lymphocytes are a part of the humoral immune system and are generated in the bone 
marrow.  Each B-cell expresses a B-cell receptor (BCR) in the form of membrane-bound 
immunoglobulin unique to a particular antigen.  The maturation of naïve B-lymphocytes into 
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 immunoglobulin (Ig) secreting plasma cells (PCs) occurs as a result of B-cell recruitment to 
germinal centers in the spleen and lymph nodes and subsequent activation following exposure to 
soluble antigen or antigen associated with follicular dendritic cells.  During this phenotypic 
change, the immunoglobulin gene undergoes several rounds of somatic hypermutation which 
result in slight changes in antigen specificity.  If the change in specificity to its specific antigen is 
lessened, this will result in B-cell anergy.  On the contrary, an increase in affinity for the antigen 
results in further maturation and differentiation.  Naïve B-cells begin by expressing surface 
bound IgM.  Along with B-cell differentiation, the Ig gene undergoes isotype switching with the 
aid of T-helper cells to IgG, IgA or IgE expressing B-cells. 
5.2.5.2. Immunoglobulin Germline Configuration 
 The murine germline configuration of the immunoglobulin heavy chain gene includes 
exons that code for hundreds of variable regions, twenty-three diversity regions, four joint 
regions and clusters of constant region exons specific for a particular isotype (Figure 14).  
Through the B-cell developmental process, the heavy chain Ig gene undergoes sequential 
germline recombination first between the diversity (D) and joint (J) regions creating a DJ gene 
segment.  Subsequently, recombination then occurs between the variable (V) region and the DJ 
gene segment creating a final VDJ Ig gene segment.  Each variable region is associated with its 
own leader sequence (L) and promoter (Figure 14).   
 Located downstream of the VDJ gene segment is the intronic Ig enhancer, Eμ (Figure 
14), that possesses several conserved cis-elements called E-boxes that bind to E-box binding 
proteins.  Activation of the intronic enhancer by these E-box binding proteins is necessary for 
proper B-cell development (55) and contributes to Ig gene transcription (149).  Further 
downstream of the intronic enhancer are the constant region exons (Figure 14).  In the naïve B-
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 cell germline configuration, the mu constant region exon cluster (Cμ) lies immediately 
downstream from the VDJ gene segment, and thus results in IgM production in naïve B-cells.  
Upon isotype switching, another genetic recombination even occurs between switch signals that 
precede each constant region exon cluster, thus relocating constant region exons from other 
isotypes immediately downstream of the VDJ gene segment.  
5.2.5.3. Alternative Ig mRNA processing in the plasma cell 
 A hallmark of B-cell differentiation into a PC is the ability of the PC to secrete copious 
amounts of antigen-specific antibody.  In order for Ig to be secreted, an alternative post-
transcriptional processing event must occur that results in the selective use of the upstream 
secretory poly(A) site (pAs) in the Ig gene (Figure 15).  This selection in upstream poly(A) site 
use would preclude the incorporation of membrane spanning exons to the final Ig transcript.  
Several hypotheses have emerged and been tested to explain the shift in poly(A) site usage on the 
Ig gene in plasma cells.   
 Because the selection of the upstream pAs removes the possibility of incorporating the 
membrane spanning exons into the mature Ig transcript, which necessitates the selection of a 5’-
splice site that is embedded in the exon immediately upstream of pAs, it is possible that changes 
in splicing and/or polyadenylation activity in the cellular environment can tip the balances 
creating the secretory form over membrane form of Ig.  Previous studies have demonstrated an 
increase in polyadenylation efficiency in PCs compared to B-cells without a change in splicing 
efficiency on the IgM gene (110).  However, further studies have shown that the particular 
cellular environment can determine whether splicing or cleavage/polyadenylation is the 
dominant processing event (15).  Work from our lab has shown that regardless of sequence 
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 composition, an increased use of a weak upstream poly(A) site over a stronger distal poly(A) site 
is observed in PCs compared to naïve or memory B lymphocytes (87). 
 Alternatively, there could be an increase in the early termination of Ig transcription 
facilitated by an increase in termination factors or a decrease in transcription elongation factors 
in PCs.  A reduction in the full extension of the Ig transcript past the membrane poly(A) site 
(pAm) would result in an increase in pAs usage  This had been shown to occur on the IgM gene 
in B-cells exhibiting a PC phenotype (148).  However, studies from our lab have shown that 
transcription continues far past the pAm on the IgG2a and IgG2b heavy chain genes in memory 
B-cells (92).  Aside from transcription termination, it has been suggested that transcriptional 
pausing downstream of the pAs in plasma cells may be a contributing mechanism to increased 
pAs selection.  Indeed the removal of nucleotide sequences immediately downstream of the IgM 
and IgA pAs decreased the production of secretory IgM in PCs (109). 
5.2.5.4. Secretory Ig Production and CstF-64 
 The selection of the upstream weak poly(A) site in the Ig gene is essential for the 
production of the secretory form of Ig.  LPS stimulation of primary splenic B-cells had 
demonstrated an accumulation of CstF-64 protein that correlated with an increase in secretory Ig 
mRNA production (139).  Furthermore, over-expression of CstF-64 in chicken DT-40 B-
lymphoma cells caused an increase in secretory Ig mRNA production (139).  However, studies 
from our lab have shown an increase in the binding efficiency of CstF-64 in plasma cells in the 
absence of increases in protein production (44).  Furthermore, the increased ability of CstF-64 to 
bind to RNA substrates in the absence of increases in protein levels have been demonstrated in 
the context of viral infections (84, 90).  One explanation for the increase in CstF-64 observed in 
the LPS-stimulated splenic B-cells is that LPS induces rapid proliferation of B-cells (117) and 
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 our lab has shown that CstF-64 protein levels increase when cells enter the Go-S portion of the 
cell cycle (86).  While there is no denying that increased levels of CstF-64 protein cause the 
increase in selection of weaker poly(A) sites, particularly when CstF-64 is the limiting 
constituent to CstF trimer formation as demonstrated through immunoprecipitation studies (86), 
we believe that increases in weak poly(A) site selection can occur on the Ig gene in the absence 
of CstF-64 protein increase; perhaps by an increase in the local concentration of the steady-state 
level of CstF at the site of pre-mRNA cleavage or increased recruitment of CstF to the migrating 
polymerase on the Ig heavy chain gene.   
5.2.6. The Strength of our Experimental System Through the Use of the AxJ 
Hybridoma Cell Line 
 When using ChIP to illustrate the dynamics of the phosphorylation state of RNAP-II 
CTD and how that correlates to transcription initiation, elongation and the association of pre-
mRNA processing factors to the CTD of RNAP-II across a gene’s genomic sequence, it is 
important to obtain a complete picture that includes data from one end of the gene to the other.  
Therefore it is necessary to have the promoter sequence of the gene of interest for primer design, 
particularly since RNAP-II is recruited to the promoter and some pre-mRNA processing factors 
have demonstrated preferential association to the polymerase while at the promoter.  Thus, we 
have employed a 5’-RACE PCR approach to obtain the promoter region of the A20 active IgG2a 
locus.  Because our studies are focusing not only on the dynamics of RNAP-II CTD 
phosphorylation across the Ig genomic locus in A20 memory B-cells, but also on the difference 
in the phosphorylation pattern and association of pre-mRNA processing factors between memory 
B-cells and Ig-secreting plasma cells, we need to be able to perform ChIP on the identical Ig 
promoter and V-region from both membrane Ig generating B-cells and secretory Ig generating 
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 plasma cells.  However, we have been unable to induce the A20 memory B-cell line to secrete 
IgG2a through LPS or cytokine stimulation (data not shown).  Furthermore, we could not simply 
choose a murine plasma cell line that expresses the same Ig isotype as the A20 memory cells 
(IgG2a), for that would only supply a cell line expressing the same constant regions with a 
different promoter and uniquely recombined VDJ region.  Therefore, our lab had generated a 
hybridoma cell line through the fusion of A20 memory B-cells and a subclone of the J558 
plasma cell line that lacks heavy chain (J558L) (93).  This AxJ hybridoma expresses the identical 
heavy chain gene (including promoter and variable regions) as the A20 memory cell line, 
demonstrates preferential use of the secretory poly(A) site on the Ig gene (93), secretes Ig 
(Figure 16) and displays a genetic profile similar to primary plasma cells (data not shown).  With 
this hybridoma unique to our laboratory, we have the ability to perform ChIP on the identical Ig 
heavy chain genomic locus between a memory B-cell line that generates primarily membrane-
bound Ig and a plasma cell line that generates primarily secretory Ig. 
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 5.3. MATERIALS AND METHODS 
5.3.1. A20 IgG2a promoter sequencing by 5’-RACE PCR 
 The Universal GenomeWalker™ Kit from BD Biosciences (K1807-1) was used to obtain 
the promoter region for A20 IgG2a.  Beginning with the published sequence for the variable 
region of A20 B-lymphoma cell line (39), two gene-specific anti-sense primers (GSPs) were 
created that targeted this known sequence (Figure 17 and Table 6).  In brief, 2.5 μg of A20 
genomic DNA, purified using the DNeasy kit (Qiagen), was digested with one of four blunt-end 
DNA restriction enzymes (DraI, EcoRV, PvuII and StuI) provided with the Universal 
GenomeWalker™ Kit creating four genomic DNA libraries.  After observing a streak of DNA on 
an ethidium bromide-stained agarose gel from a fraction of the digestion reaction confirming 
successful DNA digestion, each digestion was purified and ligated to the GenomeWalker™ 
adaptors according to manufacturer’s instructions.  Two sequential PCR reactions were 
subsequently performed using Adaptor Primer 1 (AP1) and GSP1 followed by Adaptor Primer 2 
(AP2) and GSP2 (Figure 17A).  Specifically, 1 μl of each purified genomic DNA library was 
combined with 10 pmol each of forward AP and reverse GSP, Mg2+, dNTP mix, 10X reaction 
buffer and Advantage Genomic Polymerase Mix according to manufacturer’s instructions.  A 
modified touch-down PCR program suggested by the protocol was employed to reduce non-
specific amplification.  A second round of touch-down PCR was performed using 5 μl of first-
round PCR product stemming from each genomic DNA library, and 10 pmol each of forward 
AP2 and reverse GSP2.  A significant PCR product was observed from the two sequential rounds 
of PCR stemming from the PvuII-created genomic DNA library.  This PCR product was gel 
purified using the QIAEX II gel extraction kit (Qiagen, 20021) and ligated to the pCR2.1 
plasmid as part of the TA Cloning® Kit (Invitrogen, 25-0024) according to manufacturer’s 
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 instructions.  The ligated plasmid was amplified in One Shot® DH5α-T1 competent cells 
(Invitrogen, 12297-016), purified over a Maxi-prep column (Qiagen) and sequenced (University 
of Pittsburgh, School of Med., Biotechnology Center) using M13 sense and antisense primers 
that bind to pCR2.1 regions that flank the inserted PCR amplicon (Table 6).   
5.3.2. IgG2a ELISA 
 The A20 memory B-cells (ATCC) and AxJ plasma cell hybridomas (93) were maintained 
in IMDM with 5% horse serum, 10 mM HEPES, and 0.1% penicillin-streptomycin.  Two million 
A20 and AxJ cells were seeded in 4 ml media for each time point in 6-well dishes.  Aliquots of 
media were retained at 2, 4, 6, 8, 10 and 12 hours.  Goat anti-mouse IgG antibody (Sigma 
M8642) was diluted in PBS and used to coat a 96-well ELISA plate (DYNEX, 1010) with 200 
ng capture antibody per well and incubated at 4°C overnight.  The wells were subsequently 
washed 3 times with PBS/T, blocked with 10% BSA/PBS/T for 2 hours at room temperature, and 
then washed once with PBS/T.  One hundred microliters of sample was applied in triplicate to 
each well and incubated at 37°C for one hour.  The wells were then washed five times with 
PBS/T followed by applying AP-conjugated goat anti-mouse antibody (Zymed, 62-6622) diluted 
1:1000 in 1%BSA/PBS/T to each well and incubated for two hours at room temperature.  The 
wells were then washed five times with PBS/T and 100 μl of room temperature p-NNP 
(Chemicon, ES009) was applied to each well for 15 minutes room temperature with gentle 
rotation followed by colorimetric measurement at 405 nm.   
5.3.3. Chromatin Immunoprecipitation 
 For crosslinking, 5x107 A20 cells or AxJ cells were chemically fixed with the addition of 
formaldehyde (1% final concentration) directly to the cell culture suspension for ten minutes at 
room temperature while rocking.  Fixation was stopped by the addition of glycine at a final 
78 
 concentration of 125 mM for ten minutes at room temperature while rocking.  Cells were then 
pelleted, washed with PBS, pelleted again and stored at -80°C until needed.  The ChIP procedure 
was performed using the ChIP-IT™ kit (Active Motif) as per manufacturer’s instructions with 
minor exceptions noted below.  In brief, the nuclei from 5x107 cells were harvested using cold 
ChIP-IT™ Lysis Buffer and protease inhibitors (PI) on ice for 30 minutes followed by dounce 
homogenization and subsequent centrifugation.  Nuclei were resuspended in ChIP-IT™ Shearing 
Buffer and split into three equal volumes in eppendorf tubes.  Chromatin was fragmented to 1000 
base pairs or less using a Microson XL 2000 (Misonix) for 20 15-second pulses at level 7 with 
the tubes sitting in an ice water/salt slurry, allowing at least 30 seconds to lapse between pulses.  
Each new chromatin preparation was tested for shearing efficiency and DNA concentration as 
per ChIP-IT™ protocol.   
 Ten micrograms of fragmented chromatin DNA were used for each chromatin 
immunoprecipitation.  Chromatin was pre-cleared using 100 μl supplied protein G beads, ChIP 
IP Buffer and PI to a total volume of 210 μl per 10 μg chromatin DNA.  Pre-clearing was 
performed for 1 hour at 4°C with gentle rocking.  Ten μl of pre-cleared chromatin was combined 
with 90 μl water for the Total Input sample and stored at -20°C until needed.  The remaining 
volume of pre-cleared chromatin was evenly distributed into as many tubes as the number of 
planned immunoprecipitations (10 μg per IP).  Antibodies were added to the pre-cleared 
chromatin and the ChIP reaction was incubated overnight at 4°C with gentle rocking.  One 
hundred μl of Protein G resin (ChIP IT™ kit) or anti-IgM-specific agarose (Sigma, A4540) was 
added to each ChIP reaction and rotated at 4°C for 90 minutes followed by collection by 
centrifugation.  The antibody/chromatin-resin complex was subject to one 400 μl wash using 
ChIP IT™ IP Buffer with PI, four 400 μl washes using ChIP IT™ Wash Buffer 1 with PI, one 
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 400 μl wash using ChIP IT™ Wash Buffer 2 with PI and two 400 μl washes using ChIP IT™ 
Wash Buffer 3 (no PI).  All washes were carried out with cold wash buffers at room temperature.  
Elution of antibody/chromatin complexes from the resin was performed using 50 μl of ChIP 
IT™ Elution Buffer incubated at room temperature for 15 minutes, flicking tubes every 3 
minutes.  The resin was collected by centrifugation, the eluate was retained in a new tube and the 
elution process was repeated once.  The eluates were combined and reverse crosslinking of the 
protein from the DNA was performed using 6.5 μl of 5M NaCl (325 mM) and 1 μl RNase A at 
67°C overnight.  Proteins were subsequently digested using 2 μl 0.5 M EDTA, 2 μl 1 M Tris-Cl 
pH 6.5 and 2 μl Proteinase K solution (ChIP IT™ kit) and incubated at 42°C for 2 hours.  
Purification of the immunoprecipitated DNA was performed over the DNA purification columns 
contained within the ChIP IT™ kit as per manufacturer’s instructions.  Typically, two to three 
volumes of nuclease-free water was added to the eluted DNA of all samples in order to expand 
the sample volume for subsequent QPCR analysis.  Antibodies were obtained from the following 
sources and the amounts used per ChIP are indicated: anti-TFIIB positive control (ChIP IT™, 10 
μl or 4 μg), purified mouse IgG negative control (ChIP IT™, 10 μl or 4 μg), anti-Serine-2 
phosphorylated RNAP-II CTD (H5, Covance; 10 μl or ~25 μg), anti-Serine-5 phosphorylated 
RNAP-II CTD (H14, Covance; 15 μl or ~60 μg), purified mouse IgM negative control (ICM 
Pharmaceuticals, 20 μl or 25 μg). 
5.3.4. Real-Time PCR and Data Analysis 
 Quantities of immunoprecipitated DNA were measured using the ABI Prism 7900HT and 
Sequence Detection Software v2.1 (SDS 2.1) provided by The University of Pittsburgh 
Genomics and Proteomics Core Laboratories (GPCL) (http://www.genetics.pitt.edu/).  In brief, 5 
μl of immunoprecipitated DNA were combined with 2X SYBR Green PCR Master Mix (Applied 
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 Biosystems) and 6.25 nmoles each forward and reverse primers to a final reaction volume of 25 
μl.  The following PCR program was used for all ChIP DNA samples: Taq activation for 12 
minutes at 95°C, followed by 40 cycles of a 15 second denaturing step at 95°C and a 1 minute 
annealing step at 60°C.  Quantitation of immunoprecipitated DNA was normalized at every 
genomic locus by comparing its signal to that obtained from a 1:10 dilution of the total input 
DNA sample using the same primer pair and calculating the “% input” using the following 
formula: % input = 2ΔCTx10 where ΔCT is the difference in CT values between the diluted input 
DNA and the IP’d DNA at a chosen threshold value.  ChIPs were performed between two and 
four times per locus from at least two different sources of chromatin.  Averages and SEM were 
calculated using Excel from Microsoft Office 2000.   
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 5.4. RESULTS 
5.4.1. Sequencing the A20 IgG2a promoter 
 By consulting the published V-region sequence of the A20 B-cell lymphoma line (39) 
and the genomic sequence for the murine IgG2a constant regions (Accession J100470) and 
membrane spanning exons and poly(A) sites (Accession J100471), we designed primers that 
spanned the approximately 12 kb of genomic DNA (Figure 18).  However, a great deal of 
information can be obtained by performing ChIP experiments on the promoter region of IgG2a, 
and this can only be done by determining the sequence of the promoter.  Because the sequence 
information obtained for the A20 Ig variable region was generated from cDNA, the promoter 
region contained within the 5-UTR was not available for sequencing.  The A20 B-cell line is a 
clonal population of memory B-cells where the identical VDJ recombined IgG2a gene and 
promoter are active in every cell.  Therefore, through a 5’-RACE PCR approach upstream from 
the known variable region of A20 IgG2a, we set out to obtain the promoter sequence.  The VDJ 
recombination event involves the J2 segment of the J-locus (39), so we designed the first gene-
specific primer (GSP1) to target the genomic region between J2 and J3 (Figure 17A).  The target 
sequence for the second GSP (GSP2) spanned the region where the V, D and J-regions have 
uniquely joined in A20 B-cells through recombination (Figure 17A).   
 Shown in Figure 17 (Figure 17B and 17C) is the promoter sequence obtained from the 5’-
RACE PCR protocol.  The Ig heavy chain gene promoter contains multiple conserved sequence 
motifs that bind B-cell specific transcription factors and are required for Ig production.  Octamer 
binding proteins bind the Octamer element (ATGCAAAT) that lies approximately fifty 
nucleotides upstream from the transcription start site of Ig variable regions and is a strong 
contributor to Ig gene expression (8, 58).  A heptamer motif is often associated with the Octamer 
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 element in Ig promoters and has been shown to both bind Octamer binding proteins and 
contribute to Ig transcription (112).  Both of these elements appear in the A20 V-region promoter 
(Figure 17C).  Also located in the A20 V-region promoter are a C/EBP transcription factor 
binding site, a pyrimidine stretch and a TATA box (Figure 17C), all of which have been shown 
to be functionally important to Ig transcription (28, 42).  
5.4.2. Comparing the phosphorylation state of RNAP-II CTD across the IgG2a 
genomic locus between A20 memory B–cells and AxJ plasma cells 
 Much work has been published describing the association of pre-mRNA processing 
factors to the CTD of RNAP-II (32, 47, 80, 89, 91, 113) and how these interactions are CTD 
phosphorylation dependent (2, 73, 75, 81, 125).  Because there is conflicting evidence on 
whether the alternative poly(A) site selection that occurs on the Ig gene in plasma cells is 
dependent on CstF-64 protein increases (86, 139), we hypothesize that the association of CstF-64 
to the transcriptional machinery is increased in plasma cells resulting in an elevated local 
concentration of CstF-64 to the Ig transcript that may or may not be observed by Western Blots 
on whole cell lysates or nuclear extracts.  To test this, we first set out to determine if there are 
phosphorylation changes on the RNAP-II CTD across the Ig genomic locus and if the pattern 
changes between A20 memory cells and AxJ Ig-secreting plasma cells.  
5.4.2.1. Serine-2 phosphorylation of RNAP-II CTD in A20 memory B-cells 
and AxJ plasma cells  
 By employing chromatin immunoprecipitation (ChIP), we were able to assess the 
phosphorylation state of RNAP-II CTD across the Ig genomic locus.  To do this, we designed 
several primer pairs that span the Ig genomic locus from the promoter region to downstream of 
the secretory poly(A) site (Figure 18).  Because our shearing conditions aimed at achieving 
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 genomic DNA fragments less than 1000 base pairs, our primer pairs were designed with at least 
1000 base pairs of genomic sequence between them to assure that the signals we achieved were 
authentic to the region of the Ig targeted (Figure 18).  Using an antibody specific to the Serine-2 
phosphorylated form of RNAP-II CTD, we measured a decrease in Serine-2 CTD 
phosphorylation from the A20 Ig heavy chain promoter and variable regions to the intronic 
enhancer (Eμ) (Figure 19A).  Loci 3’ of the Eμ showed phosphorylation levels lower than that 
which was measured at the A20 Ig heavy chain promoter and variable regions.  The level of 
Serine-2 CTD phosphorylation on the AxJ Ig promoter was approximately 6.5-fold more than 
that observed in A20 memory B-cells.  Furthermore, Serine-2 CTD phosphorylation at the AxJ 
variable region was approximately 5-fold more than what was measured at the A20 Ig promoter 
(Figure 19A).  Similar to the dynamics of Serine-2 CTD phosphorylation observed in A20 cells, 
the phosphorylation state of RNAP-II CTD at the Eμ was reduced to very low levels.  
Interestingly, the Serine-2 CTD phosphorylation increased slightly 3’ of the Eμ, but did not 
rebound to the level observed at the AxJ promoter and variable regions and appeared similar to 
that which was measured for A20 Ig gene in profile (Figure 19A).   
5.4.2.2. Serine-5 phosphorylation of RNAP-II CTD in A20 memory B-cells 
and AxJ plasma cells 
 Through the use of an antibody specific to the Serine-5 phosphorylated form of RNAP-II 
CTD, we observed that the overall profile of Serine-5 phosphorylation in A20 memory B-cells 
resembles that observed for Serine-2 phosphorylation in the same cell type.  Furthermore, the 
profile of Serine-5 phosphorylation in AxJ plasma cells mirrored the Serine-2 phosphorylation 
profile observed in the same cell type.  Specifically, Serine-5 phosphorylation in the A20 cells 
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 was moderate at the promoter and variable regions, and then dropped to very low levels at the Eμ 
(Figure 19B).  Downstream of the Eμ, Serine-5 phosphorylation in A20 cells rebounded to levels 
slightly below what was measured at the regions upstream of the Eμ at most loci (Figure 19B).  
It appears that Serine-5 phosphorylation spikes at the constant region in A20 cells, however this 
spike is not statistically higher than the levels observed at the promoter and variable regions.  
Similar to the observations for Serine-2 phosphorylation of RNAP-II CTD, Serine-5 
phosphorylation is approximately 6-fold higher at both the promoter and variable regions of the 
Ig in AxJ plasma cells compared to A20 memory B-cells (Figure 19B).  Likewise, the 
phosphorylation level of Serine-5 dropped to very low levels at the Eμ in AxJ cells and then 
rebounded slightly achieving levels of Serine-5 phosphorylation similar to that measured in A20 
cells.   
5.4.2.3. Summary of Serine-2 and Serine-5 Phosphorylation of RNAP-II CTD 
 From this, we conclude that the Serine-2 and Serine-5 phosphorylation of RNAP-II CTD 
in A20 memory B-cells is generally low across the entire Ig genomic locus, that there is a 
significant reduction in phosphorylation at the Eμ, and that the measured phosphorylation is 
higher after the Eμ to levels observed at the Ig heavy chain promoter and variable regions.  We 
further conclude that the Serine-2 and Serine-5 phosphorylation of RNAP-II CTD at the Ig heavy 
chain promoter and variable regions in AxJ plasma cells is between 5- and 6-fold higher than 
what was measured in A20 memory B-cells, that there is a similar drop in phosphorylation at the 
Eμ, and that the phosphorylation levels increase downstream of the Eμ but only to that which 
was observed in A20 B-cells.   
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 5.5. Conclusions and Future Directions 
 Our ChIP results demonstrate that the phosphorylation levels of RNAP-II CTD are 
dynamic across the Ig genomic locus.  Specifically, the measured level of Serine-2 and Serine-5 
phosphorylation of RNAP-II CTD across the Ig heavy chain genomic locus is relatively low in 
A20 memory B-cells.  In contrast, the Serine-2 and Serine-5 phosphorylation levels of RNAP-II 
CTD are significantly higher at the promoter and variable regions in AxJ plasma cells, then 
displays similarly low levels of phosphorylation as observed in A20 memory B-cells across the 
remainder of the IgG2a heavy chain gene. 
 The results we have reported here are unlike the phosphorylation dynamics observed in 
actively transcribed yeast genes that exhibit high Serine-5 phosphorylation at the promoter that 
decrease with transcription and low Serine-2 phosphorylation at the promoter that increase with 
transcription (75).  Our phosphorylation dynamics appear to be cell-type dependent in that both 
Serine-2 and Serine-5 phosphorylation share similar profiles in both A20 memory B-cells and 
AxJ plasma cells, yet the profiles themselves are different between the two cell lines.  There was 
more measured phosphorylation at the promoter and variable regions of Ig heavy chain gene in 
AxJ plasma cells than in A20 memory B-cells.  Because the phosphorylation of RNAP-II CTD is 
required for transcription initiation and elongation (85, 154), and because the transcription of the 
Ig gene in Ig-secreting plasma cells is significantly higher than naïve or memory B-cells (22), we 
have formulated two alternative hypotheses to explain our observations: (1) the phosphorylation 
level of RNAP-II CTD is higher at the promoter and variable regions of the Ig heavy chain gene 
in plasma cells (i.e. there are more phosphorylated residues per RNAP-II CTD molecule), or (2) 
the phosphorylation state of the RNAP-II CTD is unchanged, yet there is a build-up of RNAP-II 
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 molecules at the promoter and variable regions in plasma cells associated with an increase in Ig 
heavy chain transcription.   
 By performing the ChIP technique on the Ig gene in A20 and AxJ cells using an antibody 
that recognizes RNAP-II regardless of the phosphorylation status of the CTD, we could answer 
several questions: The first, is the phosphorylation level of RNAP-II CTD measured across the 
Ig heavy chain genomic locus in A20 memory B-cells and AxJ plasma cells representative of the 
phosphorylation state of the RNAP-II CTD?  If the abundance of RNAP-II across the Ig heavy 
chain genomic region in A20 memory B-cells and AxJ plasma cells is uniform, then the 
dynamics of CTD Serine-2 and Serine-5 phosphorylation observed are true in that there is little 
change in the phosphorylation state of RNAP-II CTD in A20 cells across the Ig heavy chain 
genomic locus.  This would also lead us to conclude that there is a high phosphorylation state of 
RNAP-II CTD at the promoter and variable regions in AxJ cells that is greatly reduced at and 
beyond the Eμ.  Furthermore, to explain the increase in RNAP-II CTD phosphorylation at the Ig 
heavy chain promoter in plasma cells, similar levels of RNAP-II would need to be associated to 
the promoter between A20 and AxJ cells.   
 The second question we could answer is, by measuring RNAP-II holoenzyme across the 
Ig heavy chain genomic region, is the increase in RNAP-II CTD phosphorylation at the Ig 
promoter in plasma cells related to an increase in polymerase loading?  If the RNAP-II profile 
reveals higher levels of RNAP-II association at the Ig promoter in AxJ cells compared to A20 
cells, this result would show a correlation between the increase in Ig transcription and an 
increase in RNAP-II promoter loading.  By calculating the fold-increase in RNAP-II association 
in plasma cells over memory B-cells, we could estimate how much of the 6-fold increase in 
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 phosphorylation is due to the abundance of the polymerase at the promoter and how much is due 
to an increase in the phosphorylation state of the polymerase.   
 The final question we could answer is, if there is an increase in polymerase loading at the 
Ig heavy chain promoter in AxJ plasma cells, what causes the decrease in detection of RNAP-II 
CTD phosphorylation at the Eμ?  If similar levels of RNAP-II are found to associate to both the 
Ig heavy chain promoter and the Eμ, this would demonstrate a decrease in the phosphorylation 
state of RNAP-II CTD as it passes through the Eμ.  If RNAP-II association drops at the Eμ as 
does its phosphorylation, this could indicate that either the polymerase is dissociating from the Ig 
heavy chain gene at this locus or that the polymerase is migrating through the Eμ at a faster rate 
that disallows an equal amount of RNAP-II capture by the ChIP technique.  Previous studies 
have shown that the high level of RNAP-II association at mammalian promoters is reduced after 
transcription begins, due to polymerase disassociation and incomplete transcription (23).  
However, work from our lab has shown that there is no difference in transcription read-through 
of the Ig heavy chain gene between memory B-cells and plasma cells (92).  Thus, if we measure 
a decrease in RNAP-II CTD association at the Eμ, we hypothesize that it may be due to stacking 
up of RNAP-II at the promoter followed by an elevated rate of transcription through the Eμ.  
With the transcriptional machinery traveling through the Eμ at higher speeds than at the 
upstream promoter and V-region, there would be less RNAP-II at any particular time at the Eμ to 
be captured by ChIP.  Research from our lab showing an increase in the PC4 and ELL2 
elongation factors in plasma cells over memory B-cells (data not shown) supports this 
hypothesis.  However, the critical experiment using an RNAP-II specific antibody across the Ig 
genomic locus will need to be performed to answer the questions above.  Preliminary attempts 
using the 8WG16 antibody that is specific for the C-terminal heptapeptide repeat present on the 
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 largest subunit of RNAP-II and which has been previously used is eukaryotic ChIP experiments 
(23, 75) were unsuccessful.  Troubleshooting the amount of antibody and obtaining other ChIP 
proven antibodies for RNAP-II are currently under way. 
 The main goal of this project was to identify the in vivo association of pre-mRNA 
processing factors to the transcriptional machinery across the mammalian Ig heavy chain gene.  
We also aimed to determine if there is a difference in association of these factors to the 
polymerase between memory B-cells and Ig secreting plasma cells.  We hypothesize that the 
amount of and/or location where these factors associate with the transcriptional machinery will 
be different between memory B-cells and plasma cells and that these differences can be 
correlated to the phosphorylation pattern RNAP-II CTD exhibits across the Ig heavy chain 
genomic locus between these two cell lines.  Unlike the majority of the yeast studies that identify 
the association of pre-mRNA processing factors by ChIP through the stable over-expression of a 
tagged version of the protein which is captured using an antibody specific to that tag, our work in 
the mammalian system requires us to obtain antibodies that are able to immunoprecipitate the 
native protein to a degree that will supply a significant signal while minimizing spurious results 
from non-specific binding.  Our lab has developed or acquired a multitude of antibodies to 
mammalian pre-mRNA processing factors, some of which have been successfully used for IP 
studies.  Through the exhaustive screening of our antibody collection, we hope to discover some 
antibodies to pre-mRNA processing factors, primarily ones specific for CPSF and CstF, that are 
compatible with our ChIP system in order to test the aforementioned hypothesis. 
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 6. SUMMARY AND CONCLUSIONS 
 Post-transcriptional control of gene expression has been identified in a number of genes 
involved in the acute inflammatory response of the immune system.  This control in gene 
expression is often due to changes in mRNA half-life and/or the translatability of the gene under 
conditions that promote this acute response and are controlled by AU-rich cis-elements (AREs) 
that lie within the 3’-UTR of the gene [reviewed in (150)].  Like other functional cis-elements 
that control transcription and 3’-end processing, AREs come in a variety of permutations that 
stem from a core consensus AUUUA element.  Other non-AUUUA containing U-rich stretches 
have also been shown to regulate gene expression post-transcriptionally.  There are many 
proteins that have been identified to bind to these regulatory cis-elements whose expression is 
also regulated under a variety of cellular conditions.  Besides regulating the abundance of these 
trans-acting factors to bestow their influences through the AREs, another way to control the 
influence of the AREs is to dictate their presence or absence in the final gene transcript.  This is 
done through alternative polyadenylation of the gene transcript where selection of one poly(A) 
site over another determines the presence or absence of the regulatory AREs in the final gene 
transcript.   
 Our work has shown that LPS-stimulation of the RAW 264.7 murine macrophage cell 
line causes alternative polyadenylation on a number of genes.  In correlation with this measured 
poly(A) site switch is an increase in the level of CstF-64, a protein involved in pre-mRNA 
cleavage and polyadenylation.  Other studies have shown that increases in CstF-64 protein 
induce poly(A) site switches on Ig heavy chain genes in B-cells (139), NF-ATc in effector T-
cells (25) and Testis Brain RNA-Binding Protein (TB-RBP) in male germ cells (24).  Despite our 
observation that CstF-64 protein increases in LPS-stimulated BMDMs (Figure 4), we were 
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 unable to detect a poly(A) site switch on our reporter mini-gene in these cells due to limitations 
in transfecting primary cells with our reporter plasmid.  However, because of our success in 
detecting alternative polyadenylation on the real genes Id-2, CTE-1, MMP-9 Tyki and Fabp-4 
through our PCR approach (MRP-PCR) using cDNA generated from RAW macrophages, 
identification of these post-transcriptional poly(A) site switching events on cDNA generated 
from LPS-stimulated BMDMs could be easily performed and provide evidence of the post-
transcriptional regulation of gene expression in vivo.  To better understand the mechanism of 
alternative polyadenylation that was observed for Id-2, CTE-1, MMP-9, Tyki and Fabp-4, it 
would be informative to perform ChIP studies on these genes in the attempt to correlate any 
changes in the phosphorylation state of RNAP-II CTD to the observed poly(A) site switch and to 
identify any changes in pre-mRNA processing factor association to the transcriptional machinery 
when the RAW cells are stimulated with LPS.   
 We have also identified AREs in the 3’-UTR of Id-2, CTE-1, MMP-9, Tyki and Fabp-4 
that lie between the active promoter-proximal and promoter-distal poly(A) sites.  Although there 
are no publications to date that identify these gene-specific elements as regulators of gene 
expression, all of them resemble regulatory elements previously identified to influence mRNA 
half-life or translation (150).  Studies that elucidate the putative role these AREs play in gene 
expression on the mRNA transcript would provide important insight into the regulation of these 
genes and further support the importance of post-transcriptional gene regulation in the LPS-
stimulated macrophage.  Such studies would include the comparison of mRNA half-lives of the 
different mRNA isoforms of these genes under untreated and LPS-stimulated conditions.  
Furthermore, in vivo and in vitro protein binding studies to these putative AREs could elucidate 
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 what mRNA binding proteins are responsible for the post-transcriptional regulation of these 
genes. 
 Since we have demonstrated that the 3’-end processing of pre-mRNA is a significant 
contributor to gene expression, altered regulation of this step can, therefore, disrupt cell 
homeostasis.  For example, a single nucleotide mutation within the poly(A) site of the human 
prothrombin gene causes an increase in the pre-mRNA processing of that gene and subsequent 
over-accumulation of the thrombin protein causing thrombosis (52).  In the case of malignancies 
of hematopoietic lineage, the t(11;14)(q13;32) translocation found most often in mantle cell 
lymphomas eliminates AREs in the 3’-UTR resulting in a profound increase in the mRNA 
stability and subsequent protein accumulation of the chimeric gene product (CCND1) resulting 
in neoplastic pathology (120).  Even though the elimination of AREs in CCND1 does not involve 
alternative polyadenylation, cases may exist in other disease states where alternative 
polyadenylation does change the number of AREs within the 3’-UTR of a particular transcript.  
For example, the aberrant over-expression of the COX-2 enzyme is linked to many forms of 
malignant tumors.  The 3’-UTR of the human COX-2 gene contains three functional 
polyadenylation sites (3) and multiple AREs that are highly conserved between human, mouse 
and rat (3, 41, 102).  Multiple forms of the COX-2 message that correspond to alternative 
poly(A) site use have been detected in IL-1β treated human lung carcinoma cells and in the heart 
and lung of rats treated with LPS intraperitoneally (100).  The proximal AREs have been shown 
to regulate translation while the distal AREs confer message stability (27).  Interestingly, the 
incorporation of the distal ARE in the mature transcript is dependent on the poly(A) site chosen.  
Because of the nature of the COX-2 3’-UTR and the fact that alternative polyadenylation dictates 
the presence or absence of known mRNA instability elements in the mature transcript, it would 
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 be noteworthy to identify the different mRNA isoforms and their half-lives present in various 
malignant tumors.  Quite possibly, the increase in COX-2 protein expression can, in part, be 
attributed to an increase in message stability caused by alternative polyadenylation.  Therefore, if 
various COX-2 mRNA isoforms are found in these tumors, studies on CstF-64 protein 
expression and 3’-end cleavage activity may be prudent to pursue.  We could not assess the 
influence CstF-64 alone had on COX-2 gene expression because COX-2 is expressed only upon 
inflammatory or cytokine stimulation, and therefore was not detectable in unstimulated cells.  
 Interestingly, other studies from our lab have clearly shown that a poly(A) site switch 
does occur on the Ig heavy chain gene when B-cells differentiate into Ig-secreting plasma cells in 
the absence of CstF-64 increases (86).  With the growing evidence that demonstrates 
transcription and pre-mRNA processing as linked events and that the splicing and 3’-end 
processing of gene transcripts is influenced by the presence of pre-mRNA processing factors on 
the migrating polymerase, we believe that CstF-64 is able to influence the selection of one 
poly(A) site over another through its local concentration to the nascent pre-mRNA.  This could 
be achieved by increasing the over-all concentration of CstF-64 in the cell, which has been 
observed to be the limiting factor for active CstF trimer formation (86).  However, we also 
believe that the local concentration of CstF-64 near the nascent pre-mRNA can be heightened 
through an increase in the recruitment of the steady state, constitutive levels of CstF-64 to the 
transcriptional machinery.  Therefore, alternative polyadenylation can occur in conditions where 
no overt change in CstF-64 protein expression is observed through Western Blot of cellular 
lysates (86).  As has been shown for other pre-mRNA processing factors in yeast, the recruitment 
of CstF-64 to the transcriptional machinery can be driven by a specific phosphorylation state of 
the RNAP-II CTD.  Through our proposed studies to perform ChIP across the Ig heavy chain 
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 locus in A20 and AxJ cells, we hypothesize that CstF-64 and/or other factors involved in pre-
mRNA 3’-end processing are associated more with RNAP-II in the plasma cell line allowing for 
a greater selection of the weaker, promoter-proximal poly(A) site on the Ig transcript as it is 
expelled from the polymerase. 
 As we have clearly demonstrated in LPS-stimulated macrophages, the role of post-
transcriptional gene regulation extends far beyond the popularly studied pro-inflammatory genes 
TNF-α and COX-2.  We have shown that literally any gene, regardless of the number of poly(A) 
sites it possesses, can be influenced by the elevated levels of cleavage and polyadenylation 
brought on by increased CstF-64 expression.  However, the more profound effects are 
demonstrated on genes that possess multiple poly(A) sites and AU-rich regulatory elements.  We 
are also actively testing in B-lymphocytes the hypothesis that alternative polyadenylation can 
occur in the absence of increases in CstF-64 expression on the Ig heavy chain gene.  Through the 
RNAP-II CTD phosphorylation-dependent recruitment of pre-mRNA processing factors (i.e. 
CstF-64) to the transcriptional machinery, we believe that alternative poly(A) site selection can 
occur on genes that possess multiple poly(A) sites without changing CstF-64 expression.  This 
would extend the already existing dogma that links transcription to pre-mRNA processing to a 
greater understanding of the impact transcription and RNAP-II CTD phosphorylation bestow on 
post-transcriptional gene regulation. 
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Table 1.  Sequences of oligonucleotides used for semi-quantitative RT-PCR and real-time QPCR 
Gene Name  Sequence (5’-3’) 
TNF-α Sense CAC GTC GTA GCA AAC CAC CAA GTG GAa
 Antisense TGG GAG TAG ACA AGG TAC AAC CC 
iNOS Sense CAC CTT GGA GTT CAC CCA GT   
 Antisense ACC ACT CGT ACT TGG GAT GC   
COX-2 Sense AAA CCG TGG GGA ATG TAT GAG Ca
 Antisense TCG CAG GAA GGG GAT GTT GTT C 
CHOP Sense GCA TGA AGG AGA AGG AGC AG 
 Antisense CTT CCG GAG AGA CAG ACA GG 
Id-2 Sense ATC AGC CAT TTC ACC AGG AG 
 Antisense TCC CCA TGG TGG GAA TAG TA 
Tyki Sense AGC TCT GCA ATC CCG TTC TA 
 Antisense CCA GAA TCC ACG GTG CTT AT 
MMP-9 Sense TGA ATC AGC TGG CTT TTG TG 
 Antisense GTG GAT AGC TCG GTG GTG TT 
PLOD-2 Sense GTC AAG CAG AAG CCA GGA AC 
 Antisense CCA CAA CTT TCC ATG ACG TG 
P4ha2 Sense AGC GAT GAC GAA GAT GCT TT 
 Antisense CCA CTT GTT GGA GAC CCA CT 
MMP-12 Sense TTT CTT CCA TAT GGC CAA GC 
 Antisense GGT CAA AGA CAG CTG CAT CA 
RARβ Sense ACA AGT CAT CGG GCT ACC AC 
 Antisense CTG TGC ATT CCT GCT TTG AA 
CTE-1 Sense GAT GGC CTC AAG GAT GTT GT 
 Antisense TAA GGG GGC TCG ATG TAA TG 
CD48 Sense CGA TCT CAT CGT CAC ACC AC 
 Antisense TGC TTC CAA GTT GCC TTC TT 
HPRT Sense CGT CGT GAT TAG CGA TGA TG   
 Antisense AGA GGT CCT TTT CAC CAG CA   
a Primer sequences obtained from (56). 
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Table 2. Genes that exhibit increased expression in CstF-64 over-expressing RAW macrophagesa
Fold Increaseb Fold Increaseb
Accession 
Number Gene Name CstF-
64 
LPS 
No. of 
Putative 
Poly(A) 
Sitesc
Accession 
Number 
Gene 
Name CstF-
64 
LPS 
No. of 
Putative 
Poly(A) 
Sitesc
Biological Regulation/Metabolism Signaling 
NM_020557 Tyki 2.64 35.12 3 AK089198 GPCR-35 4.90 - 5 
NM_013599 MMP-9 2.05 7.11 2 NM_022881 RGS-18 3.59 - 2 
NM_011961 PLOD-2 17.62 - 1 Development 
BC018411 P4ha2 13.01 - 1 NM_019733 Hermes 14.81 3.22 1 
BC019135 MMP-12 5.97 - 1 AF220524 DNMT3L 2.84 - ND 
NM_080555 Ppap2b 4.88 - NDd Other Genes/Unknown 
Transcriptional Regulation AY239223 Epsti1 2.78 5.44 1 
NM_007837 CHOP 2.81 7.22 ND BC022751 
IFN-
stimulated 
protein 
2.29 22.78 ND 
NM_010496 Id-2 2.64 3.45 4 BC057864 Digr2 2.15 7.31 1 
NM_011243 RARβ 4.93 - 2 BC010564 histone H2a 2.09 7.83 ND 
Transport BC024822 EST AW146242 3.79 - 2 
BC002148 Fabp-4 4.76 5.11 2 BC009118 
cDNA 
sequence 
BC009118 
2.51 - 1 
NM_023044 Slc15a3 2.40 20.09 ND      
NM_007752 Ceruloplasmin (Cp) 2.40 17.98 1      
NM_007443 Bikunin  5.29 - 1      
a Data are from three independent experiments and were analyzed as described in Materials and Methods.  Genes shown were 
induced an average of 2-fold or greater. 
b Fold increase in average signal value observed in CstF-64 over-expressing or LPS-stimulated RAW macrophages compared to 
untreated, control. 
c Number of AAUAAA and AUUAAA poly(A) signals with associated GU-rich regions identified in the 3’-UTR of the listed 
GenBank sequence.   
d ND – no identifiable AAUAAA or AUUAAA poly(A) site in the 3’-UTR of the listed GenBank sequence. 
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Table 3. Genes that exhibit decreased expression in CstF-64 over-expressing RAW macrophagesa
Fold Decreaseb Fold Decreaseb
Accession 
Number Gene Name CstF-
64 
LPS 
No. of 
Putative 
Poly(A) 
Sitesc
Accession 
Number 
Gene 
Name CstF-
64 
LPS 
No. of 
Putative 
Poly(A) 
Sitesc
Biological Regulation/Metabolism Transport 
AK053680 CTE-1 6.71 3.13 4 NM_007643 CD36  16.16 - ND 
NM_134188 MTE-1 5.19 2.27 1 AF057367 Uty 5.92 - 4 
NM_012011 eIF-2α Y-linked 14.74 - 5 Signaling 
NM_020026 B3galt3 7.59 - 1 BC010200 FGFR1 4.45 - 1 
NM_153153 Supervillin  4.08 - 2 NM_010336 Edg2 3.81 - 2 
NM_007945 Eps8 3.04 - 2 AB122023 Pilr-1 3.37 - 1 
AK048950 Siat10 2.95 - 3 AK028875 CXCL16 2.71 - 3 
NM_011890 sarcoglycan, beta  2.10 - 4 NM_016846 ralGDSL-1 2.67 - 2 
BC048929 Dystonin  2.01 - 3 U66888 EMR-1 2.29 - 1 
Adhesion/Binding NM_152915 DNER 2.12 - 3 
NM_021495 Nectin 3 2.21 2.38 NDd NM_008967 Ptgir 2.11 - 1 
NM_012008 Ddx3 Y-linked 16.06 - 7 Development 
NM_011419 Jumanji 1D 5.48 - 3 BC016887 DOC-2 2.42 - 4 
NM_029413 Zcwcc2 4.19 - ND Other Genes 
NM_007965 Evl 4.16 - 1 NM_153098 CD109 5.40 - 2 
AF116823 Trip6 3.39 - ND BC060977 CD48  4.30 - 2 
AK030971 coronin 2A 2.03 - 1      
a Data are from three independent experiments and were analyzed as described in Materials and Methods.  Genes shown were 
induced an average of 2-fold or greater. 
b Fold increase in average signal value observed in CstF-64 over-expressing or LPS-stimulated RAW macrophages compared to 
untreated, control. 
c Number of AAUAAA and AUUAAA poly(A) signals with associated GU-rich regions identified in the 3’-UTR of the listed 
GenBank sequence.   
d ND – no identifiable AAUAAA or AUUAAA poly(A) site in the 3’-UTR of the listed GenBank sequence. 
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Table 4.  Sequences of oligonucleotides used for MRP-PCR 
Gene Name Primer Name Primer Sequence Product Size with F 
Id-2 F CCA GCA TCC CCC AGA ACA AG  
 R1 GGG AAT TCA GAT GCC TGC AA 211 
 R2 GCT TGC TTT ATT TCA GAC AAC CAG TG 937 
CTE-1 F CTG GTG GGT GCC AAC ATC AC  
 R1 CCC AGC CCT TGA ATC AGC AC 290 
 R2 CGG GAA TGA GAG CGT TTG CT 937 
MMP-9  F CTG GAC TCC GCC TTT GAG GA  
 R1 GAA AGG ACG GTG GGC AGA GA 623 
 R2 CAG CTG CCA GCA ACC ACA GT 1204 
Tyki F TGC CCT GAG TGA GTG CCT TG  
 R1 CAG AGC CAC CAG GCT TCT CC 477 
 R2 TTC AGC CTC TGG TGC AAT CA 1163 
Fabp-4 F ATT ACC GTG CCC ACC TGC AT  
 R1 GCC CCG CCA TCT AGG GTT AT 320 
 R2 TAT GGG AGG GTG GAG CCT GA 676 
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Table 5. Groups of AU-rich Elements (AREs)a
Group Motif Example 
I WAUUUAW and a U-rich region c-fos, c-myc 
IIA AUUUAUUUAUUUAUUUAUUUA GM-CSF, TNF-a 
IIB AUUUAUUUAUUUAUUUA Interferon-a 
IIC WAUUUAUUUAUUUAW cox-2, IL-2, VEGF 
IID WWAUUUAUUUAWW FGF2 
IIE WWWWAUUUAWWWW u-PA receptor 
III U-rich, non-AUUUA c-jun 
a adapted from (150).
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Table 6. Sequences of Oligonucleotides Used For 5’-RACE PCR and ChIP 
5’-RACE 
PCR 
 Sequence (5’-3’) 
GSP1 Antisense GCC AGT GAG GGA CAA AGA AAG CAT AG 
GSP2 Antisense CCA ATA GTC GCA GGC GGA ATA ATC AC 
IgG2a 
Locusa
  
Promoter Sense ATG CAA ATC CTG TGG GTC TAC A 
 Antisense CAG CGA TCT CAG GGT TTC TGT 
V-region Sense CGG CCA CAT TAA CTG TTG ACA 
 Antisense TCG CAG GCG GAA TAA TCA C 
IgH Eμ Sense GGC CGA TCA GAA CCA GAA CA 
 Antisense CCA AAT AGC CTT GCC ACA TGA 
3’-IgH Eμ Sense CAC AGT AAT GAC CCA GAC AGA GAA G 
 Antisense CCT CGC TTA CTA GGG CTC TCA A 
IgH C1 Sense CCC TGT GTG TGG AGA TAC AAC TG 
 Antisense TCA CTG GCT CAG GGA AAT AAC C 
IgH M1 Sense CCT GCT CAG CGT GTG CTA CA 
 Antisense CAG CAG AGG GTG GGA GAC A 
3’-pAm Sense CCA GAA GAG AAG CGT GTG GTA CT 
 Antisense GGA TCC ATG CTC TTT GCT GAA 
Control 
Genea
  
MyoD1 Sense AGA GTC CAG GCC AGG GAA GA 
promoter Antisense TGT GGA GAT GCG CTC CAC TA 
GAPDH Sense GAG ACA GCC GCA TCT TCT TGT 
promoter Antisense CAC ACC GAC CTT CAC CAT TTT 
β2-Globin Sense CCT GCT AGA AGC AAG GTC AGA AA 
promoter Antisense TTT CAG GAT TCC GTG TGT AAA AG 
IgG2a 
Promoter 
Sequencing 
  
Μ13 Sense CAG GAA ACA GCT ATG AC 
 Antisense GTA AAA CGA CGG CCA G 
a All cDNA sequences used for primer design using Primer Express were obtained from the GenBank database. 
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Figure 1. Mechanism of pre-mRNA 3’-end Cleavage and Polyadenylation 
A.  Cleavage Polyadenylation Specificity Factor (CPSF) binds to the consensus AAUAAA poly(A) signal through 
it’s 160-kDa subunit, CPSF-160.  Cleavage Stimulatory Factor (CstF) binds to the less conserved GU-rich region 
downstream from the cleavage site through it’s 64-kDa subunit, CstF-64.  Studies have shown that stronger 
polyadenylation sites have a poly(A) signal approximately 11-23 nucleotides upstream of the cleavage site and the 
GU-rich region approximately 10-30 nucleotides downstream from the cleavage site.  B.  Protein/protein 
interactions between CPSF-160 and the 77 kDa subunit of CstF, CstF-77, cause an out-looping of the intervening 
RNA that exposes an adenosine residue to cleavage and subsequent polyadenylation.  In vitro studies have shown 
that Cleavage Factors I and II (CF I and CF II) and Poly(A) Polymerase (PAP) are also required to complete the pre-
mRNA 3’-end processing.  C.  Coincident with the addition of the first adenosine residues of the poly(A) tail, 
Poly(A) Binding Proteins (PABP) assemble onto the poly(A) tail and confer mRNA stability and induce rapid, 
processive addition of the remaining adenosines.   
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Figure 2. Comparison of Three Motifs of Exon Arrangement in the Context of Alternative Polyadenylation.  
Solid dark gray boxes represent exons and the thin line(s) that connect them represent introns.  Light gray, hatched 
boxes indicated the 3’-UTR upstream of the indicated poly(A) site.  Below each exon arrangement are depicted the 
two possible mRNA transcripts stemming from the particular splicing pattern shown (indicated by the dashed lines) 
and the use of either the promoter-proximal poly(A) site (pA1) or promoter-distal poly(A) site (pA2).   A.  Tandem 
poly(A) sites.  In this exon arrangement, all alternative poly(A) sites are located downstream from the 3’-most 
protein coding exon (‡).  Thus, selection of one poly(A) site over another is disconnected from splicing mechanisms 
and determines whether AU-rich regulatory elements (ARE) are retained in the mature transcript.  B.  Composite 
internal/terminal exons.  In this exon arrangement, there exists a competition between the splicing and 
polyadenylation reactions that results in an mRNA that codes for proteins possessing different carboxy-termini.  
When the cleavage and polyadenylation reaction at the proximal poly(A) site (pA1) is chosen before or instead of the 
splicing reaction at the 5’-internal splice site within the preceding exon (5’SS), then the short transcript is formed 
that possesses the complete terminal exon (‡).  If the 5’SS is selected before cleavage/polyadenylation can occur at 
pA1, then a composite exon is created and a different terminal exon is incorporated into the final transcript (‡*).  
Polyadenylation subsequently occurs at the distal poly(A) site (pA2).  C.  Skipped Exons.  The final mRNA product 
for this exon arrangement is dictated primarily by the splicing pattern of the transcript.  Cleavage and 
polyadenylation will occur at pA1 only if the exon immediately preceding the poly(A) site is incorporated into the 
final gene product.  Because this exon does not possess a splice site donor, no further splicing will occur and will 
thus be the terminal exon of the transcript (‡).   However, if the exon that is associated with pA1 is not chosen for 
incorporation into the final gene product (i.e. it is skipped), then the distal poly(A) (pA2) site will be chosen for 3’-
end processing and a different terminal exon will be in the final transcript (‡*).  Figure adapted from (45) 
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Figure 3. LPS stimulation of RAW 264.7 macrophages increases CstF-64 protein expression. 
A.  Total protein was harvested from macrophages stimulated for 18 hours with increasing amounts of LPS.  CstF-
64 protein expression was assayed by Western blot.  B.  A dilution series of the protein extracts from the 
macrophage cell line stimulated for 18 hours with 100 ng/ml LPS was performed for semi-quantitative 
determination of LPS-induced CstF-64 induction by Western blot (1x = 10 μg, 1/2x = 5 μg, 1/4x = 2.5 μg, 1/8x = 
1.25 μg, and 1/16x = 0.625 μg).  The diluted LPS-stimulated samples were compared to 10 μg of protein extract 
from untreated cells.  C.  Macrophages were cultured in the absence or presence of 100 ng/ml LPS and pulsed with 
3[H] thymidine at various time points to determine cellular proliferation.  Averages ± SEM are shown for sample 
size n=3.  
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Figure 4 LPS stimulation of RAW 264.7 macrophages and BMDM does not alter the expression levels of 
other factors involved in the cleavage/polyadenylation reaction.  
Protein extracts from macrophages stimulated for 18 hours with 100 ng/ml of LPS were probed by Western blot for 
the indicated cleavage/polyadenylation factors. 
 
 
104 
 0.0
0.5
1.0
1.5
2.0
2.5
3.0
gpt ORF SV40 UTR SV40 UTRα2-globin
Proximal poly(A) – 185 nt
Distal poly(A) – 487 nt
Full length – 649 nt
pA proximal pA distalA
N
o 
E
nz
ym
e
N
o 
R
N
A
U
nt
ra
ns
fe
ct
ed
C
on
tro
l
LP
S
α2-globin
Transfected
U
nt
ra
ns
fe
ct
ed
1    2    3    4    5    6
B
Full Length
Distal Poly(A)
Proximal 
Poly(A)
C
Fo
ld
 In
cr
ea
se
 o
f P
ro
xi
m
al
/D
is
ta
l *
CstF-64
Expression
Untreated LPS
1X ~5X
 
Figure 5. Stimulation of RAW 264.7 macrophages with LPS caused increased selection of a weaker promoter-
proximal poly(A) site.   
A.  Schematic diagram of the α2-globin reporter construct.  Predicted sizes of the protected antisense riboprobe 
fragments, based on the poly(A) site chosen on the reporter construct, are indicated.  B. mRNA from macrophages 
stimulated with LPS was used in an RNase protection assay to measure changes in poly(A) site choice.  Controls 
include probe without T2 RNase to show the full length probe (lane 1), probe without RNA plus T2 RNase to 
illustrate complete digestion of the probe in the absence of RNA (lane 2), and probe with RNA from untransfected 
macrophages to control for nonspecific hybridization (lanes 3 and 4).  Lanes 5 and 6 show protected riboprobe 
fragments from RAW-α2 RNA unstimulated or LPS-stimulated, respectively.  C. Fold changes in P/D ratios of 
macrophages stimulated with LPS are compared to the P/D ratio achieved from untreated macrophages.  Below the 
graph indicates the relative amount of CstF-64 protein measured from the same cultures the RNA was harvested 
from.  In using the paired student-t test, significant changes in poly(A) site selection were detected in LPS-
stimulated macrophages.  Averages ± SEM are shown based on sample size n=5.  *  p<0.005. 
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Figure 6. Over-expression of CstF-64 in RAW 264.7 macrophages caused increased selection of a weaker 
promoter-proximal poly(A) site.  
A.  Western blot comparing the levels of CstF-64 between untreated (U), LPS-treated (LPS), and CstF-64 over-
expressing (64) RAW macrophages.  B.  Fold changes in P/D ratios of macrophages either stimulated with LPS or 
over-expressing CstF-64.  Below the graph indicates the relative amount of CstF-64 protein measured from the same 
cultures the RNA was harvested from.  In using the paired student-t test, significant changes in poly(A) site selection 
were detected in LPS-stimulated and CstF-64 over-expressing macrophages.  Averages ± SEM are shown based on 
sample size n=5.  *  p<0.005.  **  p<0.01. 
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Figure 7. Comparison of Human and Mouse CstF-64 Amino Acid Sequence  
Shown is the amino acid sequence for the human form of CstF-64 (NM_001325) that we over-expressed in the 
RAWα2 macrophages.  Letters that appear above the primary sequence indicate the amino acid change that appears 
in the mouse form of the protein for that residue.  The primary sequence is font coded to identify structural and 
functional motifs of the protein.  Bold residues identify the conserved RNA recognition motif (RRM) shared by 
CstF-64 and many other RNA binding proteins.  The first block of normal font residues identifies the hinge region 
that is responsible for binding to CstF-77.  Emboldened and underlined residues identify proline/glycine-rich region, 
while the italics residues identify the conserved MEARA/G repeats responsible for the alpha-helical portion of the 
protein.  The last block of normal font residues identifies the C-terminal domain of CstF-64, a domain that exhibits 
affinity to the PC4 transcription elongation factor.  A triple proline insert appears in the mouse form and is located 
immediately downstream of Proline 350, as shown. 
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Figure 8. Validation of differential gene expression observed in LPS-stimulated and CstF-64 over-expressing 
RAW 264.7 macrophages by semi-quantitative RT-PCR  
Ethidium bromide-stained agarose gels show increases in product formation from 20, 25, 30 or 35 PCR cycles which 
ensures that the reactions lie within the linear range, and therefore can be accurately compared between RAW 
macrophage culture conditions. 
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Figure 9. Model of CstF-64 influences on gene expression.  
LPS treatment of RAW macrophages increases CstF-64 protein levels.  Depicted are three possible ways elevated 
levels of CstF-64 protein influence gene expression: (1) The cleavage activity of the cell is increased allowing a 
larger number of pre-mRNA transcripts to be 3’-end cleaved and polyadenylated, especially for transcripts that have 
GU-rich sequences in the 3’-UTR that are sub-optimal for CstF-64 binding.  This would create more mature mRNA 
transcripts of a given gene to be used for protein translation. (2) An alternative polyadenylation event occurs on a 
gene transcript that has multiple poly(A) sites surrounding mRNA elements that control stability.  Increased 
selection of one poly(A) site over another would determine the presence or absence of these mRNA stability 
elements from the mature transcript, thus increasing mRNA half-life and allowing the accumulation of more protein 
product. (3) The increased expression of transcriptional regulators (e.g. CHOP, Id-2, RARβ) by either of the two 
aforementioned mechanisms has effects on the expression on their targeted genes.  The Venn diagram depicts 515 
genes that change expression with LPS stimulation, 52 genes that change expression with CstF-64 over-expression, 
and 15 genes that change under both conditions.  “+” Induction of gene expression; “−” Repression of gene 
expression. 
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Figure 10. The number of overlap genes detected by microarray analysis does not occur by random chance. 
A Statistical algorithm was designed to test the random chance of the same 15 genes out of 22,690 on the array 
being selected from two separate pools at random.  We found that this overlap between the LPS stimulation and 
CstF-64 over-expression would occur far less than once in 30,000 trials. 
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Figure 11. Increased levels of CstF-64 protein induce poly(A) site switch.  
A.  Schematic diagram of multiple-reverse primer PCR (MRP-PCR) experimental approach.  The diagram on the 
top depicts the locations of the common forward primer (F), the common reverse primer (R1) and the reverse primer 
that is specific for transcripts only processed at the putative distal poly(A) site (R2).  Also shown are the locations of 
the two putative poly(A) sites and the AU-rich elements (ARE) that lie between them.  The middle and bottom 
diagram depict the mature gene product when it is processed at the distal or proximal poly(A) site, respectively.  
PCR using the F and R1 primers (denoted FR1) will amplify all gene products regardless of where they are 
processed.  PCR using the F and R2 primers (denoted FR2) will amplify only the gene products that are processed at 
the downstream poly(A) site.  B.  Ethidium bromide-stained agarose gels show decreases in distal poly(A) site use 
under LPS-stimulating and CstF-64 over-expressing conditions for Id-2, CTE-1 and MMP-9.  ‡. A lighter exposure 
of the gel for MMP-9 under LPS-stimulating conditions is also shown to better compare the reduced amount of FR2 
PCR product produced relative to FR1.  C.  Ethidium bromide-stained agarose gels show increases in distal poly(A) 
site usage under LPS-stimulating and CstF-64 over-expressing conditions for Tyki and Fabp-4.  Also shown is an 
agarose gel of HPRT that demonstrates that equal amounts of cDNA were applied to all PCR reactions. 
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 Gene Name Accession No.
2398AAUAAA2403
2445UUAUCUGUAGUUG2457
2484UUUGUAGGGUGGAUUCUG2501
2595UUUUAUUUAUUAU2607
2633UAUUUAA2639
3212AAUAAA3217
MMP-9 NM_013599
ORF
ORF
464AAUAAA469
475GGCAUUUGGGGACUUUUU488
484UUUUUCUUUUCUUUUUACUUUCUCUUUUUCUUUU517
922AUAUAUUUAUAUA934
678UAUUUAU684 1090AAUAAA1095 1186AAUAAA1191
1099GUGUGUUUAUUGAAUGUUGAUUGCUUGCUUU…
GUGCUUUGAUUUUUUUUUAUGCUAUGUUAUAACUGA1172
1229AAUAAA1234
2003AUUUA2007
Id-2 NM_010496
1578GUCAUAUUUGGU…GGUGGCUGG1621
1502AAUAAA1507
1990AUUUA1994
CTE-1 AK053680
ORF
1718UUCUUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCC
UUCCUUCCUUCUUUCCUCUCUCUUUUUCUUUUUUUCUUUCUUUUUCCCUCCCCUUUUCUCUUU
CCUUCCUUCCUUUCUGUCUGUCUUUAUUUCUUUUUUUCUUUCUUUCCUUCUUCCUGUGUG1900
1551AAUAAA1556
1568AUUAAA1573 2253AUUAAA2258
2121AUUUA2125
1149GCUGGUGGUGGUGAGUU1165
1122AAUAAA1127 1674UUGUGGGUUUUUUGUUGUUGUUGUUGUUGUUGUUGUUUUGUUUUGGUGUUGUUGUUAUUGUUG1735
Fabp-4 BC002148
ORF
2033AAUAAA2038
1936AUUUAUUGUUUUUUUUU1952
2519AAUAAA2524 2570GUCAUAUUUGGU2580
2605UAUUAUUUAACAUU2618
2751 AUAAGAUUUAAUAU2764
3000AAUAAA3005
Tyki NM_020557
ORF
2554AAUAAA2559
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 Figure 12 Diagram depicting key elements of the Id-2, CTE-1, MMP-9, Tyki and Fabp-4 3’-UTRs.  
ORF indicates the 3’-end of the transcript’s open reading frame.  Precise locations of the elements are indicated and 
derived from the Entrez accession number provided.  Open boxes indicate the consensus AAUAAA or 
nonconsensus AUUAAA poly(A) signal and where CPSF-160 binds.  Closed boxes indicate the GU-rich region that 
lies downstream from the poly(A) signal and where CstF-64 binds.  The open circle indicates a non-AUUUA 
containing U-rich region.  Closed circles indicate the putative AU-rich elements.  Emboldened within these elements 
is the core AUUUA consensus sequence.  The half-filled circle in Fabp-4 3’-UTR shows a core AUUUA consensus 
sequence with an associated U-rich stretch.  For the Id-2, CTE-1 and MMP-9 genes, increased use of the proximal 
poly(A) site was observed under LPS-stimulating and CstF-64 over-expressing conditions.  As a result, the putative 
AREs indicated would be removed from the final gene product, thus eliminating any regulatory influences these 
elements may have on the half-life or translatability of the mRNA.  For both the Tyki and Fabp-4 genes, increased 
use of the distal poly(A) site was observed under LPS-stimulating and CstF-64 over-expressing conditions.  As a 
result, the putative AREs indicated would be added to the final gene product, thus incorporating any regulatory 
influences these elements may have on the half-life or translatability of the mRNA. 
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Figure 13. Mouse CstF-64 mRNA 3’-Untranslated region  
ORF indicates the 3’-end of the transcript’s open reading frame.  Precise locations of the elements are indicated and 
derived from the Entrez accession number provided.  Open boxes indicate the consensus AAUAAA poly(A) signal 
and where CPSF-160 binds.  Closed boxes indicate the GU-rich region that lies downstream from the poly(A) signal 
and where CstF-64 binds.  Closed circles indicate the putative AU-rich elements.  Emboldened within these 
elements is the core AUUUA consensus sequence.  The open circle indicates a non-AUUUA containing U-rich 
region.  The 3’-UTR of the mouse CstF-64 gene transcript possesses a variety of putative AREs.  The AREs with the 
shaded triangles that lie immediately upstream of the distal poly(A) site are of most interest when determining the 
potential translation regulatory role they bestow on CstF-64 gene expression, although any of the putative AREs 
may contribute to the translatability of the gene transcript. 
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Figure 14. Mouse immunoglobulin germline genomic arrangement  
The germline genomic arrangement of the mouse immunoglobulin gene is indicated prior to VDJ recombination and 
isotype switching.  There are more than 1000 different heavy chain variable regions (VH) each associated with its 
own leader sequence (LH) and promoter (not shown).  Downstream of the 3’-most VH lies the diversity region (DH) 
cluster that contains 23 alternative segments followed by the joint region (JH) cluster that contains 4 segments.  
Located approximately 500 nucleotides downstream from the 3’-most JH is the intronic enhancer (Eμ) that 
contributes to B-cell development and Ig transcription.  Following Eμ is the heavy chain constant region locus 
beginning with Cμ and followed by Cδ, Cγ1, Cγ2a, Cγ2b, Cε and Cα, respectively (not shown to scale).  Each constant 
region locus possesses its own switch region (S) located immediately upstream of the constant region locus, except 
Cδ which shares the switch region with Cμ. 
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Figure 15. Alternative polyadenylation of the IgG2a gene.  
The center of the figure depicts the genomic arrangement of the IgG2a gene after VDJ recombination has occurred 
where boxes represent protein coding exons and the line that connects the boxes represent introns and untranslated 
regions.  When the 5’ internal splice site (5’SS) is selected before cleavage/polyadenylation can occur at the 
secretory poly(A) site (pAs), the membrane form of Ig is created as a result of incorporation of the downstream 
membrane spanning exons (light gray) and use of the membrane bound associated poly(A) site (pAm).  This occurs 
primarily in naïve and memory B-cells (e.g. A20 B-cell lymphoma).  When the pAs is chosen for cleavage and 
polyadenylation, the complete Cγ3 exon is incorporated into the mature transcript (black box), thus excluding the 
incorporation of membrane spanning exons and producing the secretory form of Ig.  This occurs primarily in plasma 
cells (e.g. AxJ hybridoma). 
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Figure 16. AxJ plasma cell hybridoma secretes Ig displaying a plasma cell phenotype. 
ELISA was performed to measure IgG2a secretion by the A20 memory B-cell and the AxJ plasma cell hybridoma 
over time.  Amounts of Ig per sample were measured against a standard curve and calculated per one million cells.  
An exponential curve was fit to the data.  The measurement was taken in triplicate and SEM was calculated for each 
time point. 
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 1   ACTATAGGGC ACGCGTGGTC GACGGCCCGG GCTGGTCTGT GTCACAGTGG      
51  GGCCACTGTC TCAAGCTGCA AATCTTTTTA GTGCACAGGC TCTAATGTTA 
101 CATCCATAGC CTCAACACAA GGTTCAGGGA TGAAGTATGG GATGAATTTC 
151 CACAGACAAG ATGAGGACTT GGGCTTCAGA ATCCTGATTC CTGACCCAGA 
201 TGTCCCTTCT TCTCCAGCAG GAGTAGGTGC TTATCTAATA TGTATCCTGC 
251 TCATGAATAT GCAAATCCTG TGGGTCTACA GTGGTAAATA TAGGGTTGTC 
301 TGCACGAAAC AGAAACCCTG AGATCGCTGC TCTCTTTACA GTTGCTGAAT 
351 ACACAAGACC TCACCATGGC ATCGAACTTC ATCATGGTCT TCTTGACAAC
401 AACAGCTCCA GGTGAGGGGC TCACACTAAC AGCCTTGAGG TCTGGCCACA 
451 CACATGGATG ACACTGACAC CAACCTTGCC TTTCTCTCCA CAGTTGTCCA 
501 CTCCCCGGTC CAATTGCAAC AGTCCGGGCC TGACCTTGTG AAACCTGGGA
551 TGTCCGTGAA ATTGTCCTGT AAGACTTTGG GTTACAATTT CTCCGACAAG
601 TGGATTCACT GGATTAAACA GAAGCCTGGC CGAGGCCTTG AATGGGTTGG
651 AAGGATTGAT CCTTCTAACG GTGATACTGA CTATAATGTG GACTTCAAGA
701 CCCCGGCCAC ATTAACTGTT GACAGACCCT CCAACACAGC CTACTTAGAA
751 CTCAGTAACC TGACATCTGG GGACTCTGCG GTCTATTATT GTTCAATATC
801 GGGTGATTAT TCCGCCTGCG ACTATTGG
VH DH JH2 JH3 JH3LH
A
B
LH            VH  
0
-222GAATTTCCACAGA-210
C/EBP
-77TATA-74-116CTCATGA-110
Heptamer
-107ATGCAAAT-100
Octamer
-163TCCCTTCTTCTCC-151
Pyrimidine Track
C
Genome
Walker
Adapter
AP1
AP2 GSP2
GSP1
 
118 
  
Figure 17. The A20 IgG2a promoter possesses elements common to most Ig promoters. 
A.  Illustrated is the 5’-RACE PCR strategy for obtaining the A20 IgG2a promoter sequence.  The Genome Walker 
Adapter™ is ligated to the blunt-end of genomic DNA created by enzymatic digestion using PvuII.  First round of 
PCR was performed using the linker-containing genomic library as template, the upstream-most adapter primer 
(AP1) and the downstream most gene-specific primer (GSP1).  The second round of PCR was performed using the 
PCR product generated from the first round PCR as template, the nested adapter primer (AP2) and the nested gene-
specific primer (GSP2). B.  Shown is the entire PCR product generated from the nested second round of PCR.  The 
underlined sequences are the heavy chain leader sequence and the heavy chain variable region, respectively.  The 
sequence obtained from the 5’-RACE PCR for the leader and variable region are an exact match to the published 
A20 Ig sequence (39), assuring us that we had obtained the active Ig promoter in the A20 B-cell lymphoma line.  C.  
The locations of the A20 IgG2a promoter elements are listed relative to the start codon contained in the heavy chain 
leader region. 
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Figure 18. Location of primer pairs used in chromatin immunoprecipitation across the A20 IgG2a gene. 
Illustrated is the exon arrangement of the A20 IgG2a genomic locus.  Our approach to identify the phosphorylation 
state of RNAP-II CTD across the IgG2a genomic locus required the generation of multiple primer pairs.  The 
location of many of the pairs was chosen based on important geographical features of the IgG2a genomic locus.  
Specifically, primer pair A targets the promoter of the A20 IgG2a gene, primer pair B targets the variable region, 
primer pairs C and C’ target the area on and downstream of the intronic enhancer, Eμ.  Locations of primer pairs D, 
E and F were chosen based on their locations relative to the secretory poly(A) site (pAs) and the membrane poly(A) 
site (pAm).  Because we hypothesize that the phosphorylation state of the RNAP-II CTD and the association of 
mRNA processing factors may be quite dynamic at the 3’-end of the gene, we designed primers to flank both 
poly(A) sites.  Therefore, primer pair D targets upstream of the pAs, primer pair E targets the membrane coding 
exon that lies between pAs and pAm, and primer pair F targets genomic sequence downstream of pAm.  Indicated 
are approximate lengths of the elements and the vertical arrow identifies the general location of transcription 
initiation. 
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 Figure 19. Serine-2 and Serine-5 phosphorylation levels of RNAP-II CTD change across the IgG2a heavy 
chain genomic locus in B-lymphocytes 
A.  Serine-2 phosphorylation of RNAP-II CTD was measured by chromatin immunoprecipitation (ChIP).  Shown 
are side-by-side comparisons of the level of Serine-2 phosphorylation of RNAP-II CTD between A20 memory B-
cells and AxJ plasma cells at seven loci across the IgG2a heavy chain genomic locus.  B.  Serine-5 phosphorylation 
of RNAP-II CTD was measured by ChIP.  Shown are side-by-side comparisons of the level of Serine-5 
phosphorylation of RNAP-II CTD between A20 and AxJ cells at seven loci across the IgG2a heavy chain genomic 
locus.  The amount of immunoprecipitated DNA was measured by QPCR and calculated as the percent input of total 
chromatin, as described in Materials and Methods.  ChIP experiments at each locus were performed at least three 
times and the standard error of the mean (SEM) is shown. 
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 APPENDIX A 
 
 
 
Genes that increased expression in LPS-stimulated RAW macrophagesa
Ave. Signal Log IntensitycProbe Set IDb Gene Title Gene Symbol 
Untreated LPS 
Fold 
Increased
1427747_a_at lipocalin 2 Lcn2 13.30 1846.23 138.81 
1419427_at colony stimulating factor 3 (granulocyte) Csf3 30.17 4082.86 135.32 
1416576_at suppressor of cytokine signaling 3 Socs3 10.95 1313.06 119.93 
1420380_at chemokine (C-C motif) ligand 2 Ccl2 37.72 3350.24 88.82 
1417263_at prostaglandin-endoperoxide synthase 2 Ptgs2 49.32 4276.25 86.70 
1418126_at chemokine (C-C motif) ligand 5 Ccl5 59.95 5021.78 83.76 
1449399_a_at interleukin 1 beta Il1b 48.33 4016.88 83.11 
1427381_at immunoresponsive gene 1 Irg1 60.50 4926.79 81.44 
1421473_at interleukin 1 alpha Il1a 13.78 889.39 64.56 
1449984_at chemokine (C-X-C motif) ligand 2 Cxcl2 93.05 5570.33 59.86 
1417314_at histocompatibility 2, complement component factor B H2-Bf 12.15 498.99 41.07 
1450826_a_at serum amyloid A 3 Saa3 56.95 2218.99 38.96 
1436058_at RIKEN cDNA 2510004L01 gene 2510004L01Rik 53.12 1920.50 36.15 
1420393_at nitric oxide synthase 2, inducible, macrophage Nos2 10.01 348.13 34.79 
1425951_a_at C-type lectin, superfamily member 10 Clecsf10 10.57 355.51 33.62 
1453196_a_at 2'-5' oligoadenylate synthetase-like 2 Oasl2 13.63 457.42 33.56 
1418580_at RIKEN cDNA 5830458K16 gene 5830458K16Rik 45.76 1522.32 33.27 
1450783_at interferon-induced protein with tetratricopeptide repeats 1 Ifit1 29.81 948.80 31.83 
1417244_a_at interferon regulatory factor 7 Irf7 95.21 2842.33 29.85 
1419607_at tumor necrosis factor Tnf 146.81 4291.48 29.23 
1420664_s_at protein C receptor, endothelial Procr 37.99 986.68 25.97 
1419417_at vascular endothelial growth factor C Vegfc 23.22 595.02 25.63 
1418240_at guanylate nucleotide binding protein 2 Gbp2 10.01 246.68 24.65 
1421207_at leukemia inhibitory factor Lif 11.35 273.97 24.13 
1451924_a_at endothelin 1 Edn1 10.07 233.15 23.15 
1418835_at pleckstrin homology-like domain, family A, member 1 Phlda1 24.61 568.55 23.10 
1431591_s_at interferon, alpha-inducible protein G1p2 37.34 854.09 22.87 
1419569_a_at interferon-stimulated protein Isg20 30.44 693.39 22.78 
1419309_at glycoprotein 38 Gp38 42.18 959.07 22.73 
1417266_at chemokine (C-C motif) ligand  6 Ccl6 11.48 256.64 22.36 
1420549_at guanylate nucleotide binding protein 1 Gbp1 14.10 305.49 21.66 
1417483_at expressed sequence AA408868 AA408868 47.59 1014.40 21.32 
1423602_at Tnf receptor-associated factor 1 Traf1 29.35 608.75 20.74 
1419604_at Z-DNA binding protein 1 Zbp1 10.01 205.55 20.54 
1420697_at solute carrier family 15, member 3 Slc15a3 122.99 2470.78 20.09 
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1424942_a_at myelocytomatosis oncogene Myc 22.43 441.76 19.69 
1418293_at interferon-induced protein with tetratricopeptide repeats 2 Ifit2 35.16 688.96 19.59 
1448562_at uridine phosphorylase 1 Upp1 10.01 192.69 19.26 
1460251_at tumor necrosis factor receptor superfamily, member 6 Tnfrsf6 11.17 213.44 19.11 
1427348_at cDNA sequence BC036563 BC036563 11.63 217.40 18.70 
1419603_at interferon, gamma-inducible protein 16 Ifi16 11.17 205.25 18.38 
1424339_at 2'-5' oligoadenylate synthetase-like 1 Oasl1 117.50 2132.50 18.15 
1451798_at interleukin 1 receptor antagonist Il1rn 312.22 5642.68 18.07 
1449025_at interferon-induced protein with tetratricopeptide repeats 3 Ifit3 20.50 363.82 17.75 
1417494_a_at ceruloplasmin Cp 10.01 171.93 17.18 
1421217_a_at lectin, galactose binding, soluble 9 Lgals9 103.35 1745.08 16.88 
1421551_s_at interferon activated gene 202B Ifi202b 168.18 2831.27 16.83 
1420671_x_at 
membrane-spanning 4-
domains, subfamily A, member 
4C 
Ms4a4c 12.51 202.40 16.18 
1425917_at histocompatibility 28 H28 18.98 297.26 15.66 
1435137_s_at Mus musculus transcribed sequences  198.98 3112.49 15.64 
1435331_at expressed sequence AI447904 AI447904 13.79 209.29 15.18 
1423954_at complement component 3 C3 36.02 534.20 14.83 
1418612_at schlafen 1 Slfn1 10.01 147.90 14.78 
1419149_at serine (or cysteine) proteinase inhibitor, clade E, member 1 Serpine1 69.83 1026.58 14.70 
1450297_at interleukin 6 Il6 10.01 145.95 14.59 
1421228_at chemokine (C-C motif) ligand 7 Ccl7 11.01 157.03 14.26 
1419714_at programmed cell death 1 ligand 1 Pdcd1lg1 63.59 903.58 14.21 
1434380_at 
Mus musculus diabetic 
nephropathy-related gene 1 
mRNA, partial sequence 
 16.56 231.31 13.96 
1418392_a_at guanylate nucleotide binding protein 3 Gbp3 10.45 144.73 13.85 
1419598_at 
membrane-spanning 4-
domains, subfamily A, member 
11 
Ms4a11 121.83 1603.46 13.16 
1422095_a_at thymidylate kinase family LPS-inducible member Tyki 14.46 187.36 12.96 
1427005_at serum-inducible kinase Snk 149.57 1885.37 12.61 
1448830_at dual specificity phosphatase 1 Dusp1 80.86 1009.19 12.48 
1418930_at chemokine (C-X-C motif) ligand 10 Cxcl10 31.01 378.46 12.20 
1422648_at 
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 2 
Slc7a2 10.48 126.53 12.07 
1418191_at ubiquitin specific protease 18 Usp18 85.31 988.66 11.59 
1424921_at RIKEN cDNA 2310015I10 gene 2310015I10Rik 140.94 1552.44 11.01 
1418936_at 
v-maf musculoaponeurotic 
fibrosarcoma oncogene family, 
protein F (avian) 
Maff 10.01 106.50 10.64 
1448951_at tumor necrosis factor receptor superfamily, member 1b Tnfrsf1b 71.53 752.06 10.51 
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1435792_at component of Sp100-rs Csprs 44.01 451.20 10.25 
1443414_at 
Mus musculus transcribed 
sequence with weak similarity 
to protein ref:NP_081764.1 
(M.musculus) RIKEN cDNA 
5730493B19 [Mus musculus] 
 53.81 545.32 10.13 
1427736_a_at chemokine (C-C motif) receptor-like 2 Ccrl2 39.24 397.26 10.12 
1449591_at caspase 4, apoptosis-related cysteine protease Casp4 43.61 426.25 9.77 
1418741_at integrin beta 7 Itgb7 22.25 213.29 9.58 
1450322_s_at schlafen 3 Slfn3 100.16 948.94 9.47 
1453472_a_at SLAM family member 7 Slamf7 11.24 105.38 9.37 
1434881_s_at 
potassium channel 
tetramerisation domain 
containing 12 
Kctd12 38.70 348.75 9.01 
1423240_at Rous sarcoma oncogene Src 35.28 310.16 8.79 
1451777_at cDNA sequence BC013672 BC013672 10.75 94.04 8.75 
1426276_at RIKEN cDNA 9130009C22 gene 9130009C22Rik 79.53 683.51 8.59 
1417925_at chemokine (C-C motif) ligand 22 Ccl22 10.01 85.69 8.56 
1450165_at schlafen 2 Slfn2 213.36 1826.53 8.56 
1436172_at 
Mus musculus adult male testis 
cDNA, RIKEN full-length 
enriched library, 
clone:4921508F21 
product:similar to 
HISTOCOMPATIBILITY 2, 
CLASS II ANTIGEN E BETA 
[Mus musculus], full insert 
sequence 
 25.31 210.98 8.34 
1421031_a_at RIKEN cDNA 2310016C08 gene 2310016C08Rik 130.31 1072.77 8.23 
1423555_a_at RIKEN cDNA A430056A10 gene A430056A10Rik 104.99 856.31 8.16 
1421578_at chemokine (C-C motif) ligand 4 Ccl4 558.94 4551.92 8.14 
1425156_at RIKEN cDNA 9830147J24 gene 9830147J24Rik 17.58 141.96 8.08 
1419082_at serine (or cysteine) proteinase inhibitor, clade B, member 2 Serpinb2 10.01 77.58 7.75 
1420413_at 
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 11 
Slc7a11 78.87 610.36 7.74 
1415922_s_at MARCKS-like protein Mlp 320.90 2464.17 7.68 
1452521_a_at urokinase plasminogen activator receptor Plaur 147.07 1127.49 7.67 
1427994_at RIKEN cDNA F730004D16 gene F730004D16Rik 66.95 489.45 7.31 
1422177_at interleukin 13 receptor, alpha 2 Il13ra2 26.51 193.66 7.31 
1419561_at chemokine (C-C motif) ligand 3 Ccl3 1077.22 7830.32 7.27 
1449556_at histocompatibility 2, T region locus 23 H2-T23 273.48 1984.72 7.26 
1417516_at DNA-damage inducible transcript 3 Ddit3 73.24 528.57 7.22 
1451567_a_at interferon activated gene 203 Ifi203 138.45 996.19 7.20 
1448306_at 
nuclear factor of kappa light 
chain gene enhancer in B-cells 
inhibitor, alpha 
Nfkbia 564.80 4050.51 7.17 
1416298_at matrix metalloproteinase 9 Mmp9 44.38 315.55 7.11 
1418847_at arginase type II Arg2 22.66 161.04 7.11 
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1438676_at 
Mus musculus transcribed 
sequence with weak similarity 
to protein sp:P32456 
(H.sapiens) GBP2_HUMAN 
Interferon-induced guanylate-
binding protein 2 (Guanine 
nucleotide-binding protein 2) 
 10.01 70.66 7.06 
1416593_at glutaredoxin 1 (thioltransferase) Glrx1 238.04 1668.01 7.01 
1428027_at Mus musculus BIC noncoding mRNA, complete sequence.  10.01 66.49 6.64 
1422160_at histocompatibility 2, T region locus 24 H2-T24 21.82 143.79 6.59 
1416200_at RIKEN cDNA 9230117N10 gene 9230117N10Rik 10.01 64.99 6.49 
1455265_a_at regulator of G-protein signaling 16 Rgs16 23.59 151.42 6.42 
1449124_at ral guanine nucleotide dissociation stimulator,-like 1 Rgl1 132.70 849.50 6.40 
1448383_at matrix metalloproteinase 14 (membrane-inserted) Mmp14 21.12 134.65 6.38 
1427102_at schlafen 4 Slfn4 566.07 3579.11 6.32 
1460415_a_at tumor necrosis factor receptor superfamily, member 5 Tnfrsf5 36.70 231.06 6.30 
1435226_at RIKEN cDNA 4930534K13 gene 4930534K13Rik 109.18 683.37 6.26 
1417961_a_at tripartite motif protein 30 Trim30 111.87 691.61 6.18 
1449450_at prostaglandin E synthase Ptges 57.46 353.18 6.15 
1450214_at adenosine A2b receptor Adora2b 68.30 417.72 6.12 
1418350_at diphtheria toxin receptor Dtr 25.68 156.82 6.11 
1421304_at killer cell lectin-like receptor, subfamily A, member 2 Klra2 20.45 123.84 6.06 
1451426_at DNA segment, Chr 11, Lothar Hennighausen 2, expressed D11Lgp2e 69.85 419.74 6.01 
1418186_at glutathione S-transferase, theta 1 Gstt1 15.46 89.67 5.80 
1419665_a_at nuclear protein 1 Nupr1 102.46 592.07 5.78 
1427592_at 
Mus musculus similar to 
protocadherin 7 isoform c 
precursor;  
 56.44 324.86 5.76 
1431705_a_at mucolipin 2 Mcoln2 100.22 558.14 5.57 
1420330_at 
C-type (calcium dependent, 
carbohydrate recognition 
domain) lectin, superfamily 
member 9 
Clecsf9 938.03 5149.77 5.49 
1449363_at activating transcription factor 3 Atf3 461.34 2498.09 5.41 
1426243_at cystathionase (cystathionine gamma-lyase) Cth 36.91 199.66 5.41 
1450672_a_at three prime repair exonuclease 1 Trex1 115.25 610.99 5.30 
1419609_at chemokine (C-C motif) receptor 1 Ccr1 34.51 181.11 5.25 
1424775_at 2'-5' oligoadenylate synthetase 1G Oas1g 321.83 1688.37 5.25 
1418626_a_at clusterin Clu 103.36 541.70 5.24 
1419666_x_at nuclear protein 1 Nupr1 94.77 489.04 5.16 
1417023_a_at fatty acid binding protein 4, adipocyte Fabp4 38.51 196.96 5.11 
1449731_s_at 
nuclear factor of kappa light 
chain gene enhancer in B-cells 
inhibitor, alpha 
Nfkbia 680.28 3472.31 5.10 
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1453721_a_at solute carrier family 31, member 2 Slc31a2 162.72 827.85 5.09 
1448377_at secretory leukocyte protease inhibitor Slpi 99.70 505.70 5.07 
1418901_at CCAAT/enhancer binding protein (C/EBP), beta Cebpb 635.01 3218.70 5.07 
1417876_at Fc receptor, IgG, high affinity I Fcgr1 105.80 535.68 5.06 
1423006_at proviral integration site 1 Pim1 47.72 240.72 5.04 
1456494_a_at tripartite motif protein 30-like LOC209387 42.45 213.56 5.03 
1417517_at pleiomorphic adenoma gene-like 2 Plagl2 81.86 410.05 5.01 
1439429_x_at deltex 2 homolog (Drosophila) Dtx2 39.27 196.68 5.01 
1450957_a_at sequestosome 1 Sqstm1 1099.48 5463.35 4.97 
1450234_at 
membrane-spanning 4-
domains, subfamily A, member 
6C 
Ms4a6c 64.53 320.46 4.97 
1448949_at carbonic anhydrase 4 Car4 10.01 49.13 4.91 
1417814_at phospholipase A2, group V Pla2g5 42.71 207.97 4.87 
1418133_at B-cell leukemia/lymphoma 3 Bcl3 46.74 226.19 4.84 
1421326_at 
colony stimulating factor 2 
receptor, beta 1, low-affinity 
(granulocyte-macrophage) 
Csf2rb1 75.58 364.73 4.83 
1451655_at schlafen 8 Slfn8 29.69 143.23 4.82 
1416432_at 
6-phosphofructo-2-
kinase/fructose-2,6-
biphosphatase 3 
Pfkfb3 143.63 690.68 4.81 
1417813_at inhibitor of kappaB kinase epsilon Ikbke 40.32 192.08 4.76 
1451544_at similar to hypothetical protein FLJ10143 LOC213233 24.11 114.68 4.76 
1438097_at RAB20, member RAS oncogene family Rab20 25.02 118.19 4.72 
1450639_at 
solute carrier family 28 
(sodium-coupled nucleoside 
transporter), member 2 
Slc28a2 32.51 153.37 4.72 
1420499_at GTP cyclohydrolase 1 Gch 209.91 984.80 4.69 
1452196_a_at NCK-associated protein 1 Nckap1 40.80 191.31 4.69 
1421041_s_at glutathione S-transferase, alpha 2 (Yc2) Gsta2 10.01 46.85 4.68 
1448239_at heme oxygenase (decycling) 1 Hmox1 478.68 2235.75 4.67 
1451821_a_at nuclear antigen Sp100 Sp100 62.60 291.29 4.65 
1416023_at fatty acid binding protein 3, muscle and heart Fabp3 32.41 150.67 4.65 
1426971_at 
Mus musculus NOD-derived 
CD11c +ve dendritic cells 
cDNA, clone:F630107D10 
product:similar to 
UBIQUITIN-ACTIVATING 
ENZYME E1 [Homo sapiens] 
 38.84 180.32 4.64 
1417371_at pellino 1 Peli1 115.00 533.81 4.64 
1450971_at growth arrest and DNA-damage-inducible 45 beta Gadd45b 222.81 1031.38 4.63 
1424290_at cDNA sequence BC010311 BC010311 161.37 736.61 4.56 
1415972_at myristoylated alanine rich protein kinase C substrate Marcks 10.01 45.46 4.54 
1417487_at fos-like antigen 1 Fosl1 36.03 162.90 4.52 
1424996_at 
Mus musculus cDNA clone 
MGC:28609 IMAGE:4218551 
complete cds 
 146.60 659.56 4.50 
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1418489_a_at calcitonin receptor-like Calcrl 29.26 131.51 4.49 
1417193_at superoxide dismutase 2, mitochondrial Sod2 741.14 3288.67 4.44 
1423268_at integrin alpha 5 (fibronectin receptor alpha) Itga5 80.48 356.91 4.44 
1452087_at RIKEN cDNA 2310046K10 gene 2310046K10Rik 124.20 548.33 4.41 
1418826_at 
membrane-spanning 4-
domains, subfamily A, member 
6B 
Ms4a6b 60.78 266.09 4.38 
1416975_at 
signal transducing adaptor 
molecule (SH3 domain and 
ITAM motif) 2 
Stam2 41.44 181.20 4.37 
1451458_at transmembrane protein 2 Tmem2 86.86 379.69 4.37 
1418937_at deiodinase, iodothyronine, type II Dio2 11.19 48.52 4.33 
1449453_at bone marrow stromal cell antigen 1 Bst1 232.48 992.21 4.27 
1427357_at cytidine deaminase Cda 46.17 196.44 4.25 
1427313_at prostaglandin I receptor (IP) Ptgir 62.73 264.73 4.22 
1419004_s_at B-cell leukemia/lymphoma 2 related protein A1a Bcl2a1a 663.02 2792.30 4.21 
1418261_at spleen tyrosine kinase Syk 140.99 592.18 4.20 
1422431_at melanoma antigen, family E, 1 Magee1 36.26 152.24 4.20 
1450027_at syndecan 3 Sdc3 243.97 1020.84 4.18 
1427689_a_at TNFAIP3 interacting protein 1 Tnip1 315.20 1318.67 4.18 
1429650_at RIKEN cDNA 2310004N11 gene 2310004N11Rik 82.29 343.21 4.17 
1416012_at EH-domain containing 1 Ehd1 61.43 253.86 4.13 
1448061_at macrophage scavenger receptor 1 Msr1 334.23 1376.71 4.12 
1416016_at 
transporter 1, ATP-binding 
cassette, sub-family B 
(MDR/TAP) 
Tap1 104.05 428.25 4.12 
1419721_at interferon-gamma inducible gene, Puma-g Pumag 104.54 428.20 4.10 
1416239_at argininosuccinate synthetase 1 Ass1 48.44 197.93 4.09 
1451386_at biliverdin reductase B (flavin reductase (NADPH)) Blvrb 222.13 893.80 4.02 
1416381_a_at peroxiredoxin 5 Prdx5 529.89 2113.04 3.99 
1450884_at CD36 antigen Cd36 15.19 60.31 3.97 
1418366_at histone 2, H2aa1 Hist2h2aa1 94.97 377.03 3.97 
1455581_x_at 
Mus musculus adult male testis 
cDNA, RIKEN full-length 
enriched library, 
clone:4921508F21 
product:similar to 
HISTOCOMPATIBILITY 2, 
CLASS II ANTIGEN E BETA 
[Mus musculus] 
 64.79 256.59 3.96 
1424831_at copine II Cpne2 24.62 97.31 3.95 
1416521_at selenoprotein W, muscle 1 Sepw1 86.41 341.33 3.95 
1437111_at 
Mus musculus 0 day neonate 
cerebellum cDNA, RIKEN 
full-length enriched library, 
clone:C230027N18 
product:unknown EST 
 53.71 209.14 3.89 
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 1434484_at RIKEN cDNA 1100001G20 gene 1100001G20Rik 11.65 45.09 3.87 
1418003_at RIKEN cDNA 1190002H23 gene 1190002H23Rik 37.66 145.34 3.86 
1431609_a_at acid phosphatase 5, tartrate resistant Acp5 79.95 306.12 3.83 
1452536_s_at immunoglobulin kappa chain variable 1 (V1) Igk-V1 31.05 118.13 3.80 
1449875_s_at histocompatibility 2, T region locus 10 H2-T10 127.10 479.87 3.78 
1450033_a_at signal transducer and activator of transcription 1 Stat1 137.79 518.03 3.76 
1453287_at RIKEN cDNA 0610012A05 gene 0610012A05Rik 63.39 238.18 3.76 
1416654_at solute carrier family 31, member 2 Slc31a2 215.05 803.52 3.74 
1416067_at interferon-related developmental regulator 1 Ifrd1 419.87 1566.59 3.73 
1424329_a_at 
proline-rich Gla (G-
carboxyglutamic acid) 
polypeptide 2 
Prrg2 18.24 68.00 3.73 
1416695_at benzodiazepine receptor, peripheral Bzrp 464.26 1729.85 3.73 
1451161_a_at 
EGF-like module containing, 
mucin-like, hormone receptor-
like sequence 1 
Emr1 504.91 1880.66 3.72 
1419069_at RAB guanine nucleotide exchange factor (GEF) 1 Rabgef1 21.19 78.71 3.71 
1435174_at RIKEN cDNA C230004D03 gene C230004D03Rik 163.92 606.43 3.70 
1448748_at pleckstrin Plek 940.25 3447.25 3.67 
1418946_at 
sialyltransferase 4A (beta-
galactoside alpha-2,3-
sialytransferase) 
Siat4a 38.60 141.43 3.66 
1419703_at procollagen, type V, alpha 3 Col5a3 41.93 153.48 3.66 
1456543_at G protein-coupled receptor 73 Gpr73 24.84 90.47 3.64 
1417542_at ribosomal protein S6 kinase, polypeptide 2 Rps6ka2 130.68 474.51 3.63 
1418401_a_at dual specificity phosphatase 16 Dusp16 132.50 477.78 3.61 
1423233_at CCAAT/enhancer binding protein (C/EBP), delta Cebpd 130.65 470.56 3.60 
1426622_a_at 
glutaminyl-peptide 
cyclotransferase (glutaminyl 
cyclase) 
Qpct 14.30 51.34 3.59 
1425078_x_at RIKEN cDNA 4930565N07 gene 4930565N07Rik 229.44 817.42 3.56 
1451564_at cDNA sequence BC021340 BC021340 84.86 302.20 3.56 
1450744_at elongation factor RNA polymerase II 2 Ell2 365.25 1296.75 3.55 
1421266_s_at 
nuclear factor of kappa light 
chain gene enhancer in B-cells 
inhibitor, beta 
Nfkbib 165.20 584.23 3.54 
1448417_at ninjurin 1 Ninj1 161.94 564.11 3.48 
1455366_at mitochondrial ribosomal protein L52 Mrpl52 11.03 38.35 3.48 
1435176_a_at inhibitor of DNA binding 2 Idb2 86.52 298.62 3.45 
1426244_at microtubule-associated protein, RP/EB family, member 2 Mapre2 109.21 376.04 3.44 
1423605_a_at transformed mouse 3T3 cell double minute 2 Mdm2 552.37 1890.49 3.42 
1425902_a_at 
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 2, p49/p100 
Nfkb2 106.17 363.37 3.42 
1425687_at CASP8 and FADD-like apoptosis regulator Cflar 30.44 103.97 3.42 
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1423686_a_at RIKEN cDNA 1110020C13  1110020C13Rik 296.60 1013.01 3.42 
1448575_at interleukin 7 receptor Il7r 247.54 845.22 3.41 
1452078_a_at 
solute carrier family 11 
(proton-coupled divalent metal 
ion transporters), member 2 
Slc11a2 262.28 891.04 3.40 
1416084_at zinc finger protein 216 Zfp216 67.48 229.05 3.39 
1422046_at integrin alpha M Itgam 164.83 556.47 3.38 
1456309_x_at LIM and SH3 protein 1 Lasp1 491.09 1657.21 3.37 
1426906_at interferon activated gene 205 Ifi205 311.02 1045.20 3.36 
1418280_at core promoter element binding protein Copeb 106.37 356.28 3.35 
1421308_at carbonic anhydrase 13 Car13 35.69 119.39 3.35 
1420361_at 
solute carrier family 11 
(proton-coupled divalent metal 
ion transporters), member 1 
Slc11a1 458.80 1530.87 3.34 
1434547_at carboxypeptidase D Cpd 369.63 1225.01 3.31 
1451338_at nischarin Nisch 35.97 118.89 3.31 
1422704_at glycerol kinase Gyk 143.61 470.22 3.27 
1420641_a_at sulfide quinone reductase-like  Sqrdl 197.13 639.83 3.25 
1421322_a_at 
interferon dependent positive 
acting transcription factor 3 
gamma 
Isgf3g 83.82 272.03 3.25 
1421065_at Janus kinase 2 Jak2 88.26 286.39 3.24 
1419647_a_at immediate early response 3 Ier3 1174.58 3807.91 3.24 
1416503_at latexin Lxn 107.46 346.20 3.22 
1437161_x_at RNA binding protein gene with multiple splicing Rbpms 10.01 32.21 3.22 
1448898_at chemokine (C-C motif) ligand 9 Ccl9 1640.27 5271.37 3.21 
1418641_at lymphocyte cytosolic protein 2 Lcp2 455.61 1453.42 3.19 
1434432_at ligase III, DNA, ATP-dependent Lig3 49.17 156.60 3.18 
1451905_a_at myxovirus (influenza virus) resistance 1 Mx1 10.39 33.02 3.18 
1451828_a_at fatty acid-Coenzyme A ligase, long chain 4 Facl4 169.02 535.85 3.17 
1422851_at high mobility group AT-hook 2 Hmga2 272.32 849.94 3.12 
1424976_at ras homolog gene family, member V Arhv 13.38 41.73 3.12 
1428942_at metallothionein 2 Mt2 1376.28 4268.60 3.10 
1460177_at RIKEN cDNA 0610010E05  0610010E05Rik 430.18 1329.13 3.09 
1426812_a_at RIKEN cDNA 9130404D14  9130404D14Rik 573.89 1765.11 3.08 
1416273_at tumor necrosis factor, alpha-induced protein 2 Tnfaip2 317.66 966.63 3.04 
1426696_at 
low density lipoprotein 
receptor-related protein 
associated protein 1 
Lrpap1 383.66 1161.41 3.03 
1435518_at RAS related protein 1b Rap1b 784.04 2357.14 3.01 
1452413_at RIKEN cDNA C230081A13  C230081A13Rik 86.33 258.46 2.99 
1415936_at breast cancer anti-estrogen resistance 3 Bcar3 227.41 680.77 2.99 
1421812_at TAP binding protein Tapbp 731.84 2165.64 2.96 
1425974_a_at tripartite motif protein 25 Trim25 576.34 1701.63 2.95 
1431774_a_at RIKEN cDNA 4930404J24  4930404J24Rik 18.53 54.48 2.94 
  
1426278_at RIKEN cDNA 2310061N23 gene 2310061N23Rik 356.04 1038.30 2.92 
1423947_at RIKEN cDNA 1110008P14 gene 1110008P14Rik 264.80 769.02 2.90 
1423526_at dead ringer homolog 2 (Drosophila) Dri2 10.01 28.98 2.90 
1460634_at ral guanine nucleotide dissociation stimulator Ralgds 118.74 342.96 2.89 
1422924_at tumor necrosis factor (ligand) superfamily, member 9 Tnfsf9 256.71 722.49 2.81 
1423671_at delta/notch-like EGF-related receptor Dner 72.17 199.85 2.77 
1423626_at dystonin Dst 66.31 183.54 2.77 
1422650_a_at RIO kinase 3 (yeast) Riok3 318.44 880.93 2.77 
1416901_at Niemann Pick type C2 Npc2 2358.93 6469.15 2.74 
1418842_at hematopoietic cell specific Lyn substrate 1 Hcls1 432.67 1178.21 2.72 
1418829_a_at enolase 2, gamma neuronal Eno2 305.70 827.21 2.71 
1420888_at Bcl2-like Bcl2l 199.24 528.28 2.65 
1425374_at 2'-5' oligoadenylate synthetase 3 Oas3 23.05 60.10 2.61 
1422661_at lectin, galactose binding, soluble 8 Lgals8 209.86 541.71 2.58 
1417143_at 
endothelial differentiation, 
lysophosphatidic acid G-
protein-coupled receptor, 2 
Edg2 28.53 73.58 2.58 
1421098_at expressed sequence AI586015 AI586015 822.89 2118.12 2.57 
1449455_at hemopoietic cell kinase Hck 515.63 1325.77 2.57 
1435660_at RIKEN cDNA 5830484A20 gene 5830484A20Rik 102.99 261.42 2.54 
1451941_a_at Fc receptor, IgG, low affinity IIb Fcgr2b 162.88 402.03 2.47 
1420498_a_at disabled homolog 2 (Drosophila) Dab2 1032.34 2547.06 2.47 
1420411_a_at RIKEN cDNA 2610042N09 gene 2610042N09Rik 57.19 139.48 2.44 
1419595_a_at gamma-glutamyl hydrolase Ggh 165.91 399.12 2.41 
1418718_at chemokine (C-X-C motif) ligand 16 Cxcl16 375.15 887.29 2.37 
1425548_a_at leukocyte specific transcript 1 Lst1 422.02 994.95 2.36 
1452367_at RIKEN cDNA 5830400N10 gene 5830400N10Rik 77.35 179.76 2.32 
a Data are from three independent experiments and were analyzed as described in Materials and Methods.  Genes shown were decreased an 
average of 2-fold or greater. 
b Affymetrix probe ID number.  Information on the probe set and the gene it targets can be accessed freely through 
http://www.affymetrix.com/analysis/index.affx. 
c Average signal log intensity from three independent experiments. 
d Fold decrease in average signal value observed in LPS-stimulated RAW macrophages compared to untreated, control. 
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Genes that decreased expression in LPS-stimulated RAW macrophagesa  
 
Ave. Signal Log IntensitycProbe Set IDb Gene Title Gene Symbol Untreated LPS 
Fold 
Decreased
1448650_a_at polymerase (DNA directed), epsilon Pole 157.41 11.47 13.72 
1419513_a_at ect2 oncogene Ect2 281.22 20.93 13.44 
1452954_at ubiquitin-conjugating enzyme E2C Ube2c 1248.56 99.67 12.53 
1450920_at cyclin B2 Ccnb2 915.27 73.70 12.42 
1450842_a_at centromere autoantigen A Cenpa 571.20 50.78 11.25 
1426817_at antigen identified by monoclonal antibody Ki 67 Mki67 1157.92 105.30 11.00 
1423774_a_at protein regulator of cytokinesis 1 Prc1 270.89 27.04 10.02 
1430811_a_at cell division cycle associated 1 Cdca1 356.16 37.03 9.62 
1423463_a_at DNA segment, Chr 2, ERATO Doi 750, expressed D2Ertd750e 147.86 15.50 9.54 
1449207_a_at kinesin family member 20A Kif20a 160.81 17.07 9.42 
1448205_at cyclin B1 Ccnb1 347.03 37.21 9.33 
1427161_at leucine, glutamic acid, lysine family 1 protein Lek1 493.73 53.02 9.31 
1439377_x_at 
elongation of very long chain 
fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 1 
Elovl1 823.50 91.99 8.95 
1433543_at RIKEN cDNA 2900037I21 gene 2900037I21Rik 780.72 87.34 8.94 
1416969_at G two S phase expressed protein 1 Gtse1 108.71 12.52 8.68 
1424766_at cDNA sequence BC004701 BC004701 99.22 11.47 8.65 
1424292_at RIKEN cDNA 5830484J08 gene 5830484J08Rik 98.83 11.95 8.27 
1423813_at kinesin family member 22 Kif22 93.89 11.51 8.16 
1416309_at nucleolar and spindle associated protein 1 Nusap1 502.47 62.63 8.02 
1416299_at Shc SH2-domain binding protein 1 Shcbp1 401.32 51.72 7.76 
1434695_at RIKEN cDNA 2810047L02 gene 2810047L02Rik 168.22 22.03 7.63 
1424278_a_at baculoviral IAP repeat-containing 5 Birc5 445.25 58.43 7.62 
1423847_at RIKEN cDNA 2810406C15 gene 2810406C15Rik 289.75 39.40 7.35 
1452242_at RIKEN cDNA 1200008O12 gene 1200008O12Rik 613.24 83.59 7.34 
1439040_at cDNA sequence BC049989 BC049989 102.97 14.21 7.24 
1422603_at RIKEN cDNA C730049F20 gene C730049F20Rik 156.62 21.64 7.24 
1416258_at thymidine kinase 1 Tk1 505.91 71.04 7.12 
1429171_a_at 
Mus musculus adult male 
hypothalamus cDNA, RIKEN 
full-length enriched library, 
clone:A230105F24 
product:hypothetical protein, 
full insert sequence 
 180.95 25.64 7.06 
1438009_at histone 1, H2ae Hist1h2ae 2497.44 354.76 7.04 
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 1416664_at cell division cycle 20 homolog (S. cerevisiae) Cdc20 732.14 106.18 6.90 
1422460_at MAD2 (mitotic arrest deficient, homolog)-like 1 (yeast) Mad2l1 549.55 80.24 6.85 
1417822_at DNA segment, Chr 17, human D6S56E 5 D17H6S56E-5 1268.11 187.35 6.77 
1422462_at RIKEN cDNA 2700084L22 gene 2700084L22Rik 228.33 33.99 6.72 
1434850_at hypothetical protein D030034H08 D030034H08 425.41 63.66 6.68 
1448226_at ribonucleotide reductase M2 Rrm2 499.80 74.87 6.68 
1422252_a_at cell division cycle 25 homolog C (S. cerevisiae) Cdc25c 76.32 11.47 6.65 
1437405_a_at insulin-like growth factor binding protein 4 Igfbp4 884.06 134.54 6.57 
1438852_x_at 
minichromosome maintenance 
deficient 6 (MIS5 homolog, S. 
pombe) (S. cerevisiae) 
Mcm6 335.31 51.16 6.55 
1416030_a_at 
Mus musculus adult male 
thymus cDNA, RIKEN full-
length enriched library, 
clone:5830410A10 
product:mini chromosome 
maintenance deficient 7 (S. 
cerevisiae), full insert sequence 
 791.17 121.97 6.49 
1416774_at wee 1 homolog (S. pombe) Wee1 107.78 16.66 6.47 
1416558_at maternal embryonic leucine zipper kinase Melk 220.26 34.25 6.43 
1454694_a_at topoisomerase (DNA) II alpha Top2a 1124.03 175.71 6.40 
1417450_a_at transforming, acidic coiled-coil containing protein 3 Tacc3 135.08 21.23 6.36 
1450886_at germ cell-specific gene 2 Gsg2 85.02 13.42 6.34 
1448191_at polo-like kinase (Drosophila) Plk 401.58 63.93 6.28 
1452458_s_at RIKEN cDNA 2410005L11 gene 2410005L11Rik 168.81 26.94 6.27 
1433892_at sperm associated antigen 5 Spag5 84.23 13.45 6.26 
1452314_at kinesin family member 11 Kif11 185.97 29.70 6.26 
1417910_at cyclin A2 Ccna2 604.89 96.76 6.25 
1436186_at RIKEN cDNA 4432406C08 gene 4432406C08Rik 144.78 23.57 6.14 
1419620_at pituitary tumor-transforming 1 Pttg1 102.77 16.91 6.08 
1452040_a_at cell division cycle associated 3 Cdca3 375.67 62.11 6.05 
1435306_a_at Mus musculus transcribed sequences  216.37 36.87 5.87 
1448314_at cell division cycle 2 homolog A (S. pombe) Cdc2a 943.05 161.31 5.85 
1449171_at Ttk protein kinase Ttk 202.44 35.70 5.67 
1448627_s_at DNA segment, Chr 14, ERATO Doi 732, expressed D14Ertd732e 691.19 122.80 5.63 
1450496_a_at RIKEN cDNA 2810433K01 gene 2810433K01Rik 75.21 13.42 5.60 
1452073_at RIKEN cDNA 6720460F02 gene 6720460F02Rik 207.58 37.16 5.59 
1450157_a_at hyaluronan mediated motility receptor (RHAMM) Hmmr 178.72 32.85 5.44 
1451970_at RIKEN cDNA E330036I19 gene E330036I19Rik 145.90 26.95 5.41 
1451246_s_at aurora kinase B Aurkb 167.28 31.22 5.36 
1425753_a_at uracil-DNA glycosylase Ung 178.59 33.34 5.36 
1449060_at kinesin family member 2C Kif2c 175.75 33.40 5.26 
1428870_at nucleolar and coiled-body phosphoprotein 1 Nolc1 60.30 11.47 5.26 
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 1416757_at RIKEN cDNA 2310031L18 gene 2310031L18Rik 212.86 41.15 5.17 
1417926_at RIKEN cDNA 5830426I05 gene 5830426I05Rik 212.96 41.41 5.14 
1424223_at RIKEN cDNA 1700020C11 gene 1700020C11Rik 75.09 14.66 5.12 
1415945_at 
minichromosome maintenance 
deficient 5, cell division cycle 
46 (S. cerevisiae) 
Mcm5 554.13 110.59 5.01 
1451019_at cathepsin F Ctsf 132.79 26.83 4.95 
1454011_a_at replication protein A2 Rpa2 195.34 39.67 4.92 
1418481_at expressed sequence AW209059 AW209059 249.52 51.00 4.89 
1449877_s_at kinesin family member C5A Kifc5a 165.84 33.92 4.89 
1428669_at brain expressed myelocytomatosis oncogene Bmyc 246.52 50.47 4.88 
1460713_at 
Mus musculus mRNA similar to 
putative c-Myc-responsive 
(cDNA clone MGC:54855 
IMAGE:5388297), complete 
cds 
 104.24 21.60 4.83 
1449460_at ankyrin repeat and SOCS box-containing protein 13 Asb13 64.59 13.50 4.78 
1428105_at RIKEN cDNA 2610005B21 gene 2610005B21Rik 65.53 13.74 4.77 
1452241_at RIKEN cDNA 2810429C13 gene 2810429C13Rik 489.93 103.19 4.75 
1417327_at caveolin 2 Cav2 86.99 18.50 4.70 
1438320_s_at 
Mus musculus adult male 
thymus cDNA, RIKEN full-
length enriched library, 
clone:5830410A10 
product:mini chromosome 
maintenance deficient 7 (S. 
cerevisiae), full insert sequence 
 1330.52 283.94 4.69 
1426631_at RIKEN cDNA C330017I15 gene C330017I15Rik 225.09 48.15 4.67 
1416961_at 
budding uninhibited by 
benzimidazoles 1 homolog, beta 
(S. cerevisiae) 
Bub1b 582.57 124.69 4.67 
1424692_at RIKEN cDNA 2810055F11 gene 2810055F11Rik 89.61 19.20 4.67 
1452917_at replication factor C (activator 1) 5 Rfc5 408.26 87.63 4.66 
1416746_at H2A histone family, member X H2afx 841.98 183.42 4.59 
1418264_at SoxLZ/Sox6 leucine zipper binding protein in testis Solt 163.66 35.72 4.58 
1420477_at nucleosome assembly protein 1-like 1 Nap1l1 151.18 33.15 4.56 
1426473_at RIKEN cDNA 5330419I01 gene 5330419I01Rik 304.01 68.17 4.46 
1417971_at RIKEN cDNA 2310014H01 gene 2310014H01Rik 337.32 75.88 4.45 
1453107_s_at phosphatidylethanolamine binding protein Pbp 265.37 59.86 4.43 
1449061_a_at DNA primase, p49 subunit Prim1 110.41 24.92 4.43 
1428074_at 
Mus musculus adult male 
tongue cDNA, RIKEN full-
length enriched library, 
clone:2310037P21 
product:BRAIN SPECIFIC 
BINDING PROTEIN homolog 
[Rattus norvegicus], full insert 
sequence 
 107.88 24.56 4.39 
1436824_x_at ring finger protein 26 Rnf26 450.39 102.63 4.39 
1424895_at RIKEN cDNA 6230410J09 6230410J09Rik 266.26 61.57 4.32 
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1427105_at RIKEN cDNA 2610510J17 gene 2610510J17Rik 434.50 100.69 4.32 
1456393_at programmed cell death 4 Pdcd4 215.41 49.99 4.31 
1422430_at fidgetin-like 1 Fignl1 244.93 57.02 4.30 
1416889_at troponin I, skeletal, fast 2 Tnni2 54.96 12.80 4.29 
1448134_at paladin Pald 65.49 15.40 4.25 
1422814_at calmodulin binding protein 1 Calmbp1 230.94 54.43 4.24 
1417019_a_at cell division cycle 6 homolog (S. cerevisiae) Cdc6 99.15 23.37 4.24 
1417299_at NIMA (never in mitosis gene a)-related expressed kinase 2 Nek2 129.47 30.52 4.24 
1438390_s_at pituitary tumor-transforming 1 Pttg1 2428.90 573.25 4.24 
1452534_a_at high mobility group box 2 Hmgb2 602.13 142.49 4.23 
1435194_at heat shock protein 4 Hspa4 81.61 19.32 4.22 
1450862_at RAD54 like (S. cerevisiae) Rad54l 280.91 66.65 4.21 
1452606_at RIKEN cDNA 2610034E18 gene 2610034E18Rik 48.24 11.47 4.20 
1424107_at kinesin family member 18A Kif18a 87.87 20.96 4.19 
1424629_at breast cancer 1 Brca1 263.22 63.07 4.17 
1417647_at sorting nexin 5 Snx5 339.33 81.32 4.17 
1448635_at SMC2 structural maintenance of chromosomes 2-like 1 (yeast) Smc2l1 650.21 156.82 4.15 
1429295_s_at thyroid hormone receptor interactor 13 Trip13 295.08 71.41 4.13 
1455990_at kinesin family member 23 Kif23 408.70 100.00 4.09 
1448113_at stathmin 1 Stmn1 50.42 12.36 4.08 
1448441_at CDC28 protein kinase 1 Cks1 1016.21 250.72 4.05 
1451849_a_at lamin B2 Lmnb2 46.17 11.47 4.02 
1418281_at RAD51 homolog (S. cerevisiae) Rad51 302.50 75.23 4.02 
1448777_at 
minichromosome maintenance 
deficient 2 mitotin (S. 
cerevisiae) 
Mcm2 545.91 136.68 3.99 
1450155_at integrin alpha 4 Itga4 195.73 49.16 3.98 
1418585_at cyclin H Ccnh 47.72 12.02 3.97 
1420028_s_at minichromosome maintenance deficient 3 (S. cerevisiae) Mcm3 717.01 182.52 3.93 
1451358_a_at Rac GTPase-activating protein 1 Racgap1 519.81 132.39 3.93 
1439269_x_at 
Mus musculus adult male 
thymus cDNA, RIKEN full-
length enriched library, 
clone:5830410A10 
product:mini chromosome 
maintenance deficient 7 (S. 
cerevisiae), full insert sequence 
 161.99 41.27 3.93 
1419270_a_at deoxyuridine triphosphatase Dutp 238.06 61.09 3.90 
1450019_at chemokine (C-X3-C) receptor 1 Cx3cr1 231.80 59.97 3.87 
1424321_at replication factor C (activator 1) 4 Rfc4 221.11 57.26 3.86 
1428483_a_at RIKEN cDNA 2610039C10 gene 2610039C10Rik 122.73 31.85 3.85 
1450070_s_at p21 (CDKN1A)-activated kinase 1 Pak1 254.68 66.12 3.85 
1426653_at minichromosome maintenance deficient 3 (S. cerevisiae) Mcm3 347.16 90.23 3.85 
1419153_at RIKEN cDNA 2810417H13 gene 2810417H13Rik 996.68 259.52 3.84 
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 1435054_at hypothetical protein 6820428D13 6820428D13 107.21 28.04 3.82 
1436707_x_at RIKEN cDNA A730011O11 gene A730011O11Rik 586.56 154.78 3.79 
1418969_at S-phase kinase-associated protein 2 (p45) Skp2 209.22 55.53 3.77 
1455730_at hepatoma up-regulated protein Hurp 162.36 43.44 3.74 
1424156_at retinoblastoma-like 1 (p107) Rbl1 319.02 86.58 3.68 
1428029_a_at RIKEN cDNA C530002L11 gene C530002L11Rik 293.92 79.82 3.68 
1451103_at RIKEN cDNA 9430093H08 gene 9430093H08Rik 309.50 84.12 3.68 
1435697_a_at 
pleckstrin homology, Sec7 and 
coiled-coil domains, binding 
protein 
Pscdbp 146.56 39.90 3.67 
1419998_at RIKEN cDNA C330027C09 gene C330027C09Rik 41.97 11.47 3.66 
1438386_x_at gamma-glutamyl carboxylase Ggcx 302.52 83.12 3.64 
1439381_x_at expressed sequence AI504298 AI504298 341.43 94.01 3.63 
1415810_at nuclear protein 95 Np95 187.34 51.83 3.61 
1448710_at chemokine (C-X-C motif) receptor 4 Cxcr4 56.99 15.81 3.60 
1418561_at splicing factor 3b, subunit 1 Sf3b1 59.66 16.64 3.59 
1423795_at 
splicing factor 
proline/glutamine rich 
(polypyrimidine tract binding 
protein associated) 
Sfpq 202.72 56.90 3.56 
1422016_a_at centromere autoantigen H Cenph 67.63 19.04 3.55 
1415829_at lamin B receptor Lbr 923.80 260.93 3.54 
1419397_at polymerase (DNA directed), alpha 1 Pola1 204.72 58.38 3.51 
1418167_at 
transcription factor AP-4 
(activating enhancer-binding 
protein 4) 
Tfap4 82.55 23.86 3.46 
1417586_at timeless homolog (Drosophila) Timeless 181.73 52.66 3.45 
1422513_at cyclin F Ccnf 136.05 39.49 3.45 
1416155_at high mobility group box 3 Hmgb3 309.28 89.78 3.45 
1437302_at adrenergic receptor, beta 2 Adrb2 82.48 23.99 3.44 
1424033_at splicing factor, arginine/serine-rich 7 Sfrs7 167.32 48.71 3.43 
1423524_at RIKEN cDNA 2700091H24 gene 2700091H24Rik 89.43 26.29 3.40 
1435737_a_at nuclear distribution gene E homolog 1 (A nidulans) Nde1 215.44 63.46 3.39 
1424511_at serine/threonine kinase 6 Stk6 412.30 121.48 3.39 
1422503_s_at 
ADP-ribosyltransferase (NAD+; 
poly (ADP-ribose) polymerase) 
1 
Adprt1 637.82 188.29 3.39 
1424118_a_at RIKEN cDNA 2600017H08 gene 2600017H08Rik 189.38 55.91 3.39 
1454636_at chromobox homolog 5 (Drosophila HP1a) Cbx5 348.57 104.34 3.34 
1452508_x_at RIKEN cDNA 2610009E16 gene 2610009E16Rik 51.47 15.42 3.34 
1418872_at 
ATP-binding cassette, sub-
family B (MDR/TAP), member 
1B 
Abcb1b 178.06 53.52 3.33 
1452829_at 
carbamoyl-phosphate synthetase 
2, aspartate transcarbamylase, 
and dihydroorotase 
Cad 398.96 120.15 3.32 
1450876_at complement component factor h Cfh 38.07 11.47 3.32 
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 1434856_at hypothetical protein A130096K20 A130096K20 94.36 28.47 3.31 
1420928_at beta galactoside alpha 2,6 sialyltransferase 1 St6gal1 199.23 60.18 3.31 
1437050_s_at DNA segment, Chr 1, ERATO Doi 396, expressed D1Ertd396e 73.18 22.16 3.30 
1448127_at ribonucleotide reductase M1 Rrm1 783.22 237.17 3.30 
1454699_at sestrin 1 Sesn1 155.51 47.14 3.30 
1452199_at RIKEN cDNA 2700094F01 gene 2700094F01Rik 83.59 25.37 3.30 
1423714_at ASF1 anti-silencing function 1 homolog B (S. cerevisiae) Asf1b 477.88 145.68 3.28 
1421933_at chromobox homolog 5 (Drosophila HP1a) Cbx5 37.59 11.51 3.27 
1424173_at RIKEN cDNA 2810475A17 gene 2810475A17Rik 71.47 21.90 3.26 
1423045_at nuclear cap binding protein subunit 2 Ncbp2 68.92 21.32 3.23 
1424716_at RIKEN cDNA 0610039N19 gene 0610039N19Rik 83.40 26.00 3.21 
1435323_a_at O-acyltransferase (membrane bound) domain containing 1 Oact1 158.53 49.48 3.20 
1426917_s_at RIKEN cDNA 4833415E20 gene 4833415E20Rik 52.34 16.35 3.20 
1424991_s_at thymidylate synthase Tyms 210.49 65.96 3.19 
1425798_a_at RecQ protein-like Recql 63.08 19.89 3.17 
1426767_at RIKEN cDNA 3230401M21 gene 3230401M21Rik 133.38 42.20 3.16 
1449065_at cytosolic acyl-CoA thioesterase 1 Cte1 112.39 36.13 3.13 
1424852_at myocyte enhancer factor 2C Mef2c 543.54 175.68 3.09 
1416802_a_at RIKEN cDNA 2610036L13 gene 2610036L13Rik 327.94 107.43 3.05 
1451348_at expressed sequence R75183 R75183 46.36 15.19 3.05 
1417939_at RAD51 associated protein 1 Rad51ap1 34.88 11.47 3.04 
1426258_at sortilin-related receptor, LDLR class A repeats-containing Sorl1 235.80 77.79 3.03 
1424046_at 
budding uninhibited by 
benzimidazoles 1 homolog (S. 
cerevisiae) 
Bub1 754.46 249.16 3.03 
1427496_at expressed sequence AI851464 AI851464 37.05 12.26 3.02 
1450692_at kinesin family member 4 Kif4 170.36 56.71 3.00 
1416152_a_at splicing factor, arginine/serine-rich 3 (SRp20) Sfrs3 88.25 29.99 2.94 
1420142_s_at proliferation-associated 2G4 Pa2g4 157.14 54.34 2.89 
1452659_at DEK oncogene (DNA binding) Dek 1057.96 368.17 2.87 
1418004_a_at RIKEN cDNA 1810009M01 gene 1810009M01Rik 150.74 52.48 2.87 
1424407_s_at neuronal pentraxin receptor Nptxr 200.84 70.46 2.85 
1433512_at Friend leukemia integration 1 Fli1 259.09 91.43 2.83 
1423667_at methionine adenosyltransferase II, alpha Mat2a 536.00 189.16 2.83 
1415772_at nucleolin Ncl 88.15 31.21 2.82 
1415997_at thioredoxin interacting protein Txnip 489.90 174.84 2.80 
1454971_x_at Mus musculus transcribed sequences  161.90 57.80 2.80 
1415860_at karyopherin (importin) alpha 2 Kpna2 1227.06 441.28 2.78 
1427233_at serologically defined colon cancer antigen 33 Sdccag33 110.90 40.05 2.77 
1436349_at Mus musculus 11 days embryo whole body cDNA, RIKEN  349.78 126.42 2.77 
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 full-length enriched library, 
clone:2700094K13 
product:unknown EST, full 
insert sequence 
1423074_at lectin, mannose-binding 2 Lman2 96.47 35.48 2.72 
1427469_at RIKEN cDNA 9630002H22 gene 9630002H22Rik 37.18 13.76 2.70 
1418027_at exonuclease 1 Exo1 58.36 21.97 2.66 
1423521_at lamin B1 Lmnb1 328.71 125.34 2.62 
1418288_at lipin 1 Lpin1 200.58 77.02 2.60 
1436884_x_at Ewing sarcoma homolog Ewsh 255.57 98.42 2.60 
1425742_a_at transforming growth factor beta 1 induced transcript 4 Tgfb1i4 171.15 65.93 2.60 
1418656_at 
LSM5 homolog, U6 small 
nuclear RNA associated (S. 
cerevisiae) 
Lsm5 196.00 75.69 2.59 
1418380_at telomeric repeat binding factor 1 Terf1 75.20 29.20 2.58 
1425922_a_at neuroblastoma myc-related oncogene 1 Nmyc1 516.97 201.88 2.56 
1452210_at RIKEN cDNA E130315B21 gene E130315B21Rik 242.46 94.93 2.55 
1420707_a_at TRAF-interacting protein Traip 29.11 11.47 2.54 
1450112_a_at growth arrest specific 2 Gas2 36.53 14.62 2.50 
1438169_a_at RIKEN cDNA 6030440G05 gene 6030440G05Rik 444.69 178.91 2.49 
1423440_at RIKEN cDNA 1110001A07 gene 1110001A07Rik 185.75 76.71 2.42 
1431506_s_at 
Mus musculus transcribed 
sequence with strong similarity 
to protein ref:NP_006338.1 
(H.sapiens) peptidyl prolyl 
isomerase H (cyclophilin H) 
[Homo sapiens] 
 209.52 87.13 2.40 
1423620_at RIKEN cDNA 2610528M18 gene 2610528M18Rik 176.30 73.86 2.39 
1422438_at epoxide hydrolase 1, microsomal Ephx1 438.98 184.54 2.38 
1448673_at poliovirus receptor-related 3 Pvrl3 183.87 77.69 2.38 
1428788_at RIKEN cDNA 1700012G19 gene 1700012G19Rik 167.13 70.77 2.36 
1423064_at DNA methyltransferase 3A Dnmt3a 267.42 117.46 2.28 
1422997_s_at mitochondrial acyl-CoA thioesterase 1 Mte1 134.07 58.96 2.27 
expressed sequence AA408556 1434239_at AA408556 31.57 13.93 2.27 
1436448_a_at prostaglandin-endoperoxide synthase 1 Ptgs1 24.90 11.47 2.17 
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